

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

A Prospective Descriptive Prevalence Study of Catatonia in an Acute Mental Health Unit in Urban South Africa

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-040176
Article Type:	Protocol
Date Submitted by the Author:	26-May-2020
Complete List of Authors:	Zingela, Zukiswa; Walter Sisulu University, Psychiatry and Human Behavioural Sciences; Walter Sisulu University, Dr. Stroud, Louise; Nelson Mandela University, Psychology Cronje, Johan; Nelson Mandela Metropolitan University, Psychology Fink, Max; Stony Brook University, Psychiatry Van Wyk, Stephanus ; Walter Sisulu University, Psychiatry and Human Behavioural Sciences
Keywords:	Neurology < INTERNAL MEDICINE, Adult psychiatry < PSYCHIATRY, MENTAL HEALTH

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

A Prospective Descriptive Prevalence Study of Catatonia in an Acute Mental Health Unit in Urban South Africa

Zukiswa Zingela,¹ Louise Stroud,² Johan Cronje,² Max Fink,³ Stephan van Wyk¹

Author Affiliations

¹Department of Psychiatry and Human Behavioural Science, Walter Sisulu University, Mthatha, South Africa

²Department of Psychology, Nelson Mandela University, Port Elizabeth, South Africa

³Department of Psychiatry, Stony Brook University, New York, United States of America

Word Count: 3797

Corresponding author

Zukiswa Zingela: email: zzingela@wsu.ac.za, Postnet Suite 274, Private Bag X13130, Humewood, 6013, South Africa

Tel +2747-502-1977

ORCID: 0000000234251145

ABSTRACT

Introduction

Catatonia arises from serious mental, medical, neurological, or toxic conditions. The prevalence range is from 10 to 20 percent in other countries. South African prevalence rates are currently unknown. This is a quantitative descriptive study utilising the Bush Francis Catatonia Rating Scale as a screening tool with an information sheet for clinical information. The study will investigate: 1) prevalence of catatonia, 2) clinical and demographic correlates associated with catatonia, 3) predictors of catatonia, 4) response to treatment, and 5) subjective experience of catatonia.

Methods and analysis

The setting is an acute mental health unit (MHU) within a regional, general medical hospital

1
2
3 in Nelson Mandela Bay, South Africa. Participants will be recruited from inpatients in the
4 MHU over a one-year period. Most are admitted involuntarily, under the Mental Health Care
5 Act of 2002. Patient ages range from 13 to over 65 years. Participants who screen positive for
6 catatonia will be followed up after discharge for three months to measure outcomes. Primary
7 outcomes will include:
8
9

- 10 • the 12-month prevalence rate of catatonia.
- 11 • descriptive and other data on presentation and assessment of catatonia in the MHU.

12
13
14
15 Secondary outcomes will include:

- 16 • data on treatment response.
- 17 • subjective experience of catatonia.
- 18 • predictors of catatonia.

19
20
21
22 Descriptive statistics, multivariate binomial logistic regression, and univariate analyses will be
23 conducted to evaluate associations between catatonia and clinical or demographic data which
24 could be predictors of catatonia. Survival analysis will be used to examine the time to recovery
25 after diagnosis and initiation of treatment. The 95% confidence interval will be used to
26 demonstrate the precision of estimates. The level of significance will be $p \leq .05$.

27 28 29 30 31 **Ethics and dissemination**

32
33 The study has received ethical approval from the Research and Ethics Committees of
34 the Eastern Cape Department of Health and Walter Sisulu University. The results will be
35 disseminated as follows: at various presentations and feedback sessions; as part of a Ph.D.
36 thesis in Psychology at Nelson Mandela University; and in a manuscript that will be
37 submitted to a peer-reviewed journal.
38
39
40
41
42
43
44
45
46

47
48 **Keywords:** *Catatonia, assessment, screening tool, Bush Francis Catatonia Rating Scale,*
49 *predictors*
50
51
52
53
54
55
56
57
58
59
60

Article Summary

Strengths and limitations of this study

- This is the first study to examine the prevalence of catatonia in South Africa and aims to address the lack of data on prevalence rates of catatonia, presentation, optimal management, predictors, and outcomes in this setting.
- The triangulation of information sources like the Bush Francis Catatonia Rating Scale, a validated catatonia screening tool, clinical notes, and subjective reports of catatonic episodes from the participants present a unique opportunity to investigate different aspects of catatonia.
- The descriptive nature of the study and the limited number of participants could limit the applicability of significant associations between variables regarding cause and effect and the generalisability of findings.

INTRODUCTION

In the 1880s, Kraepelin described the prevalence of catatonia as close to 20% in 500 cases.[1] Modern-day studies show a range from less than 10% to just over 20%.[1] Catatonia is often treated by psychiatrists, even though underlying causes may be other medical conditions such as neurological, infectious, endocrine, and substance-induced disorders.[1] Grover et al.[2] described close to 40% of 205 patients who had delirium and two or more catatonic symptoms on the Bush Francis Catatonia Rating Scale (BFCRS).

Luchini et al.[3] characterised catatonia as an autonomous syndrome, frequently associated with mood disorders but also observed in patients with other conditions including neurological, neurodevelopmental, physical, and toxic conditions. Current evidence has provided some answers about the categorisation of catatonia, clinical presentations, interventions, and response to treatment.[3, 4, 5, 6]

The current study will investigate the prevalence of catatonia in patients of the Dora Nginza Hospital (DNH) mental health unit (MHU) and collect data on associated risk factors and response to treatment. Due to the prominent role played by electroconvulsive therapy

1
2
3 (ECT) in the treatment of catatonia, the results from this study may have applicability in
4 public mental health planning, should the prevalence of catatonia be significant enough to
5 warrant recommendations regarding availability of ECT in public hospitals.[1]
6
7
8
9

10 **Catatonia in South Africa**

11 There are currently no studies describing the prevalence of catatonia in South Africa
12 (SA), which leaves clinicians blind to the burden of the disease linked to this potentially fatal
13 syndrome. Clinicians may, therefore, be unaware of the importance of the assessment and
14 detection of catatonia, leading to missed opportunities to intervene in what is a highly
15 treatable condition.
16
17
18
19

20
21
22 White and Robins[7] described 17 patients with catatonia in SA who received
23 antipsychotic medication. There was a deterioration in their clinical presentation into
24 neuroleptic malignant syndrome (NMS). The risk of precipitating NMS in this case series
25 was linked to the administration of antipsychotics. This study also challenged the notion of
26 NMS being viewed as a separate condition to catatonia. Since then, catatonia has not been
27 widely studied in SA, despite the researchers' observation that it continues to present a
28 significant and sometimes life-threatening challenge. Another study conducted in SA
29 described the treatment of 42 catatonic patients with ECT.[8] The current study represents the
30 first stages of aiming to fill the gap in the extant research with a prospective study on
31 prevalence and predictive data.
32
33
34
35
36
37
38
39
40

41 **Prevalence of catatonia in other parts of the world**

42
43 Fink and Taylor [1] described a rate of catatonia of 10% in acutely ill psychiatric
44 patients and Stuiivenga and Morrens [9] a rate of 16.9% when applying the DSM-5 criteria.
45 Conditions found in association with a catatonic presentation have included psychiatric
46 diagnoses like bipolar disorder, delirious mania, psychotic depression, schizophrenia, and
47 other medical conditions.[4, 9] In some instances, the cause leading to catatonia has been less
48 well-defined. DSM-5 has captured the multiple possible associations that occur with catatonia
49 by including it as a specifier for mood disorders and schizophrenia or as linked to another
50 medical condition.[10] Catatonia also appears as an entity with undefined aetiology under
51 'catatonia not otherwise specified'. [6]
52
53
54
55
56
57
58
59
60

Choice of screening tool and rating scale

In 1996, Bush et al. designed the BFCRS, a 14-item scale for screening and a 23-item scale for diagnosis of catatonia.[11, 12] They demonstrated that the scale was a reliable and valid tool for diagnosis and evaluation of response to treatment. It has a dual utility of screening and measurement of the severity of catatonia. A systematic review of seven catatonia rating scales reported a similar finding when comparing the BFCRS with other tools to screen for catatonia.[13] They recommend the BFCRS for routine use because of ease of use, reliability, and validity. Wilson et al.[14] found 300 out of 339 patients with acute medical and psychiatric illness screened positive for catatonia when applying the BFCRS.

The BFCRS has been used successfully as a screening tool and rating scale for the past seven years in the MHU which is the site of the current study. Other reasons supporting the utility of the BFCRS in this study are: 1) the reported ease of use, 2) reliability, 3) validity as both a screening tool and a measure of severity, and 4) its use since 2011 in the study site has not yielded any issues with applicability or appropriateness when used in this clinical setting. Figure 1 reflects the assessment tools and process that will be applied to assess participant and collect data.

Management of catatonia

The biological treatment for catatonia has advanced over the last century, from insulin coma therapy of the early 1930s and Meduna's use of seizure-inducing camphor oil injections to Cerletti's first documented use of an electric shock procedure in 1938.[1] Available evidence on management of catatonia includes the published works from various researchers.[1, 4, 5, 7,14-19] Lorazepam and ECT are the current recommended treatments, irrespective of aetiology. They are effective in most cases.[1, 5, 7, 14, 17]

In both in the White and Robins[7] and Fricchione et al.[5] case series, intravenous administration of benzodiazepines (diazepam or lorazepam) was demonstrated as an efficacious treatment for catatonia. Response is seen relatively rapidly, i.e. within minutes of administration. Instead of a sedative effect that one observes with the administration of benzodiazepines in non-catatonic patients, those with catatonia tend to 'wake up' from stupor or normalise from a state of extreme excitement. In the White and Robins[7] study, two

1
2
3 patients who did not receive intravenous benzodiazepines died.
4

5 The dose range used at the study site tends to be higher and is given more frequently
6 compared to the recommendation in the Rasmussen et al. paper.[19] This is mainly because
7 patients at the site present at advanced stages of catatonia and tend to respond slowly or not at
8 all when the lower or less frequent doses are employed.
9
10
11
12

13 **The subjective experience of catatonia**

14
15 Northhoff et al.[20] conducted a retrospective study on 24 catatonic patients post-
16 recovery after a catatonic episode. The patients reported intense emotions which could not be
17 controlled and ambivalence with less focus on their altered movements. Other descriptions of
18 catatonia have stated an extreme fear response characterized by freezing, likened to the
19 defence seen in animals of tonic immobility or freezing in the face of danger.[21]
20
21
22
23
24
25

26 This study will investigate the subjective experience of catatonia as described by
27 participants once discharged from the hospital, to shed light on the emotive and cognitive
28 experience of catatonia in the study cohort. This may provide clues on the psychological
29 drivers of the catatonic response and could pave the way for further research into the
30 psychology of the catatonic response.
31
32
33
34
35

36 **Aims**

37 This study aims to expand the understanding of catatonia in the South African setting
38 so that recognition and management of the syndrome can be enhanced. This will be achieved
39 through investigating the prevalence of catatonia in the DNH MHU, describing the clinical
40 and demographic correlates associated with catatonia and response to treatment, identifying
41 risk factors, and describing the subjective experience of catatonia.
42
43
44
45
46
47

48 **Objectives**

49 The research objectives are:

- 51 1. Collection of data on and description of BFCRS scores of all consenting
52 patients admitted to the DNH MHU over 12 months.
- 53 2. Identification of participants diagnosed with catatonia based on the BFCRS
54 scores and clinical assessments performed by the admitting doctor.
55
56
57
58
59
60

3. Description of the demographic and clinical information, including response to treatment, in participants diagnosed with catatonia during the study period.
4. Identification of any significant clinical correlates and risk factors in participants with catatonia.
5. Follow-up of participants with catatonia once discharged from the unit at one month, two months, and three months intervals, to assess outcomes using the BFCRS and information about readmission for recurrence of any episode of mental illness.
6. Report on the experience of catatonia as described by participants once the catatonic episode has resolved.

Research design

This is a prospective, descriptive triangulation study utilising mixed quantitative and qualitative methods. An exploratory qualitative aspect will investigate the emotive and cognitive subjective experience of participants with catatonia to establish a direction for further research. This is because there is currently limited data available on the subjective experience of catatonia, with most research focusing on quantitative aspects.

The quantitative elements of the study will include data collected from participant files of BFCRS scores upon admission, with additional clinical and demographic information collected via a pre-designed datasheet. The qualitative element will describe the participant's reported experience of the catatonic episode, post-discharge.

METHODS AND ANALYSIS

The study will take a positivist paradigm approach to investigate the potential causal relationships between catatonia and different variables via correlational studies.[22] Creswell[23] described the positivist's approach as an attempt to identify causes, which influence outcomes, the aim being to formulate laws, thus yielding a basis for prediction and generalisation. In the current study, deductive reasoning will be applied to data collected through 1) direct observation and 2) quantitative and qualitative approaches, to identify associations with catatonia, causal relationships, and possibly, predictors of catatonia.[22]

The Bradford Hill method will be applied to examine associations and determine

1
2
3 potential causality.[24] Hill proposed nine criteria that may be examined to assess an
4 association. These are: 1) the strength of association, 2) consistency, 3) specificity, 4)
5 temporality, 5) biological gradient, 6) plausibility, 7) coherence, 8) experiment, and 9)
6 analogy.[24]
7
8
9

10
11 Sources of information that will be utilised for triangulation include: the participants'
12 BFCRS scores and clinical notes; field notes taken by the research team during direct
13 observation and interviews; and participant and relative interviews focusing on response to
14 treatment, food insecurity, and the subjective experience of catatonia. Additionally, the mixed
15 methods nature of the study will enable the generation of both objective (as documented by
16 treating and research teams) and subjective data regarding the experience of catatonia. This
17 type of triangulation is an important tool for meeting the goals of this study while facilitating
18 a holistic assessment of catatonia in this cohort.
19
20
21
22
23
24
25
26

27 **The study process and outline**

28
29 Two research assistants (RAs) with a background in health will be recruited to assist
30 the researcher with fieldwork. A health background is necessary to understand the medical
31 terminology that is utilised in the clinical notes and screening tools. A part-time
32 administrative assistant will be contracted to assist with data capturing and collation.
33
34 Fieldwork will include the recruitment of participants and collection of data by the researcher
35 and RAs. There will be a limited follow-up component that extends to up to three months
36 following discharge from the hospital.
37
38
39
40
41
42

43 The RAs will be trained by the researcher on:

- 44 1) application of the BFCRS to ensure they are knowledgeable about the screening
45 tool, its application, and its interpretation, and
- 46 2) assessment of capacity to consent utilising the University of California, San Diego
47 Brief Assessment of Capacity to Consent Questionnaire (UBACC).
48
49

50 The UBACC has been applied successfully in the Eastern and Western Cape in study
51 cohorts recruited from inpatient mental health institutions.[25, 26]
52
53
54
55

56 The researcher and RAs will assess participants who meet the inclusion criteria for
57
58
59
60

1
2
3 capacity to consent, utilising the UBACC. All those with the capacity to consent will be
4 requested to consider entering the study. For participants who may be assessed as lacking the
5 capacity to consent, their closest relatives or guardians will be requested to consent on their
6 behalf through proxy consent (proxy consent and its ethical application is further discussed in
7 the section 'Ethics and dissemination' on pages 13-14). Additionally, in those assessed to
8 lack capacity to consent, such capacity will be reviewed weekly to allow for further re-
9 engagement on their consent to take part in the study, the ultimate aim being to change from
10 proxy consent to personal consent as soon as potential participants have regained capacity.
11 Data collected about any participant who chooses to withdraw from the study will be
12 removed from the study data sets and destroyed.
13
14
15
16
17
18
19
20
21

22 The research team will collect data from the clinical files of consenting participants
23 on BFCRS scores and additional descriptive and demographic information as guided by the
24 study questionnaire and study protocol. The completed data capturing forms will be
25 submitted to the administrative assistant for data collation and entry into a spreadsheet at the
26 end of each week.
27
28
29
30
31

32 During the limited follow-up period, the researcher and RAs will repeat the BFCRS
33 assessment and conduct face-to-face interviews with participants regarding their experience
34 of catatonia at one month, two months, and three months post-discharge. Recurrence of
35 symptoms or readmissions since the last discharge will be documented. The participant's
36 willingness to continue with the study will be reviewed during every visit to ensure their
37 consent remains valid throughout. Figure 2 is a summary of the study process that will be
38 followed.
39
40
41
42
43
44
45

46 **Setting**

47 The setting will be a 35-bed MHU within DNH, a general hospital in the Eastern Cape
48 Province in South Africa. The hospital is in Zwide, Port Elizabeth and serves a population of
49 over one million within an urban area with a high morbidity of mental illness.[27] The MHU
50 admits persons who present with acute mental illness requiring inpatient treatment.
51
52
53
54
55

56 **Sampling**

1
2
3 Convenience sampling of all patients admitted to the MHU over a twelve-month
4 period will be undertaken. Contact details of all consenting participants who have screened
5 positive for catatonia will be entered into a database to enable contact for future follow-up at
6 the end of one month, two months, and three months post-discharge. This information will be
7 password encrypted. Admission rates at the DNH MHU for the past three years have been
8 1200 to 1300 annually, with an average length of stay of approximately ten to fourteen days.
9 Thus, a realistic estimation based on these previous unit statistics and assuming a
10 conservative catatonia prevalence of 5% to 8% is that around 60-100 participants may be
11 expected to present with catatonia during the study period.
12
13
14
15
16
17
18
19

20 **Participants**

21 Most people admitted to the DNH MHU are involuntary admissions under the Mental
22 Health Care Act of 2002.[28] Age of admission ranges from 13 to over 65 years because
23 there are no child, adolescent, or geriatric inpatient-specific services in the region.
24
25
26
27
28

29 **Inclusion criteria**

30 All patients admitted to the unit during the study period will be eligible for inclusion.
31 Those who screen positive for two or more catatonic signs and symptoms on the BFCRS will
32 be included during the follow-up period for the qualitative part of the study.
33
34
35
36
37

38 **Exclusion criteria**

39 Refusal to take part in the study, whether through the direct patient consent process or
40 the proxy consent process, will result in the exclusion of the patient.
41
42
43
44

45 **Methods of assessment and measurement**

46 The BFCRS is a 14 or 23-item scale (see Appendix A) that is used to screen for
47 catatonia.[11] It is used as a 14-item scale on initial assessment or the full 23-items are used
48 to determine severity. Participants' responses to the standard interventions of intravenous
49 lorazepam administration or ECT will be documented by the admitting doctor in the case
50 notes. The research team will then capture this information on a predesigned data collection
51 sheet. A 50% reduction in signs and symptoms in response to the treatment intervention
52 represents a response while a 100% reduction is considered full resolution.
53
54
55
56
57
58
59
60

1
2
3
4
5 The data collection sheet will collect information on demographics, clinical data, and
6 food insecurity, using the participants' case notes as a primary source of information as well
7 as direct observation of the participants. Additional information will be sought from relatives
8 if the participant is unable to respond adequately to information required on food security
9 questions due to the severity of catatonic symptoms, or in those who are unable to provide the
10 additional information for whatever other reason.
11
12
13
14
15
16

17 Regarding social determinants of mental health, current evidence indicates that those
18 who are poor or disadvantaged suffer disproportionately from common mental disorders and
19 their adverse consequences.[29] The strength of the association with poverty has at times
20 varied depending on the type of poverty measure used. Food insecurity as a poverty measure
21 is one of the factors with a consistent and strong association with common mental
22 disorders.[30] In this study, the administration of a food security questionnaire will be
23 utilised to assess the correlation of poverty to catatonia. Two food insecurity questions are
24 drawn from the USDA's 18-question Household Food Security Scale.[31] They make up The
25 Hunger Vital Sign Questionnaire, a validated two-question food insecurity screening tool
26 used in the clinical setting. The questions are:
27
28
29
30
31
32
33

- 34 1. Within the past 12 months, we worried whether our food would run out
35 before we got money to buy more.
- 36 2. Within the past 12 months, the food we bought just did not last and we did
37 not have money to get more.
38
39
40
41
42

43 During the follow-up period, participants will be asked to describe their experience of
44 the catatonic episode as well as their perception of recovery.
45
46
47

48 **Expected outputs**

- 49 • The 12-month prevalence rate of catatonia.
- 50 • Descriptive and other data on presentation and assessment of catatonia in the DNH
51 unit.
52
- 53 • Data on treatment response, short-term outcomes, and subjective experience of
54 catatonia.
55
56
57
58
59
60

- Predictors for catatonia based on clinical correlates and other descriptive data collected.
- Recommendations and guidelines for the management of catatonia and possible prevention strategies.

Data management and analysis

Quantitative data collected will be summarised using descriptive statistics. Categorical variables will be presented using frequency tables, percentages, and graphs. Two or more categorical variables will be compared using contingency tables (e.g. 2 X 2 Table) and the expected frequencies will be calculated to determine the type of test best suited to determine the extent of any identified relative associations. If the expected frequencies in all cells are ≥ 5 then the Chi-squared test will be used and if the expected frequencies are < 5 in any cells then the Fisher's exact test will be used.

Binomial logistic regression will also be conducted to determine the predictors of catatonia and to estimate the risk ratio. If the numerical data are not normally distributed, non-parametric statistics will be used (median and interquartile range). The best fitting model of multivariate analysis will be chosen through forward selection of model building. The model with the lowest Bayesian information criterion will be selected as the better model and the 95% confidence interval will be used to estimate the precision of estimates. Survival analysis will be used to determine the time to recovery and the hazard ratio (i.e. the total number and timing of each event indicating relapse in this study) will be reported for this purpose.

Qualitative data collated during the follow-up period will be analysed to elucidate the subjective experience of catatonia in this cohort. Aspects of the thematic analysis presented by Braun and Clarke[32] will be applied to identify themes. Themes will be identified through a framework approach identifying word repetition, local expressions, metaphors and similarities, differences, and keywords. A tentative hypothesis and theory regarding the experience of catatonia will be presented based on emergent themes. Data collected during the quantitative and qualitative segments of the study will be analysed separately but compared for congruency of reported information to enhance data integration.

In summary, data integration will be in the form of:

- i. converting information gathered from the quantitative aspects of the study into numerical information that can be processed through application of statistical methods to test for correlations and associations.
- ii. identifying common themes through field notes taken when interviewing participants during the outpatient stage of the study.
- iii. Assessing congruency between common themes with regard to the subjective experience of catatonia as described by participants and commonly identified presenting symptoms as highlighted in case notes and listed in the data collection sheet. The advantage of this approach is that it strengthens the validity and reliability of the study.

ETHICS AND DISSEMINATION

Ethics clearance has been granted for the study by the Eastern Cape Department of Health Ethics Committee and the Walter Sisulu University Research and Ethics Committee. The protocol is also required to be submitted to the Nelson Mandela University Research Ethics Committee (Human) for approval. The study does not have any intervention arm.

All patients admitted to the unit will be presented with an information leaflet on the study in English or Xhosa. Consent for inclusion in the study will be obtained from all participants who have the capacity to consent, which will be determined through application of the UBACC. Proxy consent will be sought from a relative or guardian for all patients who lack the capacity to consent or are minors between the ages of 13 and 18 years of age. The use of proxy consent in mental health research is applicable for those who lack the capacity to consent and the nearest relative or guardian consents on their behalf. It is permissible within the mental health care setting due to the challenges with capacity to consent that may exist in patients with acute mental illness.[33] Proxy consent ensures that respondents' rights are guarded while making it possible to include individuals or groups who may potentially benefit from scientific advances gained from research. This approach is also supported by the Helsinki Declaration on ethical research which states that 'for a research subject who is legally incompetent, physically or mentally incapable of giving consent or is a legally incompetent minor, the investigator must obtain informed consent from the legally authorised representative in accordance with applicable law'.[34] The Department of Health Guidelines

1
2
3 on ethics in health research similarly state that persons should not be excluded unfairly based
4 on discrimination or disability.[35]
5
6
7

8 The Mental Health Care Act (MHCA) of 2002 also makes a reference as to whom
9 may be considered an associate of a patient admitted under the Mental Health Care Act: e.g. a
10 spouse, next of kin, partner, associate, parent, or guardian.[28] A similar approach will be
11 taken for this research. All data will be anonymised and stored under lock and key, with
12 access granted to the research team only.
13
14
15
16
17

18 **Dissemination of results**

19 The results will be presented at feedback sessions with the Hospital Board, Eastern
20 Cape Department of Health and at national and international congresses and may be used to
21 compile guidelines on assessment and management of catatonia in the region. They will also
22 be compiled as a thesis, which will be submitted for examination for a Ph.D. in Psychology at
23 Nelson Mandela University. A research report based on the study results will be submitted to
24 peer-reviewed journals to be considered for publication.
25
26
27
28
29
30
31
32
33

34 **REFERENCES**

- 35 1 Fink M, Taylor MA. Catatonia: A Clinician's Guide to Diagnosis and Treatment.
36 Cambridge: Cambridge University Press 2003.
37
- 38 2 Grover S, Ghosh A, Ghormode D. Do patients of delirium have catatonic features? An
39 exploratory study. *Psychiatry Clin Neurosci* 2014;68:644-51. doi:[10.1111/pcn.12168](https://doi.org/10.1111/pcn.12168)
40
- 41 3 Luchini F, Medda P, Mariani MG, Mauri M, Toni C, Perugi G. Electroconvulsive therapy
42 in catatonic patients: efficacy and predictors of response. *World J Psychiatry* 2015;5:182-
43 92. doi:[10.5498/wjp.v5.i2.182](https://doi.org/10.5498/wjp.v5.i2.182)
44
- 45 4 Fink M, Taylor MA. The many varieties of catatonia. *Eur Arch Psychiatry Clin Neurosci*
46 2001;251:I8-I13. doi:10.1007/PL00014200
47
- 48 5 Fricchione GL, Cassem NH, Hooberman D, Hobson D. Intravenous lorazepam in
49 neuroleptic-induced catatonia. *J Clin Psychopharmacol* 1983;3:338-42.
50
- 51 6 Tandon R, Heckers S, Bustillo J, et al. Catatonia in DSM-5. *Schizophr Res* 2013;150:26-
52 30. doi:[10.1016/j.schres.2013.04.034](https://doi.org/10.1016/j.schres.2013.04.034)
53
54
55
56
57

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
- 7 White DA, Robins AH. An analysis of 17 catatonic patients diagnosed with neuroleptic malignant syndrome. *CNS Spectr* 2000;5:58-65. doi:[10.1017/S1092852900013419](https://doi.org/10.1017/S1092852900013419)
- 8 Odayar K, Eloff I, Esterhuysen W. Clinical and demographic profile of catatonic patients who received electroconvulsive therapy in a South African setting. *S Afr J Psychiatr* 2018;24:1-5. doi:[10.4102/sajpsychiatry.v24i0.1100](https://doi.org/10.4102/sajpsychiatry.v24i0.1100)
- 9 Stuiivenga M, Morrens M. Prevalence of the catatonic syndrome in an acute inpatient sample. *Front Psychiatry* 2014;5:174. doi:[10.3389/fpsy.2014.00174](https://doi.org/10.3389/fpsy.2014.00174)
- 10 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM- 5. Washington: American Psychiatric Association 2013.
- 11 Bush G, Fink M, Petrides G, et al. Catatonia. I. Rating scale and standardized examination. *Acta Psychiatr Scand* 1996;93:129-36. doi:[10.3389/fpsy.2014.00174](https://doi.org/10.3389/fpsy.2014.00174)
- 12 Sienaert P, Dhossche DM, Vancampfort D, et al. A clinical review of the treatment of catatonia. *Front Psychiatry* 2014;5:181. doi:[10.3389/fpsy.2014.00181](https://doi.org/10.3389/fpsy.2014.00181)
- 13 Sienaert P, Rooseleer J, De Fruyt J. Measuring catatonia: a systematic review of rating scales. *J Affect Disord* 2011;135:1-9. doi:[10.1016/j.jad.2011.02.012](https://doi.org/10.1016/j.jad.2011.02.012)
- 14 Wilson J, Niu, K, Nicholson SE, et al. The diagnostic criteria and structure of catatonia. *Schizophr Res* 2015;164:256–62. doi:[10.1016/j.schres.2014.12.036](https://doi.org/10.1016/j.schres.2014.12.036)
- 15 Fink M, Taylor MA. Electroconvulsive therapy: evidence and challenges. *JAMA* 2007;298:330-332. doi:10.1001/jama.298.3.330
- 16 Fink M. What was learned: studies by the consortium for research in ECT (CORE) 1997–2011. *Acta Psychiatr Scand* 2014;129:417-26. doi:[10.1111/acps.12251](https://doi.org/10.1111/acps.12251)
- 17 Petrides G, Fink M, Husain MM, et al. ECT remission rates in psychotic versus nonpsychotic depressed patients: a report from CORE. *J ECT* 2001;17:244-53.
- 18 Rosebush PI, Hildebrand AM, Furlong BG, et al. Catatonic syndrome in a general psychiatric inpatient population: frequency, clinical presentation, and response to lorazepam. *J Clinical Psychiatry* 1990;51:357-62.
- 19 Rasmussen SA, Mazurek MF, Rosebush PI. Catatonia: our current understanding of its diagnosis, treatment and pathophysiology. *World J Psychiatry* 2016;6:391–8. doi:[10.5498/wjp.v6.i4.391](https://doi.org/10.5498/wjp.v6.i4.391)
- 20 Northoff G, Krill W, Wenke J, et al. The subjective experience in catatonia: systematic study of 24 catatonic patients. *Psychiatr Prax* 1996;23:69-73.
- 21 Moskowitz AK. “Scared Stiff”: catatonia as an evolutionary-based fear response. *Psychol*

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Rev 2004;111:984-1002. doi:10.1037/0033-295X.111.4.984
- 22 Scotland J. Exploring the philosophical underpinnings of research: relating ontology and epistemology to the methodology and methods of the scientific, interpretive, and critical research paradigms. *English Language Teaching* 2012;5:9-16
- 23 Creswell JW. *Research Design: Qualitative and Mixed Methods Approaches*. London: Sage 2009.
- 24 Fedak K, Bernal A, Capshaw ZA, et al. Applying the Bradford Hill criteria in the 21st century: how data integration has changed causal inference in molecular epidemiology. *Emerg Themes Epidemiol* 2015;12:14. doi:10.1186/s12982-015-0037-4
- 25 Campbell MM, Susser E, Mall S, et al. Using iterative learning to improve understanding during the informed consent process in a South African psychiatric genomics study. *PLoS ONE* 2017;12:e0188466. doi:[10.1371/journal.pone.0188466](https://doi.org/10.1371/journal.pone.0188466)
- 26 Campbell MM, de Vries J, Mqulwana SG, et al. Predictors of consent to cell line creation and immortalisation in a South African schizophrenia genomics study. *BMC Med Ethics* 2018;19:72. doi:10.1186/s12910-018-0313-2
- 27 Statistics South Africa: Nelson Mandela Bay [Internet]. Republic of South Africa, c2011 [cited 20 February 2020]. Available from: http://www.statssa.gov.za/?page_id=993&id=nelson-mandela-bay-municipality.
- 28 Mental Health Care Act 2002 (Act no. 17 of 2002) General Regulations [Internet]. Government Gazette, Republic of South Africa, 15 December 2004, No. 27117, c2004 [cited 17 February 2020]. Available from: https://www.gov.za/sites/default/files/gcis_document/201409/a17-02.pdf.
- 29 World Health Organization. Social determinants of mental health [Internet]. Geneva: World Health Organization, c2014 [cited 23 March 2020]. Available from: https://www.who.int/mental_health/publications/gulbenkian_paper_social_determinants_of_mental_health/en/.
- 30 Lund C, Breen A, Flisher AJ, et al. Poverty and common mental disorders in low-and middle-income countries: a systematic review. *Soc Sci Med* 2010;71:517–528. doi:[10.1016/j.socscimed.2010.04.027](https://doi.org/10.1016/j.socscimed.2010.04.027)
- 31 American Academy of Pediatrics. Addressing food insecurity: a toolkit for pediatricians [Internet]. c2017 [cited 21 April 2020]. Available from: <https://frac.org/wp-content/uploads/frac-aap-toolkit.pdf>Braun V, Clarke V. Using thematic analysis in

- 1
2
3 psychology. *Qual Res Psychol* 2006;3:77-101. doi:10.1191/1478088706qp063oa
4
5 32 Mason S, Barrow H, Phillips A, et al. Brief report on the experience of using proxy
6 consent for incapacitated adults. *J Med Ethics* 2006;32:61-62.
7
8 doi:10.1136/jme.2005.012302
9
10 33 World Medical Association. World Medical Association Declaration of Helsinki. Ethical
11 principles for medical research involving human subjects. *Bull World Health Organ*
12 2001;79:373-4.
13
14 34 Department of Health, Republic of South Africa. Ethics in health research: principles,
15 processes and structures, 2nd edition [Internet]. Pretoria: National Department of Health,
16 c2015 [cited 23 March 2020 __]. Available from:
17 <https://www.ru.ac.za/media/rhodesuniversity/content/ethics/documents/nationalguidelines>
18 [/DOH \(2015\) Ethics in health research Principles, processes and structures.pdf.](https://www.ru.ac.za/media/rhodesuniversity/content/ethics/documents/nationalguidelines)
19
20
21
22
23
24

25 **AUTHOR CONTRIBUTIONS**

26 Z Zingela conceived the idea and devised the project and its main conceptual ideas assisted
27 by S van Wyk and M Fink. L Stroud and J Cronje supervised the development of this
28 manuscript and provided editorial input.
29
30
31
32

33 **FUNDING STATEMENT**

34 This work was supported by the South African Medical Research Council (SAMRC), grant
35 tracking number 2017SAMRC0SIR0000157977 and an educational grant from the Health
36 and Welfare Sector Education and Training Authority (HWSETA).
37
38
39
40
41

42 **COMPETING INTERESTS STATEMENT**

43 The authors have no competing interests to declare.
44
45
46
47

48 Figure 1

49 Assessment Tools

50
51
52
53 Figure 2

54 The Study Process
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1: Assessment Tools





Figure 2: Study Process



APPENDICES

APPENDIX 1: DATA COLLECTION SHEET

DATA COLLECTION SHEET

Enrolment No:		Tick applicable box or insert answer in area shaded in white													
Unit		Catatonic now?													
B	M	72 hr	No –fill in ONLY Sections A,G,H,I,J							Yes –fill in the whole data sheet Attach an anonymised copy of the BFCRS					
	A. Age		Sex		Ethnicity				1st admission	Catatonic symptoms before?	Provisional DSM -5 Psychiatric diagnosis in file	Susbtance Use?	Another medical condition?		
	< 16	6 - 36	>												
	35 - 65	65	F (0)	M (1)	B	C	I	W	Yes	Yes	Yes	Yes	Yes		
									No - No of previous admissions =	No	No	No	No		
									Not known	Not known	Not known	Not known	Not known		
B. BFCR Scale Score		BZD or LR Rx:		Blood Pressure				Pulse	Body Temperature	Respiratory Rate/ O2 Sats	Other additional clinical				

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

		No of dose/s administered					parameters
Initial Score		Nil					
At 15 minutes		1					
		2					
		3					
At 30 minutes		1					
		2					
		3					
At 45 minutes		1					
		2					
		3					
At 60 minutes		1					
		2					
		3					
	5 min	1	Length of time from presentation to ECT			Degree of improvement	

C. Length of time to response i.e. 50 % reduction in scale	0 min		On admission	4-6 days	11-13 days	Mild = Less than 25% reduction in No. of symptoms	
	5 min		1-3 days	7 -10 days	≥14 days	Moderate = 25% to 50% reduction in No. of symptoms	
	0 min		Reason ECT delayed for more than 3 days (from clinical notes)			Good = Response of more than 50% reduction in No. of symptoms	
D. ECT	Yes		Number of Sessions	Response		Maintenance ECT prescribed or required?	
	No			Time to 50% improvement	Time to full Resolution	Yes? If so No. of sessions?	No
E. Duration of Catatonia prior to admission if known Not Known	Hours to 3 days	Duration of Catatonia Prior to admission	Any other additional information				
	4 days	NOT known					
	To 2 weeks						
	3 to 4 weeks						
	More than 4 weeks						
F. Gradual	Hours to 3	Fluctuating	Type of onset	Any additional information			

vs. Rapid type if onset of catatonic symptoms	days		Unknown				
	4 days to 2 weeks	Gradual worsening					
	3 to 4 weeks	Mostly excited form					
	More than 4 weeks	Mostly slowed Form					
G. Food Insecurity	1. Within the past 12 months, we worried whether our food would run out before we got money to buy more.						
	Often true	sometimes true /refused	never true	don't know/refused	Any additional information		
	2. Within the past 12 months, the food we bought just didn't last and we didn't have money to get more.						
	Often true	sometimes true /refused	never true	don't know/refused	Any additional information		
H. Substances	YES	NO	Alcohol Cocaine	Cannabis Opioids	Amphet Nicotine	Heroin Other (Specify)	Metamphet

I. Medical Illness	No	Yes	If Yes, chose from the following if on history only		If Yes, choose from the following if co-morbid		If HIV	
			HPT	DM	HPT	DM	On HAART?	No
			Epilepsy	HIV	Epilepsy	HIV	If HIV on HAART, Regime?	If HIV, CD4?
			Head Trauma	TB	Head Trauma	TB	If HIV Viral Load?	Other (specify)
			SLE or Auto/I	Other (specify)		Other (specify)		
J. Investigations Done	CK (u/l)		CK ≤ 200	Fe μmol/l	Fe 9 to 30	VitB12 pmol/l	B12 ≤ 107	Auto/I Screen
	CK 201 - 1000		CK ≥ 1000	Fe ≤ 9	Fe ≥ 30	B12 108 - 221	B12 ≥ 221	F NF
								NA SR
	Endocrine		TSH miu/l	≤ 0.38	≥ 5.33	Cortisol	≤ 184	≥ 618
			Normal TSH			Normal (AM)		
			038 to 5.33			185 to 617		
			T4 pmol/l	≤ 7.2	≥ 16.4	Cortisol (PM)	≤ 276 (pm)	≥ 276
			Normal T4			≤ 276		
			7.2 to 16.4					
END OF INPATIENT DATA CAPTURING SECTIONS								

J. Follow-up Period ONLY	1 month	2 months	3months	Other
Please tick the applicable box	Recurrence of Catatonia?	Recurrence of Catatonia?	Recurrence of Catatonia?	Other?
	Re-Admission?	Re-Admission?	Re-Admission?	Other?
Please describe (in your own words) your experience/ how you felt during the catatonic episode	Uyacelwa uchaze (ngawakho amazwi) ngamava akho ngexesha ubune catatonia ukuba ingaba ubuziva njani.	PARTICIPANT RESPONSE RECORDED VERBATUM (USE AUDIO RECORDER)		

APPENDIX 2: INFORMED CONSENT FORM INFORMED CONSENT – ENGLISH

INFORMED CONSENT FOR A STUDY ON CATATONIA

Dear Participant or Relative

We are requesting your consent to enroll you in a study on catatonia and how the symptoms respond to the treatment you are going to be given.

YES, I AGREE TO BE ENROLLED

I
agree in **voluntarily** taking part in the study as explained to me by the doctor/ nurse

OR

(In cases where the patient is incapable of giving consent but is not opposed to taking part in the study, then a relative or custodian may provide informed consent by also signing below)

I being theof
..... **willingly** agree that he/she may take part in the study which has been explained to us by the doctor/ nurse

Signature of participant/relative/ custodian:

Signed by at on the
..... of2019

NO, I DO NOT AGREE TO BE ENROLLED

I
do not agree in taking part in the study as explained to me by the doctor/ nurse OR

I being theof
..... do not agree that he/she may take part in the study which has been
explained to us by the doctor/ nurse

Signature of participant/relative/ custodian:

.....

FOR OFFICE USE ONLY: ASSESSMENT OF CAPACITY TO CONSENT BASED ON UBACC

<i>Does the patient....</i>		
	<i>Yes</i>	<i>No</i>
<p>1. <i>Understand the information relevant to the decision?</i></p>	<p>.....</p>	<p>...</p>
<p>2. <i>Retain the information long enough to consider it?</i></p>	<p>.....</p>	<p>...</p>
<p>3. <i>Weigh the information as part of the decision-making process?</i></p>	<p>.....</p>	<p>...</p>
<p>4. <i>Communicate their decision in some way?</i></p>	<p>.....</p>	<p>...</p>
	<p>.....</p>	<p>.....</p>

1
2
3
4 *Please Note: Should there be a no answer to any of the 4 questions above then the patient lacks capacity to*
5 *consent and a relative or custodian may then be requested to provide informed consent.*
6
7
8

9 **INFORMED CONSENT - ISIXHOSA**

10
11
12 **IPHEPHA-MVUME LOPHANDO NGESIGULO SE-CATATONIA**

13
14
15
16 *Mthathi-nxaxheba obekekileyo okanye Mzali okanye sizalwane esibekileyo*

17
18
19
20 Sicela imvume yakho yokuphanda nzulu ngeempawu zesi sigulo i-catatonia, nokuba unyango
21 ozakulufumana luzakusebenzela njani na.

22
23 Ndiye ndanikwa iphepha elichaza ngolu phando kwaye ndiluchazelwe ngu
24

25
26
27
28
29
30 **EWE NDIYAVUMA**

31
32
33 Mna (faka igama lakho apha)
34 ndiyazikhethela ukulungenela olu phando ndiluchazelwe ngugqirha okanye umongikazi, kwaye
35 andinyanzeliswanga.
36
37

38 **OKANYE**

39
40
41
42 Ukuba umntu akakwazi ukunika imvume ngasizathu sithile, kodwa abe engali ukulungenela
43 uphando, kungatyikitya umzali okanye isizalwane

44 Isayinwe ngu..... e..... ngomhla we.....
45
46 kwinyanga yeku 2019
47
48
49

50
51 **HAYI NDIKHETHA UKUNGALUNGENELI OLU PHANDO**

52 Mna (faka igama lakho apha) ndikhetha ukuba ndingalungeni olu phando
53 ndiluchazelwe ngugqirha okanye umongikazi

54 Mna ndingu.....(Chaza uhlobene njani nomthathi-nxaxheba)
55 ka.....(igama lomthathi nxaxheba)
56
57
58
59
60

Isaynwe e..... ngomhla we..... kwinyanga ye.....ku
2019

Utyikitya apha wena okanye umzali okanye isizalwane

FOR OFFICE USE ONLY: ASSESSMENT OF CAPACITY TO CONSENT BASED ON UBACC

<i>Does the patient....</i>	<i>Yes</i>	<i>No</i>
<i>1. Understand the information relevant to the decision?</i>
<i>2. Retain the information long enough to consider it?</i>
<i>3. Weigh the information as part of the decision-making process?</i>
<i>4. Communicate their decision in some way?</i>

Please Note: Should there be a no answer to any of the 4 questions above then the patient lacks capacity to consent and a relative or custodian may then be requested to provide informed consent.

APPENDIX 3: INFORMATION LEAFLETS IN ENGLISH AND XHOSA

3.1 - INFORMATION LEAFLET (XHOSA)

Iphepha lokwazisa umthathi-nxaxheba kuphando lwesigulo i-Catatonia

Mthathi-nxaxheba obekekileyo *okanye* Mzali okanye sizalwane esibekekileyo

Ngale ncwadi sikwazisa malunga ngophando nzulu oluqhutywa ziinzululwazi ezifuna ukufunda nzulu ngesigulo ekuthiwa yi-catatonia kweli ziko lempilo. Unyango obuhleli uzakulufumna alusayi kutshintsha okanye luphazamiseke wakuthatha inxaxheba kolu phando.

Yintoni i-catatonia?

I-catatonia le sisigulo esiye sibangele ukuphazamiseka kwindlela umntu ashukuma ngayo apha emzimbeni. Kwabanye abantu sibangela ukuba umzimba lo ucothe kakhulu okanye ungakwazi kushuma, umntu azive eqinile, athi nokuba uyafuna ukushumisa umzimba wakhe njengesiqhelo ungakwazi. Ide ibangele loo nto ngelinye ixesha ukuba umntu aphelele ehleli ndawoninye okanye emile ndawoninye de kugqithe imizuzu emininzi okanye iiyure zibe liqela. Iyakwazi nokubangela ukuba umntu ungakwazi ukuphuma kwasebhedini, ungakwazi kuzityisa, ungakwazi kuzihlamba, asoloko elele ebhedini okanye ehleli esitulweni.

Kwelinye icala i-catatonia iyakwazi ukubangela ukuba umntu athi ngoku sele eqalile ukushukuma esithi wenza into ethile, suka umzimba lo uqine, aphelele amalungu omzimba afana neengalo, izandla, imilenze okanye iinyawo zilenga emoyeni ungakwazi ukuyigqibezela laa nthsukumo ebeyiqalile. Intamo nentloko nazo ziyakwazi ukuphetha zikekele ngenxa yoku kuqina komzimba kuvela ngesiquphe.

Okokugqibela, i-catatonia iyakwazi ukuphinda ibangele intshukumo engaphaya kunesiqhelo, aphelele umntu eshuku-shukuma kakhulu, angahlali ndawonye okanye angazinzi. Abanye baye bazule ndawoninye, abanye baqhawabe izandla unomphelo okanye banqwale kungenjalo baninike intloko into engapheliyo. Iyakwazi nokubela ngokuba omnye umntu abetha-bethe amanqindi emoyeni, omnye athi nokuba usebhedini kube ngathi unyomfa ibhaysikili into engapheliyo. Babakhona nabaphetha bethetha into enye, okanye benze isikhalo esiphindaphindwayo okanye nayiphina intsholo abaye bayiqhube imizuzu emininzi okanye iiyure zide zibe liqela. Bakhona ke nabanye abaye balinganise loo nto ithethwa ngumntu ophambi kwabo kungenjalo balinganisa loo nto bayibona isenziwa ngumntu ophambi kwabo.

Ibangelwa yintoni i-catatonia?

I-catatonia iyakwazi ukubangelwa zizigulo ezithile zengqondo kungenjalo nezinye izigulo zomzimba ziyakwazi ukuhamba ne-catatonia. Ingxaki esiye siyifumane thina boogqirha neenzululwazi kukungazi xa siqala ukumbona umntu onale catatonia ukuba ingaba eyakhe ibangelwa sisigulo sengqondo na okanye sesomzimba kusini na. Yiloo tno side sabona ukuba kungakuhle ukuba sinokuyiphonononga nzulu le ngxaki.

Luqulethe ntoni olu phando?

Sijonge ekubeni wonke umntu oze kulaliswa kweli candelo, ahlolwe, kukhangelwe ukuba akahlaselwanga ziimpawu ezithile zale-catatonia kusini na. Wothi uhlole ngugqirha wakho ebehleli ezakuhlola kakade. Ukuba zikhona iimpawu ezithile ugqirha acinga ukuba uziqaphele apha kuwe, usenakho ukubuza ngazo umzekelo mhlawumbi ukuba ziqale nini, njani, kwaye ingaba uyaqala ukuba nazo na njalonzalo. Uzakube phofu ebhala loo nto umxelela yona. Apha ekubhaleni kwakhe kodwa akazokulibhala igama lakho nokuba ungubani kwaye uhlala phi. Oku kuhlolwa nokubuzwa nge-catatonia kungathatha imizuzu emihlanu ukuya kweli shumi kuphela. Ulwazi esiluloqokelelayo ngawe kukuba nje iimpawu zesi sigulo unazo na kwaye nale mibuzo sesiyikhakanyile kuphela.

Zimbini izinto esifuna ukuziqwalasela kolu phando nge-catatonia:

1. Ingaba bangaphi abantu abafunyanwa sesi sigulo kule ngingqi?

2. Ingaba zikhona izinto ezingunobangela wokuba abanye abantu bafunyanwe sesi sigulo abanye basinde, mhlawumbi njengobubudala bomntu, isini okanye ezinye izigulo zomzimba?

Nayiphi na into esinokuyifunda eyongezelela kulwazi esele sinalo ngesi-sigulo ingasanceda kakhulu ekubeni sikwazi ukusinyanga ngcono kwixa elizayo. Ngako oko ubukho bakho nokuthatha kwakho inxaxheba kolu phando kuya kunceda abantu abaninzi abanokuthi bafunyanwe sesi sigulo.

Alukho olunye uvavanyo oza kulwenza oludibene nolu phando. Naluphi na olunye uvavanyo okanye unyango ozakuthi ulufumane emva kokuba umongikazi okanye ugqirha egqibile ukukuhlola, lunyango lwesiqhelo obuhleli uzakulufumana kakade kugirha wakho.

Ukuba ndifunyaniswe ndinazo imipawu ze-catatonia loo nto ithetha ukuthini?

Ukuba ufunyaniswe unazo ezinye zezi mpawu ze-catatonia, ugqira wakho wokunika unyango lakho lwesiqhelo okanye enze uvavanyo ebehleli ezakulwenza kakade olunxulumene nempilo yakho.

Kuza kwenziwa ntoni ngeziphumo zolu phando?

Iziphumo zolu phando zizakudityaniswa zibhalwe kufndiswe abanye oogqirha neenzululwazi malunga nesi sigulo, kwiinkomfa zoogqirha neenzululwazi.

Ndithini ukuba ndinemibuzo?

Ukuba unemibuzo ngolu phando, cela ukuthetha nogqirha wakho okanye umongikazi ozakube encedisa kolu phando.

Siyabulela!

Sibulela kakhulu ngexesha lakho nokuzixhesha kwakho ngolu phando.

3.2 - INFORMATION LEAFLET (ENGLISH)

Information Leaflet about a Study of Catatonia

Dear Participant / Parent/ Relative

This leaflet is provided to inform you about a study being conducted by researchers who would like to investigate a condition called catatonia at his health facility. The usual care you were going to get will not be changed or disturbed through taking part in this study.

What is catatonia?

Catatonia is a condition that affects the way a person moves his whole body or body parts. In some people it slows down the body considerably to the point where some will stop moving completely, causing the person to feel very stiff such that they are unable to move even when they want to. This may lead to a person remaining in one position for a very long time (whether sitting or standing) to the point of many minutes or even hours. It can even cause some people to be bedridden, unable to feed themselves, or wash or attend to other daily needs.

Catatonia can also cause a person to appear frozen even after initiating a particular action, resulting in body

1
2
3
4 parts like legs, arms hands or feet being frozen in awkward or unusual looking positions. The head and or
5 neck may also be tilted at awkward angles. The change in movement can often occur suddenly.
6
7
8

9 Lastly catatonia can also cause an abnormality of excessive movement which is more than normal. A
10 person may show excessive movement that lasts up to many minutes or hours with a seeming inability to
11 stay still. Some people may pace up and down, others may clap or wave for long periods lasting minutes to
12 hours, while others may show head nodding, head shaking, grimacing, etc. Some people have been seen to
13 do shadow boxing or cycling movements even when lying down. It may also appear as repetitive speech of
14 the same phrase, a cry or shout or other odd sound that can last for hours. Others may repeat what they hear
15 around them non- stop or they may mimic actions of those around them as well.
16
17
18
19
20

21 **What causes catatonia?**

22
23
24

25 Catatonia may be seen with a number of mental illnesses but it can also be associated with some other
26 medical conditions. The problem we run into as doctors is when a person presents with the first time with
27 this syndrome it may be difficult in the beginning to know what the underlying cause is i.e. whether the
28 cause is a mental condition or another medical condition. This is why conducting research on catatonia is
29 so important.
30
31
32
33
34

35 **What does this research involve?**

36

37 We are looking at ensuring that everybody who is admitted into this unit is examined and screened for
38 symptoms and signs of catatonia. Your admitting doctor will examine you as usual, which will include an
39 initial screen for catatonia through examination only. Following this, a trained research assistant who is a
40 nurse will proceed to do a full screen using a rating scale, to ensure that no other signs of catatonia were
41 missed. If the research assistant finds any additional signs of catatonia, they will tell your treating doctor. In
42 addition, the nurse may ask you questions like when did the symptoms start and how fast did they appear
43 etc. She or he will note down your answers but will not include details like your name or your address which
44 can identify who you are. This further screening by the nurse not expected to take longer than 5 to 10
45 minutes. The information to be collected for the study about your condition is about the signs and
46 symptoms and the few questions already mentioned to do with the illness, nothing more. There are two
47 questions we would like to investigate about catatonia:
48
49
50
51
52
53
54

- 55 1. How many people experience this condition in this area?
56
57
58
59
60

1
2
3
4
5
6 2.Are there particular characteristics that make some people more prone to it and others less
7 vulnerable to it like age, gender or other medical conditions?

8
9 Whatever we can learn about this condition, over and above what we know already will help us to come up
10 with improved ways to diagnose it and to treat it in future. Taking part in this research will therefore help
11 many people in future who may also get this illness.
12
13
14
15

16 There are no other tests you will be expected to take part in for this study. Whatever other tests or treatment
17 interventions that follow will be those that your doctor would have undertaken anyway to help you manage
18 your condition and get you better.
19
20
21
22

23 **If I am found to show some of the symptoms or signs of catatonia what does that mean?**

24
25
26 If you are found to have some signs and symptoms of catatonia, the research nurse will inform your treating
27 doctor, so that your doctor can give you the appropriate and usual treatment for your condition. Your doctor
28 may also decide to do more tests which would be what they would have done anyway even if you were not
29 part of the study, in order to manage your condition.
30
31
32
33
34

35 **What will be done with the results of the study?**

36
37 The results of the study will be collected and put together to present to scientific congresses so that other
38 doctors and scientists can learn from them.
39
40
41

42 **What should I do if I have more questions?**

43
44 If you have more questions, ask your treating doctor or the researcher, research assistant or nurse.
45
46

47 **Thank you!**

48
49 Thank you very much for your patience and for spending the few minutes on this study.
50
51
52
53
54
55
56
57
58
59
60

APPENDIX 4: INSTITUTIONAL PERMISSIONS –DORA NGINZA HOSPITAL



Province of
EASTERN CAPE
HEALTH

DORA NGINZA REGIONAL HOSPITAL

DEPARTMENT OF PSYCHIATRY & MENTAL HEALTH UNIT
Spenix Street - Zerde - Port Elizabeth - 6205.
Private Bag X 11851 - Port Elizabeth - 6005
Telephone +27 41 405 4390 • Fax +27 41 405 4097

DEPARTMENT OF PSYCHIATRY REQUEST FOR CEO APPROVAL OF DEPARTMENTAL RESEARCH

To	Mr P Tsibolane Chief Executive Officer Dora Nginza Hospital
From	Dr A Bronkhorst, Prof S van Wyk and Prof Z Zingela Department of Psychiatry
Subject	DEPARTMENT OF PSYCHIATRY REQUEST FOR CEO APPROVAL OF DEPARTMENTAL RESEARCH
Date	08 November 2018

Introduction

The Department of Psychiatry and Walter Sisulu University have identified research projects in catatonia as a priority for the Eastern Cape due to the severity of the illness and the potentially negative outcomes resulting from delay in recognition of the cognition

Requested support

CEO approval and support for the research project on Catatonia: "Catatonia as a manifestation of serious mental illness: prevalence, presentation, management and outcomes in a mental health unit", is hereby requested on behalf of the investigators to initiate this study in the Department of Psychiatry in Dora Nginza Hospital.

Conclusion

This project is also expected to yield support for other ongoing and planned registrar research projects on Catatonia. Thank you for considering this request.

A Bronkhorst

S van Wyk

Z Zingela

The request for approval is hereby **granted / not granted** (please delete as appropriate)

Signature: Designation: CEO Date: 08.11.18

Name: M. P. TSIBOLANE

Dora Nginza Regional Hospital
Chief Executive Officer
Mr M.P. Tsibolane

Signature:
Date:

APPENDIX 5: INSTITUTIONAL PERMISSIONS

APPROVAL FROM EC HEALTH RESEARCH COMMITTEE

APPENDIX VI



Eastern Cape Department of Health

Enquiries: Madoda Xokwe
 Date: 19 December 2017
 e-mail address: madoda.xokwe@echealth.gov.za

Tel No: 040 808 0710
 Fax No: 043 642 1409

Dear Prof. Z. Zingela

Re: Catatonia As A Presentation For Severe Mental Illness: Prevalence Of Catatonia In Two Mental Health Units In Urban And Rural South Africa (EC_201712_015)

The Department of Health would like to inform you that your application for conducting a research on the abovementioned topic has been approved based on the following conditions:

1. During your study, you will follow the submitted protocol with ethical approval and can only deviate from it after having a written approval from the Department of Health in writing.
2. You are advised to ensure, observe and respect the rights and culture of your research participants and maintain confidentiality of their identities and shall remove or not collect any information which can be used to link the participants.
3. The Department of Health expects you to provide a progress on your study every 3 months (from date you received this letter) in writing.
4. At the end of your study, you will be expected to send a full written report with your findings and implementable recommendations to the Epidemiological Research & Surveillance Management. You may be invited to the department to come and present your research findings with your implementable recommendations.
5. Your results on the Eastern Cape will not be presented anywhere unless you have shared them with the Department of Health as indicated above.

Your compliance in this regard will be highly appreciated.

SECRETARIAT: EASTERN CAPE HEALTH RESEARCH COMMITTEE



APPENDIX 6:

CATATONIA RATING SCALE

APPENDIX VII

BUSH-FRANCIS CATATONIA RATING SCALE

Use presence or absence of items 1-14 for screening
Use the 0-3 scale for items 1-23 to rate severity

<p>1. Excitement:</p> <p>Extreme hyperactivity, constant motor unrest which is apparently non-purposeful. Not to be attributed to akathisia or goal directed agitation</p> <p>0 = Absent 1 = Excessive motion 2 = Constant motion, hyperkinetic without rest periods 3 = Full-blown catatonic excitement, endless frenzied motor activity</p>	<p>2. Immobility/stupor:</p> <p>Extreme hypoactivity, immobile, minimally responsive to stimuli</p> <p>0 = Absent 1 = Sits abnormally still, may interact briefly 2 = Virtually no interaction with external world 3 = Stuporous, non-reactive to painful stimuli</p>
<p>3. Mutism:</p> <p>Verbally unresponsive or minimally responsive</p> <p>0 = Absent 1 = Verbally unresponsive to majority of questions; incomprehensible whisper 2 = Speaks less than 20 words/ 5 min 3 = No speech</p>	<p>4. Staring:</p> <p>Fixed gaze, little or no visual scanning of environment, decreased blinking.</p> <p>0 = Absent 1 = Poor eye contact, repeatedly gazes less than 20 seconds between shifting of attention; decreased blinking 2 = Gaze held longer than 20 seconds, occasionally shifts attention 3 = Fixed gaze, non-reactive</p>
<p>5. Posturing/catalepsy:</p> <p>Spontaneous maintenance of posture(s), including mundane (e.g. setting or standing for long periods without reacting).</p> <p>0 = Absent 1 = Less than 1 minute 2 = Greater than one minute, less than 15 minutes 3 = Bizarre posture, or mundane maintained more than 15 minutes</p>	<p>6. Grimacing:</p> <p>Maintenance of odd facial expressions.</p> <p>0 = Absent 1 = Less than 10 seconds 2 = Less than 1 minute 3 = Bizarre expression(s) or maintained more than 1 minute</p>
<p>7. Echopraxia/echolalia:</p> <p>Mimicking of examiner's movements/speech.</p> <p>0 = Mimicking of examiner's movements/speech 1 = Occasional 2 = Frequent 3 = Constant</p>	<p>8. Stereotypy:</p> <p>Repetitive, non-goal-directed motor activity (e.g. finger-play, repeatedly touching, patting or rubbing self); abnormality not inherent in act but in frequency.</p> <p>0 = Absent 1 = Occasional 2 = Frequent 3 = Constant</p>
<p>9. Mannerisms:</p> <p>Odd, purposeful movements (hopping or walking tiptoe, saluting passers-by or exaggerated caricatures of mundane movements); abnormality inherent in act itself.</p> <p>0 = Absent 1 = Occasional 2 = Frequent 3 = Constant</p>	<p>10. Verbigeration:</p> <p>Repetition of phrases or sentences (like a scratched record).</p> <p>0 = Absent 1 = Occasional 2 = Frequent 3 = Constant</p>
<p>11. Rigidity:</p> <p>Maintenance of a rigid position despite efforts to be moved, exclude if cog-wheeling or tremor present.</p> <p>0 = Absent 1 = Mild resistance 2 = Moderate 3 = Severe, cannot be repositioned</p>	<p>12. Negativism:</p> <p>Apparently motiveless resistance to instructions or attempts to move/examine patient. Contrary behavior, does exact opposite of instruction</p> <p>0 = Absent 1 = Mild resistance and/or occasionally contrary 2 = Moderate resistance and/or frequently contrary 3 = Severe resistance and/or continually contrary</p>
<p>13. Waxy Flexibility:</p> <p>During repositioning of patient, patient offers initial resistance before allowing himself to be repositioned, similar to that of a bending candle.</p> <p>0 = Absent 3 = Present</p>	<p>14. Withdrawal:</p> <p>Refusal to eat, drink and/or make eye contact.</p> <p>0 = Absent 1 = Minimal PO intake/interaction for less than 1 day 2 = Minimal PO intake/interaction for more than 1 day 3 = No PO intake/interaction for 1 day or more.</p>

BUSH-FRANCIS CATATONIA RATING SCALE (CONT.)

<p>15. Impulsivity:</p> <p>Patient suddenly engages in inappropriate behavior (e.g. runs down hallway, starts screaming or takes off clothes) without provocation. Afterwards can give no, or only a facile explanation.</p> <p>0 = Absent 1 = Occasional 2 = Frequent 3 = Constant or not redirectable</p>	<p>16. Automatic obedience:</p> <p>Exaggerated cooperation with examiner's request or spontaneous continuation of movement requested.</p> <p>0 = Absent 1 = Occasional 2 = Frequent 3 = Constant</p>
<p>17. Mitgehen:</p> <p>"Anglepoise lamp" arm raising in response to light pressure of finger, despite instruction to the contrary.</p> <p>0 = Absent 3 = Present</p>	<p>18. Gegenhalten:</p> <p>Resistance to passive movement which is proportional to strength of the stimulus, appears automatic rather than willful.</p> <p>0 = Absent 3 = Present</p>
<p>19. Ambitendency:</p> <p>Patient appears motorically "stuck" in indecisive, hesitant movement.</p> <p>0 = Absent 3 = Present</p>	<p>20. Grasp reflex:</p> <p>Per neurological exam</p> <p>0 = Absent 3 = Present</p>
<p>21. Perseveration:</p> <p>Repeatedly returns to same topic or persists with movement.</p> <p>0 = Absent 3 = Present</p>	<p>22. Combativeness:</p> <p>Usually in an undirected manner, with no, or only a facile explanation afterwards.</p> <p>0 = Absent 1 = Occasionally strikes out, low potential for injury 2 = Frequently strikes out, moderate potential for injury 3 = Serious danger to others</p>
<p>23. Autonomic abnormality:</p> <p>Circle: temperature, BP, pulse, respiratory rate, diaphoresis.</p> <p>0 = Absent 1 = Abnormality of one parameter [excluding pre-existing hypertension] 2 = Abnormality of two parameters 3 = Abnormality of three or more parameters</p>	<p>TOTAL: _____</p>

Review only



FACULTY OF HEALTH SCIENCES
 POSTGRADUATE EDUCATION, TRAINING, RESEARCH AND ETHICS UNIT

**HUMAN RESEARCH COMMITTEE
 CLEARANCE CERTIFICATE**

PROTOCOL NUMBER : 067/2017

PROJECT : PREVALENCE OF CATATONIA IN TWO MENTAL HEALTH UNITS IN URBAN AND RURAL SOUTH AFRICA

INVESTIGATOR(S) : PROF Z ZINGELA

DEPARTMENT : PSYCHIATRY & BEHAVIOURAL SCIENCES

DECISION OF THE COMMITTEE : APPROVED

DATE OF APPROVAL : 07 MAY 2020

DURATION : 1 YEAR (07 MAY 2020 – 07 MAY 2021)

CONDITIONS : NONE

N.B You are required to provide the committee with a progress or outcome report of the research after every 6 months. The committee expects a report on any changes in the protocol as well as any untoward events that may occur at any time during the study not later than 7 days of knowing as the investigator/s.

WALTER SISULU UNIVERSITY
 ACADEMIC HEALTH SERVICE COMPLEX OF THE
 EASTERN CAPE
 POSTGRADUATE EDUCATION AND TRAINING
 FACULTY OF HEALTH SCIENCES
 WALTER SISULU UNIVERSITY
 P/BAG X 1, WSU, 5117, E.C
 TEL: (047) 502 2100 / FAX: (047) 502 2101


 DR EJ NDEBIA
 CHAIRPERSON

07.05.2020
 DATE

DECLARATION OF INVESTIGATOR(S)

(To be completed in duplicate and one copy returned to the Research Officer at Office AB 02 GF 03 Administration Building, Sisson Street Campus, Fort Gale, Mthatha, WSU)

I/We fully understand the conditions under which I am/we are authorized to carry out the abovementioned research and I/we guarantee to ensure compliance with these conditions. Should any departure to be contemplated from the research procedure as approved I/we undertake to resubmit the protocol to the Research Ethics Committee. I/We agree to a completion of a 6-monthly/ yearly progress report. The committee reserves the right to withdraw approval in the event that there are serious ethical violations.

..... (Signature)

..... (Date)

N. B. Please quote the protocol number in all enquiries.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

BMJ Open

A Protocol for a Prospective Descriptive Prevalence Study of Catatonia in an Acute Mental Health Unit in Urban South Africa

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-040176.R1
Article Type:	Protocol
Date Submitted by the Author:	03-Sep-2020
Complete List of Authors:	Zingela, Zukiswa; Walter Sisulu University, Psychiatry and Human Behavioural Sciences; Walter Sisulu University, Dr. Stroud, Louise; Nelson Mandela University, Psychology Cronje, Johan; Nelson Mandela Metropolitan University, Psychology Fink, Max; Stony Brook University, Psychiatry Van Wyk, Stephanus ; Walter Sisulu University, Psychiatry and Human Behavioural Sciences
Primary Subject Heading:	Mental health
Secondary Subject Heading:	Mental health, Neurology
Keywords:	Neurology < INTERNAL MEDICINE, Adult psychiatry < PSYCHIATRY, MENTAL HEALTH, Child & adolescent psychiatry < PSYCHIATRY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4
5
6 **A Protocol for a Prospective Descriptive Prevalence Study of Catatonia in an Acute**
7
8 **Mental Health Unit in Urban South Africa**
9

10 Zukiswa Zingela,¹ Louise Stroud,² Johan Cronje,² Max Fink,³ Stephan van Wyk¹
11
12
13
14

15 **Author Affiliations**
16

17 ¹Department of Psychiatry and Human Behavioural Science, Walter Sisulu University,
18 Mthatha, South Africa
19

20 ²Department of Psychology, Nelson Mandela University, Port Elizabeth, South Africa
21

22 ³Department of Psychiatry, Stony Brook University, New York, United States of America
23
24
25
26
27
28

29 Word Count: 4409
30
31
32
33
34

35 **Corresponding author**
36

37
38 Zukiswa Zingela: email: zzingela@wsu.ac.za, Postnet Suite 274, Private Bag X13130,
39 Humewood, 6013, South Africa
40
41

42
43 Tel +2747-502-1977
44
45

46 ORCID: 0000000234251145
47
48
49
50

51 **ABSTRACT**
52
53
54
55

56 **Introduction**
57
58
59
60

1
2
3 Catatonia arises from serious mental, medical, neurological, or toxic conditions. The
4 prevalence range depends on the setting and the range is anything from 7% to 63% percent in
5 other countries. South African prevalence rates are currently unknown. The proposed study is
6 a quantitative descriptive study utilising the Bush Francis Catatonia Screening Instrument as a
7 screening tool with a data capturing information sheet to extract clinical information from
8 patient folders. The study will investigate: 1) prevalence of catatonia, 2) clinical and
9 demographic correlates associated with catatonia, 3) predictors of catatonia, 4) response to
10 treatment, and 5) subjective experience of catatonia.
11
12
13
14
15
16
17
18
19
20
21

22 **Methods and analysis**

23
24 The setting is an acute mental health unit (MHU) within a regional, general medical hospital
25 in Nelson Mandela Bay, South Africa which accepts referrals from within the hospital and from
26 outlying clinics. Participants will be recruited from inpatients in the MHU from beginning of
27 September 2020 to end of August 2021. Most admissions are involuntarily, under the Mental
28 Health Care Act of 2002 with an age range of 13 to over 65 years. Participants who screen
29 positive for catatonia will be followed up after discharge for three months to measure outcomes.
30 Primary outcomes will include the 12-month prevalence rate of catatonia, descriptive and other
31 data on presentation and assessment of catatonia in the MHU.
32
33
34
35
36
37
38
39
40
41

42 Secondary outcomes will include data on treatment response, participants' report of their
43 subjective experience of catatonia and predictors of catatonia.
44
45
46

47 Descriptive statistics, multivariate binomial logistic regression, and univariate analyses will be
48 conducted to evaluate associations between catatonia and clinical or demographic data which
49 could be predictors of catatonia. Survival analysis will be used to examine the time to recovery
50 after diagnosis and initiation of treatment. The 95% confidence interval will be used to
51 demonstrate the precision of estimates. The level of significance will be $p \leq .05$.
52
53
54
55
56
57
58
59
60

Ethics and dissemination

The study has received ethical approval from the Research and Ethics Committees of the Eastern Cape Department of Health, Walter Sisulu University and Nelson Mandela University. The results will be disseminated as follows: at various presentations and feedback sessions; as part of a Ph.D. thesis in Psychology at Nelson Mandela University; and in a manuscript that will be submitted to a peer-reviewed journal.

Keywords: *Catatonia, assessment, screening tool, Bush Francis Catatonia Rating Scale, predictors*

Article Summary

Strengths and limitations of this study

- This is the first study to examine the prevalence of catatonia in South Africa and aims to address the lack of data on prevalence rates of catatonia, presentation, optimal management, predictors, and outcomes in this setting.
- The triangulation of information sources like the Bush Francis Catatonia Rating Scale, a validated catatonia screening tool, clinical notes, and subjective reports of catatonic episodes from the participants present a unique opportunity to investigate different aspects of catatonia.
- The descriptive nature of the study and the limited number of participants could limit the applicability of significant associations between variables regarding cause and effect and the generalisability of findings. The heterogenous nature of catatonia and interrater reliability of catatonia screening instruments are another source of potential limitations of the study.

INTRODUCTION

In the 1880s, Kraepelin described the prevalence of catatonia as close to 20% in 500 cases.[1] Modern-day studies show a range from less than 10% to 63%.[1, 2, 3] Catatonia is often treated by psychiatrists, even though underlying causes may be other medical conditions such as neurological, infectious, endocrine, and substance-induced disorders.[1] Grover et al.[4] described close to 40% of 205 patients who had delirium and two or more catatonic symptoms on the Bush Francis Catatonia Rating Scale (BFCRS).

1
2
3 Luchini et al.[5] characterised catatonia as an autonomous syndrome, frequently
4 associated with mood disorders but also observed in patients with other conditions including
5 neurological, neurodevelopmental, physical, and toxic conditions. Current evidence has
6 provided some answers about the categorisation of catatonia, clinical presentations,
7 interventions, and response to treatment.[5, 6, 7, 8]
8
9
10
11
12
13
14
15
16

17 The current study will investigate the prevalence of catatonia in patients of the Dora
18 Nginza Hospital (DNH) mental health unit (MHU), associated risk factors and response to
19 treatment. Due to the prominent role played by electroconvulsive therapy (ECT) in the
20 treatment of catatonia, the results from this study may have applicability in public mental
21 health planning, and availability of ECT in public hospitals.[1]
22
23
24
25
26
27
28
29
30
31
32

33 **Catatonia in South Africa**

34
35 There are currently no studies describing the prevalence of catatonia in South Africa
36 (SA), which leaves clinicians blind to the burden of the disease linked to this potentially fatal
37 syndrome. Clinicians may, therefore, be unaware of the importance of the assessment and
38 detection of catatonia, leading to missed opportunities to intervene in what is a highly
39 treatable condition.
40
41
42
43
44
45
46
47
48

49 White and Robins[9] described 17 patients with catatonia in SA who received
50 antipsychotic medication. There was a deterioration in their clinical presentation into
51 neuroleptic malignant syndrome (NMS). The risk of precipitating NMS in this case series
52 was linked to the administration of antipsychotics. This study also challenged the notion of
53
54
55
56
57
58
59
60

1
2
3 NMS being viewed as a separate condition to catatonia. Since then, catatonia has not been
4
5 widely studied in SA, despite the researchers' observation that it continues to present a
6
7 significant and sometimes life-threatening challenge. Another study conducted in SA
8
9 described the treatment of 42 catatonic patients with ECT.[10] The current study represents
10
11 the first stages of aiming to fill the gap in the extant research with a prospective study on
12
13 prevalence and predictive data.
14
15
16
17
18

19 **Prevalence of catatonia in other parts of the world**

20
21 Fink and Taylor [1] described a rate of catatonia of 10% in acutely ill psychiatric
22
23 patients and Stuiivenga and Morrens [2] a rate of 16.9% when applying the DSM-5 criteria.
24
25 Conditions found in association with a catatonic presentation have included psychiatric
26
27 diagnoses like bipolar disorder, delirious mania, psychotic depression, schizophrenia, and
28
29 other medical conditions.[6, 2] In some instances, the cause leading to catatonia has been less
30
31 well-defined. DSM-5 has captured the multiple possible associations that occur with catatonia
32
33 by including it as a specifier for mood disorders and schizophrenia or as linked to another
34
35 medical condition.[11] Catatonia also appears as an entity with undefined aetiology under
36
37 'catatonia not otherwise specified'. [8]
38
39
40
41
42
43
44

45 **Choice of screening tool and rating scale**

46
47 In 1996, Bush et al. designed the Bush Francis Catatonia Screening Instrument
48
49 (BFCSI) a 14-item scale for screening for catatonia and a 23-item scale for rating severity of
50
51 catatonia.[3, 12] They demonstrated that the scales were reliable and valid tool for diagnosis
52
53 and evaluation of response to treatment. The scales have a dual utility of screening and
54
55 measurement of the severity of catatonia. A systematic review of seven catatonia rating scales
56
57
58
59
60

1
2
3 reported a similar finding when comparing the BFCRS with other tools to screen for
4
5 catatonia.[13] They recommend the BFCRS for routine use because of ease of use, reliability,
6
7 and validity. Wilson et al.[14] found 300 out of 339 patients with acute medical and
8
9 psychiatric illness screened positive for catatonia when applying the BFCRS.
10
11
12
13

14
15 The BFCRS and BFCRS have been used successfully in the MHU as screening and
16
17 rating scales for the past seven years in the MHU which is the site of the current study. Other
18
19 reasons supporting the utility of the scales in this study are: 1) the reported ease of use, 2)
20
21 reliability, 3) validity as both a screening tool and a measure of severity, and 4) its use since
22
23 2011 in the study site has not yielded any issues with applicability or appropriateness when
24
25 used in this clinical setting. Figure 1 reflects the assessment tools and process that will be
26
27 applied to assess participant and collect data.
28
29
30
31
32

33 **Management of catatonia**

34
35 The biological treatment for catatonia has advanced over the last century, from insulin
36
37 coma therapy of the early 1930s and Meduna's use of seizure-inducing camphor oil injections
38
39 to Cerletti's first documented use of an electric shock procedure in 1938.[1] Available
40
41 evidence on management of catatonia includes the published works from various
42
43 researchers.[1, 6, 7, 9,14-19] Lorazepam and ECT are the current recommended treatments,
44
45 irrespective of aetiology. They are effective in most cases.[1, 7, 9, 14, 17]
46
47
48

49 In both in the White and Robins[9] and Fricchione et al.[7] case series, intravenous
50
51 administration of benzodiazepines (diazepam or lorazepam) was demonstrated as an
52
53 efficacious treatment for catatonia. Response is seen relatively rapidly, i.e. within minutes of
54
55 administration. Instead of a sedative effect that one observes with the administration of
56
57
58
59
60

1
2
3 benzodiazepines in non-catatonic patients, those with catatonia tend to ‘wake up’ from stupor
4
5 or normalise from a state of extreme excitement. In the White and Robins[9] study, two
6
7 patients who did not receive intravenous benzodiazepines died.
8
9

10
11
12 The dose range used at the study site tends to be higher and is given more frequently
13
14 compared to the recommendation in the Rasmussen et al. paper.[19] This is mainly because
15
16 patients at the site present at advanced stages of catatonia and tend to respond slowly or not at
17
18 all when the lower or less frequent doses are employed.
19
20
21
22

23 24 **The subjective experience of catatonia**

25
26 Northoff et al.[20] conducted a retrospective study on 24 catatonic patients post-
27
28 recovery after a catatonic episode. The patients reported intense emotions which could not be
29
30 controlled and ambivalence with less focus on their altered movements. Other descriptions of
31
32 catatonia have stated an extreme fear response characterized by freezing, likened to the
33
34 defence seen in animals of tonic immobility or freezing in the face of danger.[21]
35
36
37
38
39

40 This study will investigate the subjective experience of catatonia as described by
41
42 participants once discharged from the hospital, to shed light on the emotive and cognitive
43
44 experience of catatonia in the study cohort. This may provide clues on the psychological
45
46 drivers of the catatonic response and could pave the way for further research into the
47
48 psychology of the catatonic response.
49
50
51
52

53 54 **Aims**

55
56 This study aims to determine the prevalence of catatonia in an acute mental health
57
58
59
60

unit in urban South Africa and research its assessment and management in this setting.

Objectives

The two main research objectives are:

1. Screening of consenting participants admitted to the mental health unit in Dora Nginza Hospital using the BFCSI for catatonia, over a 12-month period from the 1st of September 2020 to the end of August 2021, to describe the prevalence of catatonia in this setting.
2. Description of demographic and clinical information, including response to treatment, in participants diagnosed with catatonia based on their BFCSI scores and clinical assessments performed by the admitting doctor.

In addition, significant clinical correlates and risk factors in participants with catatonia will be described, and participants with catatonia will be followed up once discharged at one month, two months, and three months intervals, to assess outcomes using the BFCSI and information about readmission or recurrence of any episode of mental illness. The association that will be looked at is between catatonia and demographic or clinical correlates such as age, gender, DSM 5 diagnosis, substance use, vitamin 12 deficiency and food insecurity and other co-occurring medical conditions. Participant's experience of catatonia once it has resolved will also be described.

Research design

This is a prospective, descriptive triangulation study utilising mixed quantitative and qualitative methods. An exploratory qualitative aspect will investigate the emotive and

1
2
3 cognitive subjective experience of participants with catatonia to establish a direction for
4
5 further research. This is because there is currently limited data available on the subjective
6
7 experience of catatonia, with most research focusing on quantitative aspects.
8
9

10
11
12 The quantitative elements of the study will include data collected from participant
13
14 files of BFCSI scores upon admission, with additional clinical and demographic information
15
16 collected via a pre-designed datasheet. The qualitative element will describe the participant's
17
18 reported experience of the catatonic episode, post-discharge.
19
20
21
22

23 24 **METHODS AND ANALYSIS**

25
26 The study will take a positivist paradigm approach to investigate the potential causal
27
28 relationships between catatonia and different variables via correlational studies.[22]
29
30 Creswell[23] described the positivist's approach as an attempt to identify causes, which
31
32 influence outcomes, the aim being to formulate laws, thus yielding a basis for prediction and
33
34 generalisation. In the current study, deductive reasoning will be applied to data collected
35
36 through 1) direct observation and 2) quantitative and qualitative approaches, to identify
37
38 associations with catatonia, causal relationships, and possibly, predictors of catatonia.[22]
39
40
41
42
43
44
45
46

47 Sources of information that will be utilised for triangulation include: the participants'
48
49 BFCSI/ BFCRS scores and clinical notes; field notes taken by the research team during direct
50
51 observation and interviews; and participant and relative interviews focusing on response to
52
53 treatment, food insecurity, and the subjective experience of catatonia. Additionally, the mixed
54
55 methods nature of the study will enable the generation of both objective (as documented by
56
57
58
59
60

1
2
3 treating and research teams) and subjective data regarding the experience of catatonia. This
4 type of triangulation is an important tool for meeting the goals of this study while facilitating
5 a holistic assessment of catatonia in this cohort.
6
7
8
9

10 11 12 **The study process and outline**

13
14 Two research assistants (RAs) with a background in health will be recruited to assist
15 the researcher with fieldwork. A health background is necessary to understand the medical
16 terminology that is utilised in the clinical notes and screening tools. A part-time
17 administrative assistant will be contracted to assist with data capturing and collation.
18
19 Fieldwork will include the recruitment of participants and collection of data by the researcher
20 and RAs. There will be a limited follow-up component that extends to up to three months
21 following discharge from the hospital.
22
23
24
25
26
27
28
29
30
31

32
33 The RAs will be trained by the researcher on:

- 34 1) application of the BFCSI and BFCRS to ensure they are knowledgeable about the
35 screening tool and its interpretation, and
36
- 37 2) assessment of capacity to consent utilising the University of California, San Diego
38 Brief Assessment of Capacity to Consent Questionnaire (UBACC).
39

40 The UBACC has been applied successfully in the Eastern and Western Cape in study
41 cohorts recruited from inpatient mental health institutions. [24, 25]
42
43
44

45 The inter-rater reliability (IRR) of the BFCRS was demonstrated to be good ($\alpha=0.779$)
46 in a study looking at four different instruments to assess for catatonia. [26] In the planned
47 study, training that will be provided by the lead researcher to the RAs on the use of the
48 BFCRS/BFCRS will be through:
49
50
51
52
53
54
55
56
57
58
59
60

- explaining the meaning of terms used in the BFCSI/BFCRS to describe clinical signs and symptoms of catatonia and
- providing a demonstration of how to elicit and document the 14-items and 23-items in the BFCSI/BFCRS, how to capture the relevant information accurately onto the data capturing form
- ensuring RAs start with practice participants initially under direct observation of the lead researcher, before starting the actual recruitment. An IRR in the range of ($\alpha=0.61$ to 0.8) during the practice scoring will be deemed acceptable for RAs to proceed to the scoring of study participants.

Inter-rater reliability will also be addressed through ensuring that everyone has a similar understanding of all items to be rated in the screening tool and how these should be recorded.

The researcher and RAs will assess participants who meet the inclusion criteria for capacity to consent, utilising the UBACC. All those with intact capacity to consent will be requested to consider entering the study. For participants who may be assessed as lacking the capacity to consent, their closest relatives or guardians will be requested to consent on their behalf through proxy consent (proxy consent and its ethical application is further discussed in the section 'Ethics and dissemination' below). Additionally, in those assessed to lack capacity to consent, such capacity will be reviewed weekly to allow for further re-engagement on their consent to take part in the study, the ultimate aim being to change from proxy consent to personal consent as soon as potential participants have regained capacity. Data collected about any participant who chooses to withdraw from the study will be removed from the study data sets and destroyed.

1
2
3
4
5
6 The research team will collect data from the clinical files of consenting participants
7
8 on BFCSI/BFCRS scores and additional descriptive and demographic information as guided
9
10 by the study questionnaire and study protocol. The completed data capturing forms will be
11
12 submitted to the administrative assistant for data collation and entry into a spreadsheet at the
13
14 end of each week. The assessment of new admissions will be daily on weekdays with the
15
16 expectation being to conduct daily screening or within the first 48-hours at least. Information
17
18 on clinical presentation of patients admitted over weekends will be supplemented from the
19
20 clinical folders. In cases where the Researcher or RAs identify possible missed catatonia, the
21
22 treating doctor will be provided with any additional information picked up during the
23
24 participants' assessment to allow for a review of the patient's clinical case and management.
25
26
27
28
29

30
31 During the limited follow-up period, the researcher and RAs will repeat the BFCSI
32
33 assessment and conduct face-to-face interviews with participants regarding their experience
34
35 of catatonia at one month, two months, and three months post-discharge. Recurrence of
36
37 symptoms or readmissions since the last discharge will be documented. The participant's
38
39 willingness to continue with the study will be reviewed during every visit to ensure their
40
41 consent remains valid throughout. Figure 2 is a summary of the study process that will be
42
43 followed.
44
45
46
47
48

49 **Setting**

50
51 The setting will be a 35-bed acute mental health unit in Dora Nginza Hospital, a
52
53 general hospital in the Eastern Cape Province in South Africa. The hospital is in Zwide, in the
54
55 iBhayi area of Port Elizabeth which has a population of over one million within an urban
56
57
58
59
60

1
2
3 area that has a high morbidity of mental illness.[27] Close to 70% of the population is
4
5 comprised of working age adults between 15 and 64 years and the city has an unemployment
6
7 rate of close to 30%. [27] Zwide itself has a population of 238 000. [28] Health services in
8
9 the hospital include obstetrics and gynaecology, paediatrics, basic surgical, internal medicine,
10
11 and family medicine. The MHU is an acute inpatient unit offering 24-hour care to persons
12
13 who present with acute mental illness requiring inpatient treatment. It accepts referrals from
14
15 all the other hospital departments including the Accident and Emergency Department, as well
16
17 as referrals from primary care clinics and district hospitals in the nearby vicinity. The usual
18
19 period of admission ranges anything from three days to a few weeks.
20
21
22

23
24 All cases of suspected catatonia, from any of the referring departments are discussed
25
26 with the MHU team and prioritized for admission into the unit. Any treatment given
27
28 thereafter is discussed with the MHU team and documented in the patient's folder.
29
30
31

32 33 **Sampling**

34
35 Convenience sampling of all patients admitted to the MHU over a twelve-month
36
37 period (September 2020 to August 2021) will be undertaken. Contact details of all consenting
38
39 participants who have screened positive for catatonia will be entered into a database to enable
40
41 contact for future follow-up at the end of one month, two months, and three months post-
42
43 discharge. This information will be password encrypted.
44
45

46
47 The number of patients expected to be admitted during the study period is around 1000
48
49 based on previous unit stats over the last three years and adjusted down slightly to
50
51 accommodate the effect of the COVID-19 outbreak on hospital admissions. The margin of
52
53 error or confidence interval will be set at 95% and the standard deviation will be set at 0.05.
54
55 To determine the total sample size required, the formula: $n=N/(1+Ne^2)$ will be utilized and
56
57

1
2
3 yields a minimum sample size of 286 subjects. A further 20% (57) will be added to account
4
5 for data entry errors and non-responses. The appropriate sample size of participants to be
6
7 screened for the prevalence of catatonia in the unit is 343.
8
9

10 **Participants**

11
12 Most people admitted to the DNH MHU are involuntary admissions under the Mental
13
14 Health Care Act of 2002.[29] Age of admission ranges from 13 to over 65 years because
15
16 there are no child, adolescent, or geriatric inpatient-specific services in the region.
17
18
19
20
21

22 **Inclusion criteria**

23
24 All patients admitted to the unit during the study period will be eligible for inclusion.
25
26 Those who screen positive for two or more catatonic signs and symptoms on the BFCSI will
27
28 be included during the follow-up period for the qualitative part of the study.
29
30
31
32

33 **Exclusion criteria**

34
35 Refusal to take part in the study, whether through the direct patient consent process or
36
37 the proxy consent process, will result in the exclusion of the patient.
38
39
40
41

42 **Methods of assessment and measurement**

43
44 The BFCSI is a 14-item scale (see Appendix A) that is used to screen for catatonia
45
46 and the BFCRS is a 21-item scale used to rate severity.[11] The BFCSI is used on initial
47
48 assessment and the full BFCRS is used to determine severity. Participants' responses to the
49
50 standard interventions of intravenous lorazepam administration or ECT will be documented
51
52 by the admitting doctor in the case notes. The research team will then capture this
53
54 information on a predesigned data collection sheet. A 50% reduction in signs and symptoms
55
56
57
58
59
60

1
2
3 in response to the treatment intervention represents a response while a 100% reduction is
4 considered full resolution. When a patient presents with two or more positive items on the
5 BFCRS, they are deemed catatonic and further management is guided by the unit protocol. A
6 lorazepam infusion of 1mg or 2 mg is administered and a response of 50% or greater
7 reduction in the scale score verifies the diagnosis although absence of verification does not
8 exclude catatonia. The research team will capture information on participant's
9 BFCRS/BFCRS scores and other clinical data this information on a predesigned data
10 collection sheet. A 50% reduction in signs and symptoms in response to the treatment
11 intervention represents a response while a 100% reduction is considered full resolution.
12
13
14
15
16
17
18
19
20
21
22
23

24 The clinical data collection that will be collected include current psychiatric
25 diagnosis, co-occurring medical conditions, any other treatment administered, history of
26 substance use, history of previous catatonic episodes, vital signs like temperature on
27 admission, blood pressure, pulse, investigations like creatinine kinase, iron levels, thyroid
28 function teste urea and electrolytes or any other relevant clinical investigations reflected in
29 the file which are noted by the treating team to be of relevance to the current admission., and
30 food insecurity. The participants' case notes will form a primary source of information as
31 well as direct observation of the participants. Additional information will be sought from
32 relatives if the participant is unable to respond adequately to information required on food
33 security questions due to the severity of catatonic symptoms, or in those who are unable to
34 provide the additional information for whatever other reason.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 Regarding social determinants of mental health, current evidence indicates that those
52 who are poor or disadvantaged suffer disproportionately from common mental disorders and
53 their adverse consequences.[30] The strength of the association with poverty has at times
54
55
56
57
58
59
60

1
2
3 varied depending on the type of poverty measure used. Food insecurity as a poverty measure
4 is one of the factors with a consistent and strong association with common mental
5 disorders.[31] In this study, the administration of a food security questionnaire will be
6 utilised to assess the correlation of poverty to catatonia. Two food insecurity questions are
7 drawn from the USDA's 18-question Household Food Security Scale.[32] They make up The
8 Hunger Vital Sign Questionnaire, a validated two-question food insecurity screening tool
9 used in the clinical setting. The questions are:

- 19 1. Within the past 12 months, we worried whether our food would run out
20 before we got money to buy more.
- 21 2. Within the past 12 months, the food we bought just did not last and we did
22 not have money to get more.

23
24
25
26
27
28
29
30
31 During the follow-up period, participants will be asked to describe their experience of
32 the catatonic episode as well as their perception of recovery.

33 34 35 36 37 **Expected outputs**

- 38 • The 12-month prevalence rate of catatonia.
- 39 • Descriptive and other data on presentation and assessment of catatonia in the DNH
40 unit.
- 41 • Data on treatment response, short-term outcomes, and subjective experience of
42 catatonia.
- 43 • Predictors for catatonia based on clinical correlates and other descriptive data
44 collected.
- 45 • Recommendations and guidelines for the management of catatonia and possible

1
2
3 prevention strategies.
4

5 **Data management and analysis**

6
7 Quantitative data collected will be summarised using descriptive statistics.
8

9
10 Categorical variables will be presented using frequency tables, percentages, and graphs. Two
11
12 or more categorical variables will be compared using contingency tables (e.g. 2 X 2 Table)
13
14 and the expected frequencies will be calculated to determine the type of test best suited to
15
16 determine the extent of any identified relative associations. If the expected frequencies in all
17
18 cells are ≥ 5 then the Chi-squared test will be used and if the expected frequencies are < 5 in
19
20 any cells, then the Fisher's exact test will be used.
21
22
23
24
25

26 Binomial logistic regression will also be conducted to determine the predictors of
27
28 catatonia and to estimate the risk ratio. If the numerical data are not normally distributed,
29
30 non-parametric statistics will be used (median and interquartile range). The best fitting model
31
32 of multivariate analysis will be chosen through forward selection of model building. The
33
34 model with the lowest Bayesian information criterion will be selected as the better model and
35
36 the 95% confidence interval will be used to estimate the precision of estimates. Survival
37
38 analysis will be used to determine the time to recovery and the hazard ratio (i.e. the total
39
40 number and timing of each event indicating relapse in this study) will be reported for this
41
42 purpose.
43
44
45
46
47
48

49 Qualitative data collated during the follow-up period will be analysed to elucidate the
50
51 subjective experience of catatonia in this cohort. Aspects of the thematic analysis presented
52
53 by Braun and Clarke [32] will be applied to identify themes. Themes will be identified
54
55 through a framework approach identifying word repetition, local expressions, metaphors and
56
57
58
59
60

1
2
3 similarities, differences, and keywords. A tentative hypothesis and theory regarding the
4 experience of catatonia will be presented based on emergent themes. Data collected during
5 the quantitative and qualitative segments of the study will be analysed separately but
6 compared for congruency of reported information to enhance data integration.
7
8
9
10
11
12
13
14

15 In summary, data integration will be in the form of:

- 16
17 i. converting information gathered from the quantitative aspects of the study into
18 numerical information that can be processed through application of statistical methods
19 to test for correlations and associations.
20
21
22
- 23
24 ii. identifying common themes through field notes taken when interviewing participants
25 during the outpatient stage of the study.
26
27
- 28
29 iii. Assessing congruency between common themes about the subjective experience of
30 catatonia as described by participants and commonly identified presenting symptoms
31 as highlighted in case notes and listed in the data collection sheet. The advantage of
32 this approach is that it strengthens the validity and reliability of the study.
33
34
35
36
37
- 38
39 iv.

40 **Patient and public involvement**

41
42 No formal patient advisory committee was set up. The research was developed after
43 the researchers noted mostly young patients in their mid-30's of less being admitted to the
44 study site with catatonia. Some patients presenting with catatonia wanted to know why some
45 people present with catatonia while others do not and whether there were risk factors that
46 could indicate those who were susceptible. Patients who had recovered from catatonia also
47 seemed to indicate varying experiences of the catatonic state. The observational descriptive
48 nature of the sign was to ensure that data is collected in "real life" terms, such that if the
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 study reveals limitations in the resources for managing catatonia at the site, then the results
4
5 could be used to motivate for proper resourcing of the health facility to improve care of those
6
7 with catatonia.
8
9

10 11 12 **ETHICS AND DISSEMINATION** 13

14
15 Ethics clearance has been granted for the study by the Eastern Cape Department of
16
17 Health Ethics Committee, the Walter Sisulu University Research and Ethics Committee and
18
19 the Nelson Mandela University Human Research Ethics Committee. The study does not have
20
21 any intervention arm.
22
23

24
25
26 All patients admitted to the unit will be presented with an information leaflet on the
27
28 study in English or Xhosa. Consent for inclusion in the study will be obtained from all
29
30 participants who have the capacity to consent, which will be determined through application
31
32 of the UBACC. Proxy consent will be sought from a relative or guardian for all patients who
33
34 lack the capacity to consent or are minors between the ages of 13 and 18 years of age. The
35
36 use of proxy consent in mental health research is applicable for those who lack the capacity to
37
38 consent and the nearest relative or guardian consents on their behalf. It is permissible within
39
40 the mental health care setting due to the challenges with capacity to consent that may exist in
41
42 patients with acute mental illness.[33] Proxy consent ensures that respondents' rights are
43
44 guarded while making it possible to include individuals or groups who may potentially
45
46 benefit from scientific advances gained from research. This approach is also supported by the
47
48 Helsinki Declaration on ethical research which states that 'for a research subject who is
49
50 legally incompetent, physically or mentally incapable of giving consent or is a legally
51
52 incompetent minor, the investigator must obtain informed consent from the legally authorised
53
54
55
56
57
58
59
60

1
2
3 representative in accordance with applicable law'.[34] The Department of Health Guidelines
4
5 on ethics in health research similarly state that persons should not be excluded unfairly based
6
7 on discrimination or disability.[35]
8
9

10
11
12 The Mental Health Care Act (MHCA) of 2002 also makes a reference as to whom
13
14 may be considered an associate of a patient admitted under the Mental Health Care Act: e.g. a
15
16 spouse, next of kin, partner, associate, parent, or guardian.[29] A similar approach will be
17
18 taken for this research. All data will be anonymised and stored under lock and key, with
19
20 access granted to the research team only.
21
22

23 24 25 26 **Dissemination of results**

27
28 The results will be presented at feedback sessions with the Hospital Board, Eastern
29
30 Cape Department of Health and at national and international congresses and may be used to
31
32 compile guidelines on assessment and management of catatonia in the region. They will also
33
34 be compiled as a thesis, which will be submitted for examination for a Ph.D. in Psychology at
35
36 Nelson Mandela University. A research report based on the study results will be submitted to
37
38 peer-reviewed journals to be considered for publication.
39
40
41
42
43
44
45
46

47 **REFERENCES**

- 48
49 1 Fink M, Taylor MA. Catatonia: A Clinician's Guide to Diagnosis and Treatment.
50
51 Cambridge: Cambridge University Press 2003.
52
53 2 Stuivenga M, Morrens M. Prevalence of the catatonic syndrome in an acute inpatient
54
55 sample. *Front Psychiatry* 2014;5:174. doi:[10.3389/fpsy.2014.00174](https://doi.org/10.3389/fpsy.2014.00174)
56
57

- 1
2
3 3 Bush G, Fink M, Petrides G, et al. Catatonia. I. Rating scale and standardized
4
5 examination. *Acta Psychiatr Scand* 1996;93:129-36. doi:10.3389/fpsyt.2014.00174
6
7
- 8 4 Grover S, Ghosh A, Ghormode D. Do patients of delirium have catatonic features? An
9
10 exploratory study. *Psychiatry Clin Neurosci* 2014;68:644-51. doi:[10.1111/pcn.12168](https://doi.org/10.1111/pcn.12168)
11
12
- 13 5 Luchini F, Medda P, Mariani MG, Mauri M, Toni C, Perugi G. Electroconvulsive therapy
14
15 in catatonic patients: efficacy and predictors of response. *World J Psychiatry* 2015;5:182-
16
17 92. doi:[10.5498/wjp.v5.i2.182](https://doi.org/10.5498/wjp.v5.i2.182)
18
19
- 20 6 Fink M, Taylor MA. The many varieties of catatonia. *Eur Arch Psychiatry Clin Neurosci*
21
22 2001;251:I8-I13. doi:10.1007/PL00014200
23
24
- 25 7 Fricchione GL, Cassem NH, Hooberman D, Hobson D. Intravenous lorazepam in
26
27 neuroleptic-induced catatonia. *J Clin Psychopharmacol* 1983;3:338-42.
28
- 29 8 Tandon R, Heckers S, Bustillo J, et al. Catatonia in DSM-5. *Schizophr Res* 2013;150:26-
30
31 30. doi:[10.1016/j.schres.2013.04.034](https://doi.org/10.1016/j.schres.2013.04.034)
32
33
- 34 9 White DA, Robins AH. An analysis of 17 catatonic patients diagnosed with neuroleptic
35
36 malignant syndrome. *CNS Spectr* 2000;5:58-65. doi:[10.1017/S1092852900013419](https://doi.org/10.1017/S1092852900013419)
37
38
- 39 10 Odayar K, Eloff I, Esterhuysen W. Clinical and demographic profile of catatonic patients
40
41 who received electroconvulsive therapy in a South African setting. *S Afr J Psychiatr*
42
43 2018;24:1-5. doi:[10.4102/sajpsychoiatry.v24i0.1100](https://doi.org/10.4102/sajpsychoiatry.v24i0.1100)
44
45
- 46 11 American Psychiatric Association. Diagnostic and Statistical Manual of Mental
47
48 Disorders: DSM- 5. Washington: American Psychiatric Association 2013.
49
- 50 12 Sienaert P, Dhossche DM, Vancampfort D, et al. A clinical review of the treatment of
51
52 catatonia. *Front Psychiatry* 2014;5:181. doi:[10.3389/fpsyt.2014.00181](https://doi.org/10.3389/fpsyt.2014.00181)
53
54
- 55 13 Sienaert P, Rooseleer J, De Fruyt J. Measuring catatonia: a systematic review of rating
56
57 scales. *J Affect Disord* 2011;135:1-9. doi:[10.1016/j.jad.2011.02.012](https://doi.org/10.1016/j.jad.2011.02.012)
58
59

- 1
2
3 14 Wilson J, Niu, K, Nicholson SE, et al. The diagnostic criteria and structure of catatonia.
4
5 *Schizophr Res* 2015;164:256–62. doi:[10.1016/j.schres.2014.12.036](https://doi.org/10.1016/j.schres.2014.12.036)
6
7
8 15 Fink M, Taylor MA. Electroconvulsive therapy: evidence and challenges. *JAMA*
9
10 2007;298:330-332. doi:10.1001/jama.298.3.330
11
12 16 Fink M. What was learned: studies by the consortium for research in ECT (CORE) 1997–
13
14 2011. *Acta Psychiatr Scand* 2014;129:417-26. doi:[10.1111/acps.12251](https://doi.org/10.1111/acps.12251)
15
16
17 17 Petrides G, Fink M, Husain MM, et al. ECT remission rates in psychotic versus
18
19 nonpsychotic depressed patients: a report from CORE. *J ECT* 2001;17:244-53.
20
21
22 18 Rosebush PI, Hildebrand AM, Furlong BG, et al. Catatonic syndrome in a general
23
24 psychiatric inpatient population: frequency, clinical presentation, and response to
25
26 lorazepam. *J Clinical Psychiatry* 1990;51:357-62.
27
28
29 19 Rasmussen SA, Mazurek MF, Rosebush PI. Catatonia: our current understanding of its
30
31 diagnosis, treatment, and pathophysiology. *World J Psychiatry* 2016;6:391–8.
32
33 doi:[10.5498/wjp.v6.i4.391](https://doi.org/10.5498/wjp.v6.i4.391)
34
35
36 20 Northoff G, Krill W, Wenke J, et al. The subjective experience in catatonia: systematic
37
38 study of 24 catatonic patients. *Psychiatr Prax* 1996;23:69-73.
39
40
41 21 Moskowitz AK. “Scared Stiff”: catatonia as an evolutionary-based fear response. *Psychol*
42
43 *Rev* 2004;111:984-1002. doi:10.1037/0033-295X.111.4.984
44
45
46 22 Scotland J. Exploring the philosophical underpinnings of research: relating ontology and
47
48 epistemology to the methodology and methods of the scientific, interpretive, and critical
49
50 research paradigms. *English Language Teaching* 2012;5:9-16
51
52
53 23 Creswell JW. *Research Design: Qualitative and Mixed Methods Approaches*. London:
54
55 Sage 2009.
56
57 24 Campbell MM, Susser E, Mall S, et al. Using iterative learning to improve understanding

- 1
2
3 during the informed consent process in a South African psychiatric genomics study. *PloS*
4
5 *ONE* 2017;12:e0188466. doi:[10.1371/journal.pone.0188466](https://doi.org/10.1371/journal.pone.0188466)
6
7
8 25 Campbell MM, de Vries J, Mqulwana SG, et al. Predictors of consent to cell line creation
9
10 and immortalisation in a South African schizophrenia genomics study. *BMC Med Ethics*
11
12 2018;19:72. doi:10.1186/s12910-018-0313-2
13
14
15 26 Sarkar S, Sakey S, Mathan K, Bharadwaj B, Kattimani S, Rajkumar RP. Assessing
16
17 catatonia using four different instruments: Inter-rater reliability and prevalence in
18
19 inpatient clinical population. *Asian J Psychiatr.* 2016;23:27-31.
20
21
22 doi:10.1016/j.ajp.2016.07.003
23
24 27 Statistics South Africa: Nelson Mandela Bay [Internet]. Republic of South Africa, c2011
25
26 [cited 20 February 2020]. Available from:
27
28 http://www.statssa.gov.za/?page_id=993&id=nelson-mandela-bay-municipality.
29
30
31 28 Statistics South Africa: Statistics South Africa to release the Quarterly Labour Force
32
33 Survey (QLFS), 2nd Quarter 2019 [Internet]. Republic of South Africa [cited 24 August
34
35 2029]. Available from: <http://www.statssa.gov.za/?p=12358>
36
37
38 29 Mental Health Care Act 2002 (Act no. 17 of 2002) General Regulations [Internet].
39
40 Government Gazette, Republic of South Africa, 15 December 2004, No. 27117, c2004
41
42 [cited 17 February 2020]. Available from:
43
44 https://www.gov.za/sites/default/files/gcis_document/201409/a17-02.pdf.
45
46
47 30 World Health Organization. Social determinants of mental health [Internet]. Geneva:
48
49 World Health Organization, c2014 [cited 23 March 2020]. Available from:
50
51 [https://www.who.int/mental_health/publications/gulbenkian_paper_social_determinants](https://www.who.int/mental_health/publications/gulbenkian_paper_social_determinants_of_mental_health/en/)
52
53 [of_mental_health/en/](https://www.who.int/mental_health/publications/gulbenkian_paper_social_determinants_of_mental_health/en/).
54
55
56 31 Lund C, Breen A, Flisher AJ, et al. Poverty and common mental disorders in low-and
57
58
59
60

- 1
2
3 middle-income countries: a systematic review. *Soc Sci Med* 2010;71:517–528.
4
5 doi:[10.1016/j.socscimed.2010.04.027](https://doi.org/10.1016/j.socscimed.2010.04.027)
6
7
8 32 American Academy of Pediatrics. Addressing food insecurity: a toolkit for pediatricians
9
10 [Internet]. c2017 [cited 21 April 2020]. Available from: [https://frac.org/wp-](https://frac.org/wp-content/uploads/frac-aap-toolkit.pdf)
11
12 content/uploads/frac-aap-toolkit.pdf Braun V, Clarke V. Using thematic analysis in
13
14 psychology. *Qual Res Psychol* 2006;3:77-101. doi:10.1191/1478088706qp063oa
15
16
17 33 Mason S, Barrow H, Phillips A, et al. Brief report on the experience of using proxy
18
19 consent for incapacitated adults. *J Med Ethics* 2006;32:61-62.
20
21 doi:10.1136/jme.2005.012302
22
23
24 34 World Medical Association. World Medical Association Declaration of Helsinki. Ethical
25
26 principles for medical research involving human subjects. *Bull World Health Organ*
27
28 2001;79:373-4.
29
30
31 35 Department of Health, Republic of South Africa. Ethics in health research: principles,
32
33 processes and structures, 2nd edition [Internet]. Pretoria: National Department of Health,
34
35 c2015 [cited 23 March 2020__]. Available from:
36
37 <https://www.ru.ac.za/media/rhodesuniversity/content/ethics/documents/nationalguidelines>
38
39 [/DOH_\(2015\)_Ethics_in_health_research_Principles_processes_and_structures.pdf](https://www.ru.ac.za/media/rhodesuniversity/content/ethics/documents/nationalguidelines/DOH_(2015)_Ethics_in_health_research_Principles_processes_and_structures.pdf).
40
41
42
43
44

AUTHOR CONTRIBUTIONS

45
46 Z Zingela conceived the idea and devised the project and its main conceptual ideas assisted
47
48 by S van Wyk and M Fink. L Stroud and J Cronje supervised the development of this
49
50 manuscript and provided editorial input.
51
52
53

FUNDING STATEMENT

1
2
3 This work was supported by the South African Medical Research Council (SAMRC), grant
4 tracking number 2017SAMRC0SIR0000157977 and an educational grant from the Health
5 and Welfare Sector Education and Training Authority (2018/2019HWSETA219986789).
6
7
8
9
10
11

12 **COMPETING INTERESTS STATEMENT**

13
14 The authors have no competing interests to declare.
15
16
17
18

19 Figure 1

20
21 Assessment Tools
22
23
24
25

26 Figure 2

27
28 The Study Process
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1: Assessment Tools





Figure 2: Study Process



APPENDICES

APPENDIX 1: DATA COLLECTION SHEET

Enrolment No:	Tick applicable box or insert answer in area shaded in white														
Unit	Is the Patient Catatonic now? (Fill in the BFCRS item 1 to 14 to answer this question), 2 or more signs mean Yes, there is catatonia														
DNH	If No then tick this box and fill in ONLY Sections A,G,H,I, and J							If Yes then tick this box and fill in sections A, B, C, D, E, F, G, H, I, and J.							
A. Age				Sex		Ethnicity				1st admission	Catatonic symptoms before?	Provisional DSM -5 Diagnosis in file?	Substance Use?	Another medical conditions	
< 16	6 - 36	>		F	M (1)						Yes	Yes	Yes	Yes	Yes
	35 - 65			(0)		B	C	I	W	No	No	Diagnosis	No	No	
		65												
														
											No	No			
										No of previous admissions	No of times had catatonia previously	No of previous diagnoses?		No of medical conditions?	
										Not known	Not known	Not known	Not known	Not known	
B.				BZD or		Blood Pressure				Pulse	Body	Respiratory	Name of BZD		

BFCR Scale Score	LRZ	Systolic:	Diastolic:		Temp	Rate/ O2	given:
	Dose:	<120	<70	<70	<35	Sats	Lorazepam
	1-2mg	120 -139	80 -90	71-100	35 -37	<90%	Clonazepam
	2-4 mg	140 – 180	91-110	101-120	38 – 40	91 – 93	Diazepam
	>4 mg	181 – 220	110-120	121-160	>40	94 – 96	Midazolam
	No of dose/s	>220		>160		97 – 99	Dose.....
	1 -2		>120			100	Other Treatment?
	3 - 4					
	5 or more						
Initial Score	1st dose	2nd dose		3rd dose		4th dose	5th dose
<6	<6	<6		<6		<6	<6
6-12	6-12	6-12		6-12		6-12	6-12
12-24	12-24	12-24		12-24		12-24	12-24
24-36	24-36	24-36		24-36		24-36	24-36
>36	>36	>36		>36		>36	>36

C. Length of time and degree of response to BZD	1 st hour after admission	2-3 days		4-6 days	Degree of Response	
					Mild = Less than 25% reduction in No. of symptoms	
	2 to 6 hours after admission	7-10 days	11-14 days	>14 days	Moderate = 25% to 50% reduction in No. of symptoms	
	7 to 47 hours after admission	Reason ECT was not given after the 1 st 3 days of admission (from clinical notes)			Good = Response of more than 50% reduction in No. of symptoms	
					Response to BZD not sustained	
D. ECT and response	Yes	Number of Sessions	Response		Response to ECT not sustained	
		<4	Nil		Maintenance ECT prescribed or required?	
		5-9	Remission of catatonia			
	10-12	Other (specify).....				
No	>12	Time to 50% improvement	Time to full Resolution	Yes, prescribed?	No, not prescribed	
		<3 days	<3 days	If so what is the No. of sessions?		
		4-7 days	4-7 days			
		>1 week	>1 week			
E. Duration of Catatonia prior to admission if known OR Not Known	Hours to 3 days	Duration of Catatonia Prior to admission?	Any other additional information?			
	4 days to 2 weeks		NOT known OR			
	3 to 4 weeks		< 3 days			
	More than 4 weeks		4 to 7 days			
		>7 days				
F. Type of onset	Hours to days	Gradual	Fluctuating	Mostly Excited Form?		Mostly Slowed Form?

				Excited/ Stereotypy/ Mannerism	Stupor/ Withdrawal/ Rigidity/ Mutism/ Staring			
G.	1. Within the past 12 months, we worried whether our food would run out before we got money to buy more.							
Food Insecurity	Often True	Sometimes true	Never true	Don't know	Other			
	2. Within the past 12 months, the food we bought just didn't last and we didn't have money to get more.							
	Often true	Sometimes true	Never true	Don't know	Other			
H.		YES	NO	Alcohol	Cannabis	Amphet	Heroin	Metamphet
Substances				Cocaine	Opioids	Nicotine	Other (Specify)	

I. Medical Illness	No	Yes	If Yes, chose from the following if on history only		If Yes, choose from the following if current		If HIV			
			HPT	DM	HPT	DM	On HAART?	No		
			Epilepsy	HIV	Epilepsy	HIV	If HIV on HAART, Regime?	If HIV, CD4?		
			Head Trauma	TB	Head Trauma	TB	If HIV, Viral Load?	Other (specify)		
			SLE or Auto/I	Other (specify)		Other (specify)				
J. Investigations:	CK (u/l)		CK ≤ 200	Fe μmol/l	Fe 9 to 30	VitB12 pmol/l	B12 ≤ 107		Auto/I Screen	
	CK		CK	Fe	Fe	B12	B12	RF	ESR	ANA
	201 - 1000		≥ 1000	≤ 9	≥ 30	108 - 221	≥ 221	< 14IU/ml OR > 14IU/ml	< 29	Pos
									OR	OR
									> 29	Neg
Endocrine		TSH miu/l	≤ 0.38	≥ 5.33	Cortisol	≤ 184		≥ 618		
Rheumatoid Factor		Normal TSH	0.38 to 5.33		Normal (AM)	185 to 617				
		T4 pmol/l	≤ 7.2	≥ 16.4	Cortisol (PM)	≤ 276 (pm)		≥ 276		
		Normal T4	7.2 to 16.4		≤ 276					

END OF INPATIENT DATA CAPTURING SECTIONS

BEGINNING OF OUTPATIENT FOLLOW UP SECTION FIR PATIENTS WHO HAD CATATONIA

K. Follow-up Period ONLY	Date of Discharge	1 month	2 months	3months	Other
Please tick the applicable box	Recurrence of Catatonia? Yes No	Recurrence of Catatonia? Yes No	Recurrence of Catatonia? Yes No	Other?	
Please describe (in your own words) your experience/ of the catatonic episode in terms of your thoughts, feelings and behaviour	Uyacelwa uchaze (ngawakho amazwi) ngamava akho ngexesha ubune catatonia ngokwengcing a zakho, indlela obuziva ngayo nezinto obuzenza.	PARTICIPANT RESPONSE RECORDED VERBATUM (USE AUDIO RECORDER) Thoughts Feelings Behaviour			

APPENDIX 2: INFORMED CONSENT FORM INFORMED CONSENT – ENGLISH

INFORMED CONSENT FOR A STUDY ON CATATONIA

Dear Participant or Relative

We are requesting your consent to enroll you in a study on catatonia and how the symptoms respond to the treatment you are going to be given.

YES, I AGREE TO BE ENROLLED

I
 agree in **voluntarily** taking part in the study as explained to me by the doctor/ nurse

OR

(In cases where the patient is incapable of giving consent but is not opposed to taking part in the study, then a relative or custodian may provide informed consent by also signing below)

I being the..... of
 **willingly** agree that he/she may take part in the study which has been explained to us by the doctor/ nurse

Signature of participant/relative/ custodian:

.....

Signed by at.....on the
 of..... 2019

NO, I DO NOT AGREE TO BE ENROLLED

I

do not agree in taking part in the study as explained to me by the doctor/ nurse OR

I being the..... of
 do not agree that he/she may take part in the study which has been
 explained to us by the doctor/ nurse

Signature of **participant/relative/** **custodian:**

.....

FOR OFFICE USE ONLY: ASSESSMENT OF CAPACITY TO CONSENT BASED ON UBACC

<i>Does the patient....</i>		
	<i>Yes</i>	<i>No</i>
1. <i>Understand the information relevant to the decision?</i>
2. <i>Retain the information long enough to consider it?</i>
3. <i>Weigh the information as part of the decision-making process?</i>
4. <i>Communicate their decision in some way?</i>

Please Note: Should there be a no answer to any of the 4 questions above then the patient lacks capacity to consent and a relative or custodian may then be requested to provide informed consent.

1
2
3
4 **INFORMED CONSENT - ISIXHOSA**
5
6

7 **IPHEPHA-MVUME LOPHANDO NGESIGULO SE-CATATONIA**
8
9

10
11 *Mthathi-nxaxheba obekekileyo okanye Mzali okanye sizalwane esibekileyo*
12
13

14 Sicela imvume yakho yokuphanda nzulu ngeempawu zesi sigulo i-catatonia, nokuba unyango
15 ozakulufumana luzakusebenzela njani na.
16

17 Ndiye ndanikwa iphepha elichaza ngolu phando kwaye ndiluchazelwe ngu
18
19

20
21
22
23
24
25 **EWE NDIYAVUMA**
26

27
28 Mna (faka igama lakho apha)
29 ndiyazikhethela ukulungenela olu phando ndiluchazelwe ngugqirha okanye umongikazi, kwaye
30 andinyanzeliswanga.
31
32

33 **OKANYE**
34
35

36
37 Ukuba umntu akakwazi ukunika imvume ngasizathu sithile, kodwa abe engali ukulungenela
38 uphando, kungatyikitya umzali okanye isizalwane
39

40 Isayinwe ngu..... e..... ngomhla we.....
41
42 kwinyanga ye.....ku 2019
43
44

45 **HAYI NDIKHETHA UKUNGALUNGENELI OLU PHANDO**
46

47 Mna (faka igama lakho apha) ndikhetha ukuba ndingalungeni olu phando
48 ndiluchazelwe ngugqirha okanye umongikazi
49

50 Mna ndingu.....(Chaza uhlobene njani nomthathi-nxaxheba)
51 ka.....(igama lomthathi nxaxheba)
52
53
54
55
56
57
58
59
60

1
2
3
4 Isaynwe e..... ngomhla we..... kwinyanga ye.....ku
5 2019

6
7 Utyikitya apha wena okanye umzali okanye isizalwane
8
9

12 APPENDIX 3: INFORMATION LEAFLETS IN ENGLISH AND XHOSA

14 3.1 - INFORMATION LEAFLET (XHOSA)

17 **Iphepha lokwazisa umthathi-nxaxheba kuphando lwesigulo i-Catatonia**

18 Mthathi-nxaxheba obekekileyo okanye Mzali okanye sizalwane esibekekileyo

19 Ngale ncwadi sikwazisa malunga ngophando nzulu oluqhutywa ziinzululwazi ezifuna ukufunda nzulu
20 ngesigulo ekuthiwa yi-catatonia kweli ziko lempilo. Unyango obuhleli uzakulufumna alusayi kutshintsha
21 okanye luphazamiseke wakuthatha inxaxheba kolu phando.

27 **Yintoni i-catatonia?**

28 I-catatonia le sisigulo esiye sibangele ukuphazamiseka kwindlela umntu ashukuma ngayo apha emzimbeni.
29 Kwabanye abantu sibangela ukuba umzimba lo ucothe kakhulu okanye ungakwazi kushuma, umntu azive
30 eqinile, athi nokuba uyafuna ukushumisa umzimba wakhe njengesiqhelo angakwazi. Ide ibangele loo nto
31 ngelinye ixesha ukuba umntu aphelele ehleli ndawoninye okanye emile ndawoninye de kugqithe imizuzu
32 emininzi okanye iiyure zibe liqela. Iyakwazi nokubangela ukuba umntu angakwazi ukuphuma
33 kwasebhedini, angakwazi kuzityisa, angakwazi kuzihlamba, asoloko elele ebhedini okanye ehleli
34 esitulweni.

35 Kwelinye icala i-catatonia iyakwazi ukubangela ukuba umntu athi ngoku sele eqalile ukushukuma esithi
36 wenza into ethile, suka umzimba lo uqine, aphelele amalungu omzimba afana neengalo, izandla, imilenze
37 okanye iinyawo zilenga emoyeni angakwazi ukuyigqibezela laa nthsukumo ebeyiqalile. Intamo nentloko
38 nazo ziyakwazi ukuphetha zikekele ngenxa yoku kuqina komzimba kuvela ngesiquphe.

39 Okokugqibela, i-catatonia iyakwazi ukuphinda ibangele intshukumo engaphaya kunesiqhelo, aphelele
40 umntu eshuku-shukuma kakhulu, angahlali ndawonye okanye angazinzi. Abanye baye bazule ndawoninye,
41 abanye baqhwabe izandla unomphelo okanye banqwale kungenjalo baninike intloko into engapheliyo.
42 Iyakwazi nokubela ngokuba omnye umntu abetha-bethe amanqindi emoyeni, omnye athi nokuba
43 usebhedini kube ngathi unyomfa ibhaysikili into engapheliyo. Babakhona nabaphetha bethetha into enye,
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

okanye benze isikhalo esiphindaphindwayo okanye nayiphina intsholo abaye bayiqhube imizuzu emininzi okanye iiyure zide zibe liqela. Bakhona ke nabanye abaye balinganise loo nto ithethwa ngumntu ophambi kwabo kungenjalo balinganisa loo nto bayibona isenziwa ngumntu ophambi kwabo.

Ibangelwa yintoni i-catatonia?

I-catatonia iyakwazi ukubangelwa zizigulo ezithile zengqondo kungenjalo nezinye izigulo zomzimba ziyakwazi ukuhamba ne-catatonia. Ingxaki esiye siyifumane thina boogqirha neenzululwazi kukungazi xa siqala ukumbona umntu onale catatonia ukuba ingaba eyakhe ibangelwa sisigulo sengqondo na okanye sesomzimba kusini na. Yiloo tno side sabona ukuba kungakuhle ukuba sinokuyiphonononga nzulu le ngxaki.

Luqulethe ntoni olu phando?

Sijonge ekubeni wonke umntu oze kulaliswa kweli candelo, ahlolwe, kukhangelwe ukuba akahlaselwanga ziimpawu ezithile zale-catatonia kusini na. Wothi uhlolwe ngugqirha wakho ebehleli ezakuhlola kakade. Ukuba zikhona iimpawu ezithile ugqirha acinga ukuba uziqaphele apha kuwe, usenakho ukubuza ngazo umzekelo mhlawumbi ukuba ziqale nini, njani, kwaye ingaba uyaqala ukuba nazo na njalonzalo. Uzakube phofu ebhala loo nto umxelela yona. Apha ekubhaleni kwakhe kodwa akazokulibhala igama lakho nokuba ungubani kwaye uhlala phi. Oku kuhlolwa nokubuzwa nge-catatonia kungathatha imizuzu emihlanu ukuya kweli shumi kuphela. Ulwazi esiluloqokelelayo ngawe kukuba nje iimpawu zesi sigulo unazo na kwaye nale mibuzo sesiyikhakanyile kuphela.

Zimbini izinto esifuna ukuziqwalasela kolu phando nge-catatonia:

1. Ingaba bangaphi abantu abafunyanwa sesi sigulo kule ngingqi?

2. Ingaba zikhona izinto ezingunobangela wokuba abanye abantu bafunyanwe sesi sigulo abanye basinde, mhlawumbi njengobubudala bomntu, isini okanye ezinye izigulo zomzimba?

Nayiphi na into esinokuyifunda eyongezelela kulwazi esele sinalo ngesi-sigulo ingasinceda kakhulu ekubeni sikwazi ukusinyanga ngcono kwixa elizayo. Ngako oko ubukho bakho nokuthatha kwakho inxaxheba kolu phando kuya kunceda abantu abaninzi abanokuthi bafunyanwe sesi sigulo.

Alukho olunye uvavanyo oza kulwenza oludibene nolu phando. Naluphi na olunye uvavanyo okanye unyango ozakuthi ulufumane emva kokuba umongikazi okanye ugqirha egqibile ukukuhlola, lunyango lwesiqhelo obuhleli uzakulufumana kakade kugirha wakho.

1
2
3
4
5
6 **Ukuba ndifunyaniswe ndinazo imipawu ze-catatonia loo nto ithetha ukuthini?**

7 Ukuba ufunyaniswe unazo ezinye zezi mpawu ze-catatonia, ugqira wakho wokunika unyango lakho
8 lwesiqhelo okanye enze uvavanyo ebehleli ezakulwenzela kakade olunxulumene nempilo yakho.
9
10
11

12
13 **Kuza kwenziwa ntoni ngeziphumo zolu phando?**

14 Iziphumo zolu phando zizakudityaniswa zibhalwe kufndiswe abanye oogqirha neenzululwazi malunga nesi
15 sigulo, kwiinkomfa zoogqirha neenzululwazi.
16
17
18

19
20 **Ndithini ukuba ndinemibuzo?**

21 Ukuba unemibuzo ngolu phando, cela ukuthetha nogqirha wakho okanye umongikazi ozakube encedisa
22 kolu phando.
23
24
25

26
27 **Siyabulela!**

28 Sibulela kakhulu ngexesha lakho nokuzixhesha kwakho ngolu phando.
29
30

31
32 **3.2 - INFORMATION LEAFLET (ENGLISH)**

33
34
35 **Information Leaflet about a Study of Catatonia**
36
37
38
39

40 Dear Participant / Parent/ Relative
41
42
43

44 This leaflet is provided to inform you about a study being conducted by researchers who would like to
45 investigate a condition called catatonia at his health facility. The usual care you were going to get will not
46 be changed or disturbed through taking part in this study.
47
48
49

50
51 **What is catatonia?**

52 Catatonia is a condition that affects the way a person moves his whole body or body parts. In some people
53 it slows down the body considerably to the point where some will stop moving completely, causing the
54 person to feel very stiff such that they are unable to move even when they want to. This may lead to a
55
56
57
58
59
60

1
2
3
4 person remaining in one position for a very long time (whether sitting or standing) to the point of many
5 minutes or even hours. It can even cause some people to be bedridden, unable to feed themselves, or wash
6 or attend to other daily needs.
7
8

9
10
11 Catatonia can also cause a person to appear frozen even after initiating a particular action, resulting in body
12 parts like legs, arms hands or feet being frozen in awkward or unusual looking positions. The head and or
13 neck may also be tilted at awkward angles. The change in movement can often occur suddenly.
14
15

16
17
18 Lastly catatonia can also cause an abnormality of excessive movement which is more than normal. A
19 person may show excessive movement that lasts up to many minutes or hours with a seeming inability to
20 stay still. Some people may pace up and down, others may clap or wave for long periods lasting minutes to
21 hours, while others may show head nodding, head shaking, grimacing, etc. Some people have been seen to
22 do shadow boxing or cycling movements even when lying down. It may also appear as repetitive speech of
23 the same phrase, a cry or shout or other odd sound that can last for hours. Others may repeat what they hear
24 around them non- stop or they may mimic actions of those around them as well.
25
26
27
28
29

30 **What causes catatonia?**

31
32
33 Catatonia may be seen with a number of mental illnesses but it can also be associated with some other
34 medical conditions. The problem we run into as doctors is when a person presents with the first time with
35 this syndrome it may be difficult in the beginning to know what the underlying cause is i.e. whether the
36 cause is a mental condition or another medical condition. This is why conducting research on catatonia is
37 so important.
38
39
40
41
42

43 **What does this research involve?**

44
45 We are looking at ensuring that everybody who is admitted into this unit s examined and screened for
46 symptoms and signs of catatonia. Your admitting doctor will examine you as usual, which will include an
47 initial screen for catatonia through examination only. Following this, a trained research assistant who is a
48 nurse will proceed to do a full screen using a rating scale, to ensure that no other signs of catatonia were
49 missed. If there search assistant finds any additional signs of catatonia, they will tell your treating doctor. In
50 addition, the nurse may ask you questions like when did the symptoms start and how fast did they appear
51 etc. She or he will note down you answers but will not include details like your name or your address which
52
53
54
55
56
57
58
59
60

1
2
3
4 can identify who you are. This further screening by the nurse not expected to take longer than 5 to 10
5 minutes. The information to be collected for the study about your condition is about the signs and
6 symptoms and the few questions already mentioned to do with the illness, nothing more. There are two
7 questions we would like to investigate about catatonia:
8
9

10
11 1. How many people experience this condition in this area?
12

13
14 2. Are there particular characteristics that make some people more prone to it and others less
15 vulnerable to it like age, gender or other medical conditions?
16

17 Whatever we can learn about this condition, over and above what we know already will help us to come up
18 with improved ways to diagnose it and to treat it in future. Taking part in this research will therefore help
19 many people in future who may also get this illness.
20
21
22

23
24 There are no other tests you will be expected to take part in for this study. Whatever other tests or treatment
25 interventions that follow will be those that your doctor would have undertaken anyway to help you manage
26 your condition and get you better.
27
28
29

30
31 **If I am found to show some of the symptoms or signs of catatonia what does that mean?**
32

33
34
35 If you are found to have some signs and symptoms of catatonia, the research nurse will inform your treating
36 doctor, so that your doctor can give you the appropriate and usual treatment for your condition. Your doctor
37 may also decide to do more tests which would be what they would have done anyway even if you were not
38 part of the study, in order to manage your condition.
39
40
41

42
43 **What will be done with the results of the study?**
44

45 The results of the study will be collected and put together to present to scientific congresses so that other
46 doctors and scientists can learn from them.
47
48
49

50
51 **What should I do if I have more questions?**
52

53 If you have more questions, ask your treating doctor or the researcher, research assistant or nurse.
54
55

56 **Thank you! Thank you very much for your patience and for spending the few minutes on this study.**
57
58
59
60

APPENDIX 4: INSTITUTIONAL PERMISSIONS –DORA NGINZA HOSPITAL



Province of
EASTERN CAPE
HEALTH

DORA NGINZA REGIONAL HOSPITAL

DEPARTMENT OF PSYCHIATRY & MENTAL HEALTH UNIT
Spence Street - Zinda - Fort Elizabeth - 6205
Private Bag X 11851 - Fort Elizabeth - 6005
Telephone +27 41 405 4350 - Fax +27 41 405 4057

DEPARTMENT OF PSYCHIATRY REQUEST FOR CEO APPROVAL OF DEPARTMENTAL RESEARCH

To	Mr P Tsibolane Chief Executive Officer Dora Nginza Hospital
From	Dr A Bronkhorst, Prof S van Wyk and Prof Z Zingela Department of Psychiatry
Subject	DEPARTMENT OF PSYCHIATRY REQUEST FOR CEO APPROVAL OF DEPARTMENTAL RESEARCH
Date	08 November 2018

Introduction

The Department of Psychiatry and Walter Sisulu University have identified research projects in catatonia as a priority for the Eastern Cape due to the severity of the illness and the potentially negative outcomes resulting from delay in recognition of the cognition

Requested support

CEO approval and support for the research project on Catatonia: "Catatonia as a manifestation of serious mental illness: prevalence, presentation, management and outcomes in a mental health unit", is hereby requested on behalf of the investigators to initiate this study in the Department of Psychiatry in Dora Nginza Hospital.

Conclusion

This project is also expected to yield support for other ongoing and planned registrar research projects on Catatonia. Thank you for considering this request.

A Bronkhorst

S van Wyk

Z Zingela

The request for approval is hereby **granted** / not granted (please delete as appropriate)

Signature: Designation: CEO Date: 08.11.18

Name: M. P. TSIBOLANE

Dora Nginza Regional Hospital
Chief Executive Officer
Mr M.P. Tsibolane

Signature:
Date:

APPENDIX 5: INSTITUTIONAL PERMISSIONS

APPROVAL FROM EC HEALTH RESEARCH COMMITTEE

APPENDIX VI



Eastern Cape Department of Health

Enquiries: Madoda Xokwe
 Date: 19 December 2017
 e-mail address: madoda.xokwe@echealth.gov.za

Tel No: 040 808 0710
 Fax No: 043 642 1409

Dear Prof. Z. Zingela

Re: Catatonia As A Presentation For Severe Mental Illness: Prevalence Of Catatonia In Two Mental Health Units In Urban And Rural South Africa (EC_201712_015)

The Department of Health would like to inform you that your application for conducting a research on the abovementioned topic has been approved based on the following conditions:

1. During your study, you will follow the submitted protocol with ethical approval and can only deviate from it after having a written approval from the Department of Health in writing.
2. You are advised to ensure, observe and respect the rights and culture of your research participants and maintain confidentiality of their identities and shall remove or not collect any information which can be used to link the participants.
3. The Department of Health expects you to provide a progress on your study every 3 months (from date you received this letter) in writing.
4. At the end of your study, you will be expected to send a full written report with your findings and implementable recommendations to the Epidemiological Research & Surveillance Management. You may be invited to the department to come and present your research findings with your implementable recommendations.
5. Your results on the Eastern Cape will not be presented anywhere unless you have shared them with the Department of Health as indicated above.

Your compliance in this regard will be highly appreciated.

SECRETARIAT: EASTERN CAPE HEALTH RESEARCH COMMITTEE



Ikawa siqamketyo!

APPENDIX 6:

CATATONIA RATING SCALE

APPENDIX VII

BUSH-FRANCIS CATATONIA RATING SCALE

Use presence or absence of items 1-14 for screening
Use the 0-3 scale for items 1-23 to rate severity

<p>1. Excitement:</p> <p>Extreme hyperactivity, constant motor unrest which is apparently non-purposeful. Not to be attributed to akathisia or goal directed agitation</p> <p>0 = Absent 1 = Excessive motion 2 = Constant motion, hyperkinetic without rest periods 3 = Full-blown catatonic excitement, endless frenzied motor activity</p>	<p>2. Immobility/stupor:</p> <p>Extreme hypoactivity, immobile, minimally responsive to stimuli</p> <p>0 = Absent 1 = Sits abnormally still, may interact briefly 2 = Virtually no interaction with external world 3 = Stuporous, non-reactive to painful stimuli</p>
<p>3. Mutism:</p> <p>Verbally unresponsive or minimally responsive</p> <p>0 = Absent 1 = Verbally unresponsive to majority of questions; incomprehensible whisper 2 = Speaks less than 20 words/ 5 min 3 = No speech</p>	<p>4. Staring:</p> <p>Fixed gaze, little or no visual scanning of environment, decreased blinking.</p> <p>0 = Absent 1 = Poor eye contact, repeatedly gazes less than 20 seconds between shifting of attention; decreased blinking 2 = Gaze held longer than 20 seconds, occasionally shifts attention 3 = Fixed gaze, non-reactive</p>
<p>5. Posturing/catalepsy:</p> <p>Spontaneous maintenance of posture(s), including mundane (e.g. setting or standing for long periods without reacting).</p> <p>0 = Absent 1 = Less than 1 minute 2 = Greater than one minute, less than 15 minutes 3 = Bizarre posture, or mundane maintained more than 15 minutes</p>	<p>6. Grimacing:</p> <p>Maintenance of odd facial expressions.</p> <p>0 = Absent 1 = Less than 10 seconds 2 = Less than 1 minute 3 = Bizarre expression(s) or maintained more than 1 minute</p>
<p>7. Echopraxia/echolalia:</p> <p>Mimicking of examiner's movements/speech.</p> <p>0 = Mimicking of examiner's movements/speech 1 = Occasional 2 = Frequent 3 = Constant</p>	<p>8. Stereotypy:</p> <p>Repetitive, non-goal-directed motor activity (e.g. finger-play, repeatedly touching, patting or rubbing self); abnormality not inherent in act but in frequency.</p> <p>0 = Absent 1 = Occasional 2 = Frequent 3 = Constant</p>
<p>9. Mannerisms:</p> <p>Odd, purposeful movements (hopping or walking tiptoe, saluting passers-by or exaggerated caricatures of mundane movements); abnormality inherent in act itself.</p> <p>0 = Absent 1 = Occasional 2 = Frequent 3 = Constant</p>	<p>10. Verbigeration:</p> <p>Repetition of phrases or sentences (like a scratched record).</p> <p>0 = Absent 1 = Occasional 2 = Frequent 3 = Constant</p>
<p>11. Rigidity:</p> <p>Maintenance of a rigid position despite efforts to be moved, exclude if cog-wheeling or tremor present.</p> <p>0 = Absent 1 = Mild resistance 2 = Moderate 3 = Severe, cannot be repositioned</p>	<p>12. Negativism:</p> <p>Apparently motiveless resistance to instructions or attempts to move/examine patient. Contrary behavior, does exact opposite of instruction</p> <p>0 = Absent 1 = Mild resistance and/or occasionally contrary 2 = Moderate resistance and/or frequently contrary 3 = Severe resistance and/or continually contrary</p>
<p>13. Waxy Flexibility:</p> <p>During repositioning of patient, patient offers initial resistance before allowing himself to be repositioned, similar to that of a bending candle.</p> <p>0 = Absent 3 = Present</p>	<p>14. Withdrawal:</p> <p>Refusal to eat, drink and/or make eye contact.</p> <p>0 = Absent 1 = Minimal PO intake/interaction for less than 1 day 2 = Minimal PO intake/interaction for more than 1 day 3 = No PO intake/interaction for 1 day or more.</p>

BUSH-FRANCIS CATATONIA RATING SCALE (CONT.)

<p>15. Impulsivity:</p> <p>Patient suddenly engages in inappropriate behavior (e.g. runs down hallway, starts screaming or takes off clothes) without provocation. Afterwards can give no, or only a facile explanation.</p> <p>0 = Absent 1 = Occasional 2 = Frequent 3 = Constant or not redirectable</p>	<p>16. Automatic obedience:</p> <p>Exaggerated cooperation with examiner's request or spontaneous continuation of movement requested.</p> <p>0 = Absent 1 = Occasional 2 = Frequent 3 = Constant</p>
<p>17. Mitgehen:</p> <p>"Anglepoise lamp" arm raising in response to light pressure of finger, despite instruction to the contrary.</p> <p>0 = Absent 3 = Present</p>	<p>18. Gegenhalten:</p> <p>Resistance to passive movement which is proportional to strength of the stimulus, appears automatic rather than willful.</p> <p>0 = Absent 3 = Present</p>
<p>19. Ambitendency:</p> <p>Patient appears motorically "stuck" in indecisive, hesitant movement.</p> <p>0 = Absent 3 = Present</p>	<p>20. Grasp reflex:</p> <p>Per neurological exam</p> <p>0 = Absent 3 = Present</p>
<p>21. Perseveration:</p> <p>Repeatedly returns to same topic or persists with movement.</p> <p>0 = Absent 3 = Present</p>	<p>22. Combative:</p> <p>Usually in an undirected manner, with no, or only a facile explanation afterwards.</p> <p>0 = Absent 1 = Occasionally strikes out, low potential for injury 2 = Frequently strikes out, moderate potential for injury 3 = Serious danger to others</p>
<p>23. Autonomic abnormality:</p> <p>Circle: temperature, BP, pulse, respiratory rate, diaphoresis.</p> <p>0 = Absent 1 = Abnormality of one parameter [excluding pre-existing hypertension] 2 = Abnormality of two parameters 3 = Abnormality of three or more parameters</p>	<p>TOTAL: _____</p>

Review only

APPENDIX 7:

ETHICS APPROVAL



PO Box 77000, Nelson Mandela University, Port Elizabeth, 6031, South Africa mandela.ac.za

Chairperson: Research Ethics Committee (Human)
Tel: +27 (0)41 504 2347
shariene.govender@mandela.ac.za

NHREC registration nr: REC-042508-025

Ref: [H20-HEA-PSY-002] / Approval]

18 August 2020

Prof L Stroud
Faculty: Health Sciences

Dear Prof Stroud

CATATONIA AS A MANIFESTATION OF SERIOUS MENTAL ILLNESS: PREVALENCE, PRESENTATION, MANAGEMENT AND OUTCOMES OF CATATONIA IN A MENTAL HEALTH UNIT

PRP: Prof L Stroud
PI: Dr Z Zingela

Your above-entitled application served at the Research Ethics Committee (Human) (meeting of 29 July 2020 2020) for approval. The study is classified as a high risk study. The ethics clearance reference number is H20-HEA-PSY-002 and approval is subject to the following conditions:

1. The immediate completion and return of the attached acknowledgement to Imtiaz.Khan@mandela.ac.za, the date of receipt of such returned acknowledgement determining the final date of approval for the study where after data collection may commence.
2. Approval for data collection is for 1 calendar year from date of receipt of above mentioned acknowledgement.
3. The submission of an annual progress report by the PRP on the data collection activities of the study (form RECH-004 available on Research Ethics Committee (Human) portal) by 15 November this year for studies approved/extended in the period October of the previous year up to and including September of this year, or 15 November next year for studies approved/extended after September this year.
4. In the event of a requirement to extend the period of data collection (i.e. for a period in excess of 1 calendar year from date of approval), completion of an extension request is required (form RECH-005 available on Research Ethics Committee (Human) portal)
5. In the event of any changes made to the study (excluding extension of the study), completion of an amendments form is required (form RECH-006 available on Research Ethics Committee (Human) portal).
6. Immediate submission (and possible discontinuation of the study in the case of serious events) of the relevant report to RECH (form RECH-007 available on Research Ethics Committee (Human) portal) in the event of any unanticipated problems, serious incidents or adverse events observed during the course of the study.
7. Immediate submission of a Study Termination Report to RECH (form RECH-008 available on Research Ethics Committee (Human) portal) upon expected or unexpected closure/termination of study.
8. Immediate submission of a Study Exception Report of RECH (form RECH-009 available on Research Ethics Committee (Human) portal) in the event of any study deviations, violations and/or exceptions.
9. Acknowledgement that the study could be subjected to passive and/or active monitoring without prior notice at the discretion of Research Ethics Committee (Human).


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

2

Please quote the ethics clearance reference number in all correspondence and enquiries related to the study. For speedy processing of email queries (to be directed to Imtiaz.Khan@mandela.ac.za), it is recommended that the ethics clearance reference number together with an indication of the query appear in the subject line of the email.

We wish you well with the study.

Yours sincerely



Dr S Govender
Chairperson: Research Ethics Committee (Human)

Cc: Department of Research Development
Faculty Manager: Health Sciences

[Appendix 1: Acknowledgement of conditions for ethical approval](#)

Peer review only



FACULTY OF HEALTH SCIENCES
POSTGRADUATE EDUCATION, TRAINING, RESEARCH AND ETHICS UNIT

**HUMAN RESEARCH COMMITTEE
CLEARANCE CERTIFICATE**

PROTOCOL NUMBER : 067/2017

PROJECT : PREVALENCE OF CATATONIA IN TWO MENTAL HEALTH UNITS IN URBAN AND RURAL SOUTH AFRICA

INVESTIGATOR(S) : PROF Z ZINGELA

DEPARTMENT : PSYCHIATRY & BEHAVIOURAL SCIENCES

DECISION OF THE COMMITTEE : APPROVED

DATE OF APPROVAL : 07 MAY 2020

DURATION : 1 YEAR (07 MAY 2020 – 07 MAY 2021)

CONDITIONS : NONE

N.B You are required to provide the committee with a progress or outcome report of the research after every 6 months. The committee expects a report on any changes in the protocol as well as any untoward events that may occur at any time during the study not later than 7 days of knowing as the investigator/s.

WALTER SISULU UNIVERSITY
ACADEMIC HEALTH SERVICE COMPLEX OF THE
EASTERN CAPE
POSTGRADUATE EDUCATION AND TRAINING
FACULTY OF HEALTH SCIENCES
WALTER SISULU UNIVERSITY
P/BAG X 1, WSU, 5117, E.C
TEL: (047) 502 2100 / FAX: (047) 502 2101


DR EJ NDEBIA
CHAIRPERSON

07.05.2020
DATE

DECLARATION OF INVESTIGATOR(S)

(To be completed in duplicate and one copy returned to the Research Officer at Office AB 02 GF 03 Administration Building, Sisson Street Campus, Fort Gale, Mthatha, WSU)

I/We fully understand the conditions under which I am/we are authorized to carry out the abovementioned research and I/we guarantee to ensure compliance with these conditions. Should any departure to be contemplated from the research procedure as approved I/we undertake to resubmit the protocol to the Research Ethics Committee. I/We agree to a completion of a 6-monthly/ yearly progress report. The committee reserves the right to withdraw approval in the event that there are serious ethical violations.

..... (Signature)
N. B. Please quote the protocol number in all enquiries.

..... (Date)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

BMJ Open

A Protocol for a Prospective Descriptive Prevalence Study of Catatonia in an Acute Mental Health Unit in Urban South Africa

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-040176.R2
Article Type:	Protocol
Date Submitted by the Author:	25-Sep-2020
Complete List of Authors:	Zingela, Zukiswa; Walter Sisulu University, Psychiatry and Human Behavioural Sciences; Walter Sisulu University, Dr. Stroud, Louise; Nelson Mandela University, Psychology Cronje, Johan; Nelson Mandela Metropolitan University, Psychology Fink, Max; Stony Brook University, Psychiatry Van Wyk, Stephanus ; Walter Sisulu University, Psychiatry and Human Behavioural Sciences
Primary Subject Heading:	Mental health
Secondary Subject Heading:	Mental health, Neurology
Keywords:	Neurology < INTERNAL MEDICINE, Adult psychiatry < PSYCHIATRY, MENTAL HEALTH, Child & adolescent psychiatry < PSYCHIATRY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

A Protocol for a Prospective Descriptive Prevalence Study of Catatonia in an Acute Mental Health Unit in Urban South Africa

Zukiswa Zingela,¹ Louise Stroud,² Johan Cronje,² Max Fink,³ Stephan van Wyk¹

Author Affiliations

¹Department of Psychiatry and Human Behavioural Science, Walter Sisulu University, Mthatha, South Africa

²Department of Psychology, Nelson Mandela University, Port Elizabeth, South Africa

³Department of Psychiatry, Stony Brook University, New York, United States of America

Word Count: 4451

Corresponding author

Zukiswa Zingela: email: zzingela@wsu.ac.za, Postnet Suite 274, Private Bag X13130, Humewood, 6013, South Africa

Tel +2747-502-1977

ORCID: 0000000234251145

ABSTRACT

Introduction

1
2
3 Catatonia arises from serious mental, medical, neurological, or toxic conditions. The
4 prevalence range depends on the setting and the range is anything from 7% to 63% percent in
5 other countries. South African prevalence rates are currently unknown. The proposed study is
6 a quantitative descriptive study utilising the Bush Francis Catatonia Screening Instrument as a
7 screening tool with a data capturing information sheet to extract clinical information from
8 patient folders. The study will investigate: 1) prevalence of catatonia, 2) clinical and
9 demographic correlates associated with catatonia, 3) predictors of catatonia, 4) response to
10 treatment, and 5) subjective experience of catatonia.
11
12
13
14
15
16
17
18
19
20
21

22 **Methods and analysis**

23
24 The setting is an acute mental health unit (MHU) within a regional, general medical hospital
25 in Nelson Mandela Bay, South Africa which accepts referrals from within the hospital and from
26 outlying clinics. Participants will be recruited from inpatients in the MHU from beginning of
27 September 2020 to end of August 2021. Most admissions are involuntarily, under the Mental
28 Health Care Act of 2002 with an age range of 13 to over 65 years. Participants who screen
29 positive for catatonia will be followed up after discharge for three months to measure outcomes.
30 Primary outcomes will include the 12-month prevalence rate of catatonia, descriptive and other
31 data on presentation and assessment of catatonia in the MHU.
32
33
34
35
36
37
38
39
40
41

42 Secondary outcomes will include data on treatment response, participants' report of their
43 subjective experience of catatonia and predictors of catatonia.
44
45
46

47 Descriptive statistics, multivariate binomial logistic regression, and univariate analyses will be
48 conducted to evaluate associations between catatonia and clinical or demographic data which
49 could be predictors of catatonia. Survival analysis will be used to examine the time to recovery
50 after diagnosis and initiation of treatment. The 95% confidence interval will be used to
51 demonstrate the precision of estimates. The level of significance will be $p \leq .05$.
52
53
54
55
56
57
58
59
60

Ethics and dissemination

The study has received ethical approval from the Research and Ethics Committees of the Eastern Cape Department of Health, Walter Sisulu University and Nelson Mandela University. The results will be disseminated as follows: at various presentations and feedback sessions; as part of a Ph.D. thesis in Psychology at Nelson Mandela University; and in a manuscript that will be submitted to a peer-reviewed journal.

Keywords: *Catatonia, assessment, screening tool, Bush Francis Catatonia Rating Scale, predictors*

Article Summary

Strengths and limitations of this study

- This is the first study to examine the prevalence of catatonia in South Africa and aims to address the lack of data on prevalence rates of catatonia, presentation, optimal management, predictors, and outcomes in this setting.
- The triangulation of information sources like the Bush Francis Catatonia Rating Scale, a validated catatonia screening tool, clinical notes, and subjective reports of catatonic episodes from the participants present a unique opportunity to investigate different aspects of catatonia.
- The descriptive nature of the study and the limited number of participants could limit the applicability of significant associations between variables regarding cause and effect and the generalisability of findings. The heterogenous nature of catatonia and interrater reliability of catatonia screening instruments are another source of potential limitations of the study.

INTRODUCTION

In the 1880s, Kraepelin described the prevalence of catatonia as close to 20% in 500 cases.[1] Modern-day studies show a range from less than 10% to 63%.[1, 2, 3] Catatonia is often treated by psychiatrists, even though underlying causes may be other medical conditions such as neurological, infectious, endocrine, and substance-induced disorders.[1] Grover et al.[4] described close to 40% of 205 patients who had delirium and two or more catatonic symptoms on the Bush Francis Catatonia Rating Scale (BFCRS).

1
2
3 Luchini et al.[5] characterised catatonia as an autonomous syndrome, frequently
4 associated with mood disorders but also observed in patients with other conditions including
5 neurological, neurodevelopmental, physical, and toxic conditions. Current evidence has
6 provided some answers about the categorisation of catatonia, clinical presentations,
7 interventions, and response to treatment.[5, 6, 7, 8]
8
9
10
11
12
13
14
15
16

17 The current study will investigate the prevalence of catatonia in patients of the Dora
18 Nginza Hospital (DNH) mental health unit (MHU), associated risk factors and response to
19 treatment. Due to the prominent role played by electroconvulsive therapy (ECT) in the
20 treatment of catatonia, the results from this study may have applicability in public mental
21 health planning, and availability of ECT in public hospitals.[1]
22
23
24
25
26
27
28
29
30

31 **Catatonia in South Africa**

32
33 There are currently no studies describing the prevalence of catatonia in South Africa
34 (SA), which leaves clinicians blind to the burden of the disease linked to this potentially fatal
35 syndrome. Clinicians may, therefore, be unaware of the importance of the assessment and
36 detection of catatonia, leading to missed opportunities to intervene in what is a highly
37 treatable condition.
38
39
40
41
42
43
44
45
46

47 White and Robins[9] described 17 patients with catatonia in SA who received
48 antipsychotic medication. There was a deterioration in their clinical presentation into
49 neuroleptic malignant syndrome (NMS). The risk of precipitating NMS in this case series
50 was linked to the administration of antipsychotics. This study also challenged the notion of
51 NMS being viewed as a separate condition to catatonia. Since then, catatonia has not been
52
53
54
55
56
57
58
59
60

1
2
3 widely studied in SA, despite the researchers' observation that it continues to present a
4
5 significant and sometimes life-threatening challenge. Another study conducted in SA
6
7 described the treatment of 42 catatonic patients with ECT.[10] The current study represents
8
9 the first stages of aiming to fill the gap in the extant research with a prospective study on
10
11 prevalence and predictive data.
12
13
14
15
16

17 **Prevalence of catatonia in other parts of the world**

18
19 Fink and Taylor [1] described a rate of catatonia of 10% in acutely ill psychiatric
20
21 patients and Stuivenga and Morrens [2] a rate of 16.9% when applying the DSM-5 criteria.
22
23 Conditions found in association with a catatonic presentation have included psychiatric
24
25 diagnoses like bipolar disorder, delirious mania, psychotic depression, schizophrenia, and
26
27 other medical conditions.[6, 2] In some instances, the cause leading to catatonia has been less
28
29 well-defined. DSM-5 has captured the multiple possible associations that occur with catatonia
30
31 by including it as a specifier for mood disorders and schizophrenia or as linked to another
32
33 medical condition.[11] Catatonia also appears as an entity with undefined aetiology under
34
35 'catatonia not otherwise specified'. [8]
36
37
38
39
40
41
42

43 **Choice of screening tool and rating scale**

44
45 In 1996, Bush et al. designed the Bush Francis Catatonia Screening Instrument
46
47 (BFCSI) a 14-item scale for screening for catatonia and a 23-item scale for rating severity of
48
49 catatonia.[3, 12] They demonstrated that the scales were reliable and valid tool for diagnosis
50
51 and evaluation of response to treatment. The scales have a dual utility of screening and
52
53 measurement of the severity of catatonia. A systematic review of seven catatonia rating scales
54
55 reported a similar finding when comparing the BFCRS with other tools to screen for
56
57
58
59
60

1
2
3 catatonia.[13] They recommend the BFCRS for routine use because of ease of use, reliability,
4 and validity. Wilson et al.[14] found 300 out of 339 patients with acute medical and
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

catatonia.[13] They recommend the BFCRS for routine use because of ease of use, reliability, and validity. Wilson et al.[14] found 300 out of 339 patients with acute medical and psychiatric illness screened positive for catatonia when applying the BFCRS.

The BFCSI and BFCRS have been used successfully in the MHU as screening and rating scales for the past seven years in the MHU which is the site of the current study. Other reasons supporting the utility of the scales in this study are: 1) the reported ease of use, 2) reliability, 3) validity as both a screening tool and a measure of severity, and 4) its use since 2011 in the study site has not yielded any issues with applicability or appropriateness when used in this clinical setting. Figure 1 reflects the assessment tools and process that will be applied to assess participant and collect data.

Management of catatonia

The biological treatment for catatonia has advanced over the last century, from insulin coma therapy of the early 1930s and Meduna's use of seizure-inducing camphor oil injections to Cerletti's first documented use of an electric shock procedure in 1938.[1] Available evidence on management of catatonia includes the published works from various researchers.[1, 6, 7, 9,14-19] Lorazepam and ECT are the current recommended treatments, irrespective of aetiology. They are effective in most cases.[1, 7, 9, 14, 17]

In both in the White and Robins[9] and Fricchione et al.[7] case series, intravenous administration of benzodiazepines (diazepam or lorazepam) was demonstrated as an efficacious treatment for catatonia. Response is seen relatively rapidly, i.e. within minutes of administration. Instead of a sedative effect that one observes with the administration of benzodiazepines in non-catatonic patients, those with catatonia tend to 'wake up' from stupor

1
2
3 or normalise from a state of extreme excitement. In the White and Robins[9] study, two
4
5 patients who did not receive intravenous benzodiazepines died.
6
7
8
9

10 The dose range used at the study site tends to be higher and is given more frequently
11 compared to the recommendation in the Rasmussen et al. paper.[19] This is mainly because
12 patients at the site present at advanced stages of catatonia and tend to respond slowly or not at
13
14 all when the lower or less frequent doses are employed.
15
16
17
18
19

20 21 **The subjective experience of catatonia**

22
23 Northhoff et al.[20] conducted a retrospective study on 24 catatonic patients post-
24 recovery after a catatonic episode. The patients reported intense emotions which could not be
25 controlled and ambivalence with less focus on their altered movements. Other descriptions of
26 catatonia have stated an extreme fear response characterized by freezing, likened to the
27 defence seen in animals of tonic immobility or freezing in the face of danger.[21]
28
29
30
31
32
33
34
35
36
37

38 This study will investigate the subjective experience of catatonia as described by
39 participants once discharged from the hospital, to shed light on the emotive and cognitive
40 experience of catatonia in the study cohort. This may provide clues on the psychological
41 drivers of the catatonic response and could pave the way for further research into the
42
43 psychology of the catatonic response.
44
45
46
47
48
49
50

51 **Aims**

52 This study aims to determine the prevalence of catatonia in an acute mental health
53 unit in urban South Africa and research its assessment and management in this setting.
54
55
56
57
58
59
60

Objectives

The two main research objectives are:

1. Screening of consenting participants admitted to the mental health unit in Dora Nginza Hospital using the BFCSI for catatonia, over a 12-month period from the 1st of September 2020 to the end of August 2021, to describe the prevalence of catatonia in this setting.
2. Description of demographic and clinical information, including response to treatment, in participants diagnosed with catatonia based on their BFCSI scores and clinical assessments performed by the admitting doctor.

Response to treatment will be according to the following parameters: A 50% reduction in signs and symptoms will be considered a response while a 100% reduction will be a considered a full resolution. Conversely, a reduction in symptoms of less than 50% will be regarded as a suboptimal response and a reduction that is more than 50% but less than 100% will be a response but without full resolution. In addition, significant clinical correlates and risk factors in participants with catatonia will be described, and participants with catatonia will be followed up once discharged at one month, two months, and three months intervals, to assess outcomes using the BFCSI and information about readmission or recurrence of any episode of mental illness. The association that will be looked at is between catatonia and demographic or clinical correlates such as age, gender, DSM 5 diagnosis, substance use, vitamin 12 deficiency and food insecurity and other co-occurring medical conditions. Participant's experience of catatonia once it has resolved will also be described.

Research design

This is a prospective, descriptive triangulation study utilising mixed quantitative and

1
2
3 qualitative methods. An exploratory qualitative aspect will investigate the emotive and
4
5 cognitive subjective experience of participants with catatonia to establish a direction for
6
7 further research. This is because there is currently limited data available on the subjective
8
9 experience of catatonia, with most research focusing on quantitative aspects.
10
11
12
13
14

15 The quantitative elements of the study will include data collected from participant
16
17 files of BFCSI scores upon admission, with additional clinical and demographic information
18
19 collected via a pre-designed datasheet (see Appendix 1). The qualitative element will
20
21 describe the participant's reported experience of the catatonic episode, post-discharge.
22
23
24
25

26 **METHODS AND ANALYSIS**

27

28 The study will take a positivist paradigm approach to investigate the potential causal
29
30 relationships between catatonia and different variables via correlational studies.[22]
31
32 Creswell[23] described the positivist's approach as an attempt to identify causes, which
33
34 influence outcomes, the aim being to formulate laws, thus yielding a basis for prediction and
35
36 generalisation. In the current study, deductive reasoning will be applied to data collected
37
38 through 1) direct observation and 2) quantitative and qualitative approaches, to identify
39
40 associations with catatonia, causal relationships, and possibly, predictors of catatonia.[22]
41
42
43
44
45
46

47 Sources of information that will be utilised for triangulation include: the participants'
48
49 BFCSI/ BFCRS scores (see Appendix 2) and clinical notes; field notes taken by the research
50
51 team during direct observation and interviews; and participant and relative interviews
52
53 focusing on response to treatment, food insecurity, and the subjective experience of catatonia.
54
55 Additionally, the mixed methods nature of the study will enable the generation of both
56
57
58
59
60

1
2
3 objective (as documented by treating and research teams) and subjective data regarding the
4
5 experience of catatonia. This type of triangulation is an important tool for meeting the goals
6
7 of this study while facilitating a holistic assessment of catatonia in this cohort.
8
9

10 11 12 **The study process and outline**

13
14
15 Two research assistants (RAs) with a background in health will be recruited to assist
16
17 the researcher with fieldwork. A health background is necessary to understand the medical
18
19 terminology that is utilised in the clinical notes and screening tools. A part-time
20
21 administrative assistant will be contracted to assist with data capturing and collation.
22
23 Fieldwork will include the recruitment of participants and collection of data by the researcher
24
25 and RAs. There will be a limited follow-up component that extends to up to three months
26
27 following discharge from the hospital.
28
29

30
31
32
33 The RAs will be trained by the researcher on:

- 34
35 1) application of the BFCSI and BFCRS to ensure they are knowledgeable about the
36
37 screening tool and its interpretation, and
38
39 2) assessment of capacity to consent utilising the University of California, San Diego
40
41 Brief Assessment of Capacity to Consent Questionnaire (UBACC).
42
43

44
45 The UBACC has been applied successfully in the Eastern and Western Cape in study
46
47 cohorts recruited from inpatient mental health institutions. [24, 25]
48

49
50 The inter-rater reliability (IRR) of the BFCRS was demonstrated to be good ($\alpha=0.779$)
51
52 in a study looking at four different instruments to assess for catatonia. [26] In the planned
53
54 study, training that will be provided by the lead researcher to the RAs on the use of the
55
56 BFCSI/BFCRS will be through:
57
58

- explaining the meaning of terms used in the BFCSI/BFCRS to describe clinical signs and symptoms of catatonia and
- providing a demonstration of how to elicit and document the 14-items and 23-items in the BFCSI/BFCRS, how to capture the relevant information accurately onto the data capturing form
- ensuring RAs start with practice participants initially under direct observation of the lead researcher, before starting the actual recruitment. An IRR in the range of ($\alpha=0.61$ to 0.8) during the practice scoring will be deemed acceptable for RAs to proceed to the scoring of study participants.

Inter-rater reliability will also be addressed through ensuring that everyone has a similar understanding of all items to be rated in the screening tool and how these should be recorded.

The researcher and RAs will assess participants who meet the inclusion criteria for capacity to consent, utilising the UBACC. All those with intact capacity to consent will be requested to consider entering the study (see Appendix 3 and Appendix 4). For participants who may be assessed as lacking the capacity to consent, their closest relatives or guardians will be requested to consent on their behalf through proxy consent (proxy consent and its ethical application is further discussed in the section 'Ethics and dissemination' below). Additionally, in those assessed to lack capacity to consent, such capacity will be reviewed weekly to allow for further re-engagement on their consent to take part in the study, the ultimate aim being to change from proxy consent to personal consent as soon as potential participants have regained capacity. Data collected about any participant who chooses to withdraw from the study will be removed from the study data sets and destroyed.

1
2
3
4
5
6 The research team will collect data from the clinical files of consenting participants
7
8 on BFCSI/BFCRS scores and additional descriptive and demographic information as guided
9
10 by the study questionnaire and study protocol. The completed data capturing forms will be
11
12 submitted to the administrative assistant for data collation and entry into a spreadsheet at the
13
14 end of each week. The assessment of new admissions will be daily on weekdays with the
15
16 expectation being to conduct daily screening or within the first 48-hours at least. Information
17
18 on clinical presentation of patients admitted over weekends will be supplemented from the
19
20 clinical folders. In cases where the Researcher or RAs identify possible missed catatonia, the
21
22 treating doctor will be provided with any additional information picked up during the
23
24 participants' assessment to allow for a review of the patient's clinical case and management.
25
26
27
28
29

30
31 During the limited follow-up period, the researcher and RAs will repeat the BFCSI
32
33 assessment and conduct face-to-face interviews with participants regarding their experience
34
35 of catatonia at one month, two months, and three months post-discharge. Recurrence of
36
37 symptoms or readmissions since the last discharge will be documented. The participant's
38
39 willingness to continue with the study will be reviewed during every visit to ensure their
40
41 consent remains valid throughout. Figure 2 is a summary of the study process that will be
42
43 followed.
44
45
46
47
48

49 **Setting**

50
51 The setting will be a 35-bed acute mental health unit in Dora Nginza Hospital, a
52
53 general hospital in the Eastern Cape Province in South Africa. The hospital is in Zwide, in the
54
55 iBhayi area of Port Elizabeth which has a population of over one million within an urban
56
57
58
59
60

1
2
3 area that has a high morbidity of mental illness.[27] Close to 70% of the population is
4
5 comprised of working age adults between 15 and 64 years and the city has an unemployment
6
7 rate of close to 30%. [27] Zwide itself has a population of 238 000. [28] Health services in
8
9 the hospital include obstetrics and gynaecology, paediatrics, basic surgical, internal medicine,
10
11 and family medicine. The MHU is an acute inpatient unit offering 24-hour care to persons
12
13 who present with acute mental illness requiring inpatient treatment. It accepts referrals from
14
15 all the other hospital departments including the Accident and Emergency Department, as well
16
17 as referrals from primary care clinics and district hospitals in the nearby vicinity. The usual
18
19 period of admission ranges anything from three days to a few weeks.
20
21
22

23
24 All cases of suspected catatonia, from any of the referring departments are discussed
25
26 with the MHU team and prioritized for admission into the unit. Any treatment given
27
28 thereafter is discussed with the MHU team and documented in the patient's folder.
29
30
31

32 33 **Sampling**

34
35 Convenience sampling of all patients admitted to the MHU over a twelve-month
36
37 period (September 2020 to August 2021) will be undertaken. Contact details of all consenting
38
39 participants who have screened positive for catatonia will be entered into a database to enable
40
41 contact for future follow-up at the end of one month, two months, and three months post-
42
43 discharge. This information will be password encrypted.
44
45

46
47 The number of patients expected to be admitted during the study period is around 1000
48
49 based on previous unit stats over the last three years and adjusted down slightly to
50
51 accommodate the effect of the COVID-19 outbreak on hospital admissions. The margin of
52
53 error or confidence interval will be set at 95% and the standard deviation will be set at 0.05.
54
55 To determine the total sample size required, the formula: $n=N/(1+Ne^2)$ will be utilized and
56
57

1
2
3 yields a minimum sample size of 286 subjects. A further 20% (57) will be added to account
4
5 for data entry errors and non-responses. The appropriate sample size of participants to be
6
7 screened for the prevalence of catatonia in the unit is 343.
8
9

10 11 12 **Participants**

13
14 Most people admitted to the DNH MHU are involuntary admissions under the Mental
15
16 Health Care Act of 2002.[29] Age of admission ranges from 13 to over 65 years because
17
18 there are no child, adolescent, or geriatric inpatient-specific services in the region.
19
20
21
22

23 24 **Inclusion criteria**

25
26 All patients admitted to the unit during the study period will be eligible for inclusion.
27
28 Those who screen positive for two or more catatonic signs and symptoms on the BFCSI will
29
30 be included during the follow-up period for the qualitative part of the study.
31
32
33
34

35 36 **Exclusion criteria**

37
38 Refusal to take part in the study, whether through the direct patient consent process or
39
40 the proxy consent process, will result in the exclusion of the patient.
41
42
43
44

45 46 **Methods of assessment and measurement**

47
48 The BFCSI is a 14-item scale (see Appendix 2) that is used to screen for catatonia and
49
50 the BFCRS is a 21-item scale used to rate severity.[11] The BFCSI is used on initial
51
52 assessment and the full BFCRS is used to determine severity. Participants' responses to the
53
54 standard interventions of intravenous lorazepam administration or ECT will be documented
55
56 by the admitting doctor in the case notes. The research team will then capture this
57
58
59
60

1
2
3 information on a predesigned data collection sheet. When a patient presents with two or more
4
5 positive items on the BFCSI, they are deemed catatonic and further management is guided by
6
7 the unit protocol. A lorazepam infusion of 1mg or 2 mg is administered and a response of
8
9 50% or greater reduction in the scale score verifies the diagnosis although absence of
10
11 verification does not exclude catatonia. The research team will capture information on
12
13 participant's BFCSI/BFCRS scores and other clinical data this information on a predesigned
14
15 data collection sheet.
16
17

18
19 The clinical data that will be collected include current psychiatric diagnosis, co-
20
21 occurring medical conditions, any other treatment administered, history of substance use,
22
23 history of previous catatonic episodes, vital signs like temperature on admission, blood
24
25 pressure, pulse, investigations like creatinine kinase, iron levels, thyroid function tests, urea
26
27 and electrolytes or any other relevant clinical investigations reflected in the file which are
28
29 noted by the treating team to be of relevance to the current admission., and food insecurity.
30
31 The participants' case notes will form a primary source of information as well as direct
32
33 observation of the participants. Additional information will be sought from relatives if the
34
35 participant is unable to respond adequately to information required on food security questions
36
37 due to the severity of catatonic symptoms, or in those who are unable to provide the
38
39 additional information for whatever other reason.
40
41
42
43
44
45
46

47 Regarding social determinants of mental health, current evidence indicates that those
48
49 who are poor or disadvantaged suffer disproportionately from common mental disorders and
50
51 their adverse consequences.[30] The strength of the association with poverty has at times
52
53 varied depending on the type of poverty measure used. Food insecurity as a poverty measure
54
55 is one of the factors with a consistent and strong association with common mental
56
57

1
2
3 disorders.[31] In this study, the administration of a food security questionnaire will be
4
5 utilised to assess the correlation of poverty to catatonia. Two food insecurity questions are
6
7 drawn from the USDA's 18-question Household Food Security Scale.[32] They make up The
8
9 Hunger Vital Sign Questionnaire, a validated two-question food insecurity screening tool
10
11 used in the clinical setting. The questions are:
12
13

- 14 1. Within the past 12 months, we worried whether our food would run out
15 before we got money to buy more.
- 16 2. Within the past 12 months, the food we bought just did not last and we did
17 not have money to get more.

18
19
20
21
22
23
24
25
26 During the follow-up period, participants will be asked to describe their experience of
27
28 the catatonic episode as well as their perception of recovery.
29
30

31 32 33 **Expected outputs**

- 34 • The 12-month prevalence rate of catatonia.
 - 35 • Descriptive and other data on presentation and assessment of catatonia in the DNH
36 unit.
 - 37 • Data on treatment response, short-term outcomes, and subjective experience of
38 catatonia.
 - 39 • Predictors for catatonia based on clinical correlates and other descriptive data
40 collected.
 - 41 • Recommendations and guidelines for the management of catatonia and possible
42 prevention strategies.
- 43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Data management and analysis

Quantitative data collected will be summarised using descriptive statistics. Categorical variables will be presented using frequency tables, percentages, and graphs. Two or more categorical variables will be compared using contingency tables (e.g. 2 X 2 Table) and the expected frequencies will be calculated to determine the type of test best suited to determine the extent of any identified relative associations. If the expected frequencies in all cells are ≥ 5 then the Chi-squared test will be used and if the expected frequencies are < 5 in any cells, then the Fisher's exact test will be used.

Binomial logistic regression will also be conducted to determine the predictors of catatonia and to estimate the risk ratio. If the numerical data are not normally distributed, non-parametric statistics will be used (median and interquartile range). The best fitting model of multivariate analysis will be chosen through forward selection of model building. The model with the lowest Bayesian information criterion will be selected as the better model and the 95% confidence interval will be used to estimate the precision of estimates. Survival analysis will be used to determine the time to recovery and the hazard ratio (i.e. the total number and timing of each event indicating relapse in this study) will be reported for this purpose.

Qualitative data collated during the follow-up period will be analysed to elucidate the subjective experience of catatonia in this cohort. Aspects of the thematic analysis presented by Braun and Clarke [32] will be applied to identify themes. Themes will be identified through a framework approach identifying word repetition, local expressions, metaphors and similarities, differences, and keywords. A tentative hypothesis and theory regarding the

1
2
3 experience of catatonia will be presented based on emergent themes. Data collected during
4 the quantitative and qualitative segments of the study will be analysed separately but
5 compared for congruency of reported information to enhance data integration.
6
7
8
9
10

11
12 In summary, data integration will be in the form of:

- 13
14
15 i. converting information gathered from the quantitative aspects of the study into
16 numerical information that can be processed through application of statistical methods
17 to test for correlations and associations.
18
19 ii. identifying common themes through field notes taken when interviewing participants
20 during the outpatient stage of the study.
21
22 iii. Assessing congruency between common themes about the subjective experience of
23 catatonia as described by participants and commonly identified presenting symptoms
24 as highlighted in case notes and listed in the data collection sheet. The advantage of
25 this approach is that it strengthens the validity and reliability of the study.
26
27
28
29
30
31
32
33
34
35
36
37

38 **Patient and public involvement**

39
40 No formal patient advisory committee was set up and there was no patient or public
41 involvement in the design and planning of the study.
42
43
44
45
46

47 **ETHICS AND DISSEMINATION**

48
49 Ethics clearance has been granted for the study by the Eastern Cape Department of
50 Health Ethics Committee (see Appendix 5 and 6), the Walter Sisulu University Research and
51 Ethics Committee and the Nelson Mandela University Human Research Ethics Committee
52 (see Appendix 7). The study does not have any intervention arm.
53
54
55
56
57
58
59
60

1
2
3
4
5
6 All patients admitted to the unit will be presented with an information leaflet on the
7
8 study in English or Xhosa. Consent for inclusion in the study will be obtained from all
9
10 participants who have the capacity to consent, which will be determined through application
11
12 of the UBACC. Proxy consent will be sought from a relative or guardian for all patients who
13
14 lack the capacity to consent or are minors between the ages of 13 and 18 years of age. The
15
16 use of proxy consent in mental health research is applicable for those who lack the capacity to
17
18 consent and the nearest relative or guardian consents on their behalf. It is permissible within
19
20 the mental health care setting due to the challenges with capacity to consent that may exist in
21
22 patients with acute mental illness.[33] Proxy consent ensures that respondents' rights are
23
24 guarded while making it possible to include individuals or groups who may potentially
25
26 benefit from scientific advances gained from research. This approach is also supported by the
27
28 Helsinki Declaration on ethical research which states that 'for a research subject who is
29
30 legally incompetent, physically or mentally incapable of giving consent or is a legally
31
32 incompetent minor, the investigator must obtain informed consent from the legally authorised
33
34 representative in accordance with applicable law'.[34] The Department of Health Guidelines
35
36 on ethics in health research similarly state that persons should not be excluded unfairly based
37
38 on discrimination or disability.[35]

39
40
41
42
43
44
45
46
47 The Mental Health Care Act (MHCA) of 2002 also makes a reference as to whom
48
49 may be considered an associate of a patient admitted under the Mental Health Care Act: e.g. a
50
51 spouse, next of kin, partner, associate, parent, or guardian.[29] A similar approach will be
52
53 taken for this research. All data will be anonymised and stored under lock and key, with
54
55 access granted to the research team only.
56
57

Dissemination of results

The results will be presented at feedback sessions with the Hospital Board, Eastern Cape Department of Health and at national and international congresses and may be used to compile guidelines on assessment and management of catatonia in the region. They will also be compiled as a thesis, which will be submitted for examination for a Ph.D. in Psychology at Nelson Mandela University. A research report based on the study results will be submitted to peer-reviewed journals to be considered for publication.

ACKNOWLEDGEMENT

The authors thank Dr Sikhumbuzo Mabunda for the valuable comments and assistance provided in the data analysis section.

REFERENCES

- 1 Fink M, Taylor MA. Catatonia: A Clinician's Guide to Diagnosis and Treatment. Cambridge: Cambridge University Press 2003.
- 2 Stuiivenga M, Morrens M. Prevalence of the catatonic syndrome in an acute inpatient sample. *Front Psychiatry* 2014;5:174. doi:[10.3389/fpsy.2014.00174](https://doi.org/10.3389/fpsy.2014.00174)
- 3 Bush G, Fink M, Petrides G, et al. Catatonia. I. Rating scale and standardized examination. *Acta Psychiatr Scand* 1996;93:129-36. doi:[10.3389/fpsy.2014.00174](https://doi.org/10.3389/fpsy.2014.00174)
- 4 Grover S, Ghosh A, Ghormode D. Do patients of delirium have catatonic features? An exploratory study. *Psychiatry Clin Neurosci* 2014;68:644-51. doi:[10.1111/pcn.12168](https://doi.org/10.1111/pcn.12168)
- 5 Luchini F, Medda P, Mariani MG, Mauri M, Toni C, Perugi G. Electroconvulsive therapy in catatonic patients: efficacy and predictors of response. *World J Psychiatry* 2015;5:182-

- 1
2
3 92. doi:[10.5498/wjp.v5.i2.182](https://doi.org/10.5498/wjp.v5.i2.182)
4
5
6 6 Fink M, Taylor MA. The many varieties of catatonia. *Eur Arch Psychiatry Clin Neurosci*
7
8 2001;251:I8-I13. doi:10.1007/PL00014200
9
10 7 Fricchione GL, Cassem NH, Hooberman D, Hobson D. Intravenous lorazepam in
11
12 neuroleptic-induced catatonia. *J Clin Psychopharmacol* 1983;3:338-42.
13
14
15 8 Tandon R, Heckers S, Bustillo J, et al. Catatonia in DSM-5. *Schizophr Res* 2013;150:26-
16
17 30. doi:[10.1016/j.schres.2013.04.034](https://doi.org/10.1016/j.schres.2013.04.034)
18
19
20 9 White DA, Robins AH. An analysis of 17 catatonic patients diagnosed with neuroleptic
21
22 malignant syndrome. *CNS Spectr* 2000;5:58-65. doi:[10.1017/S1092852900013419](https://doi.org/10.1017/S1092852900013419)
23
24
25 10 Odayar K, Eloff I, Esterhuysen W. Clinical and demographic profile of catatonic patients
26
27 who received electroconvulsive therapy in a South African setting. *S Afr J Psychiatr*
28
29 2018;24:1-5. doi:[10.4102/sajpsychiatry.v24i0.1100](https://doi.org/10.4102/sajpsychiatry.v24i0.1100)
30
31
32 11 American Psychiatric Association. Diagnostic and Statistical Manual of Mental
33
34 Disorders: DSM- 5. Washington: American Psychiatric Association 2013.
35
36
37 12 Sienaert P, Dhossche DM, Vancampfort D, et al. A clinical review of the treatment of
38
39 catatonia. *Front Psychiatry* 2014;5:181. doi:[10.3389/fpsy.2014.00181](https://doi.org/10.3389/fpsy.2014.00181)
40
41
42 13 Sienaert P, Rooseleer J, De Fruyt J. Measuring catatonia: a systematic review of rating
43
44 scales. *J Affect Disord* 2011;135:1-9. doi:[10.1016/j.jad.2011.02.012](https://doi.org/10.1016/j.jad.2011.02.012)
45
46
47 14 Wilson J, Niu, K, Nicholson SE, et al. The diagnostic criteria and structure of catatonia.
48
49 *Schizophr Res* 2015;164:256–62. doi:[10.1016/j.schres.2014.12.036](https://doi.org/10.1016/j.schres.2014.12.036)
50
51
52 15 Fink M, Taylor MA. Electroconvulsive therapy: evidence and challenges. *JAMA*
53
54 2007;298:330-332. doi:10.1001/jama.298.3.330
55
56
57 16 Fink M. What was learned: studies by the consortium for research in ECT (CORE) 1997–
58
59 2011. *Acta Psychiatr Scand* 2014;129:417-26. doi:[10.1111/acps.12251](https://doi.org/10.1111/acps.12251)
60

- 1
2
3 17 Petrides G, Fink M, Husain MM, et al. ECT remission rates in psychotic versus
4 nonpsychotic depressed patients: a report from CORE. *J ECT* 2001;17:244-53.
5
6
7
8 18 Rosebush PI, Hildebrand AM, Furlong BG, et al. Catatonic syndrome in a general
9 psychiatric inpatient population: frequency, clinical presentation, and response to
10 lorazepam. *J Clinical Psychiatry* 1990;51:357-62.
11
12
13
14
15 19 Rasmussen SA, Mazurek MF, Rosebush PI. Catatonia: our current understanding of its
16 diagnosis, treatment, and pathophysiology. *World J Psychiatry* 2016;6:391-8.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 20 Northoff G, Krill W, Wenke J, et al. The subjective experience in catatonia: systematic
study of 24 catatonic patients. *Psychiatr Prax* 1996;23:69-73.
- 21 Moskowitz AK. "Scared Stiff": catatonia as an evolutionary-based fear response. *Psychol
Rev* 2004;111:984-1002. doi:10.1037/0033-295X.111.4.984
- 22 Scotland J. Exploring the philosophical underpinnings of research: relating ontology and
epistemology to the methodology and methods of the scientific, interpretive, and critical
research paradigms. *English Language Teaching* 2012;5:9-16
- 23 Creswell JW. *Research Design: Qualitative and Mixed Methods Approaches*. London:
Sage 2009.
- 24 Campbell MM, Susser E, Mall S, et al. Using iterative learning to improve understanding
during the informed consent process in a South African psychiatric genomics study. *PloS
ONE* 2017;12:e0188466. doi:10.1371/journal.pone.0188466
- 25 Campbell MM, de Vries J, Mqulwana SG, et al. Predictors of consent to cell line creation
and immortalisation in a South African schizophrenia genomics study. *BMC Med Ethics*
2018;19:72. doi:10.1186/s12910-018-0313-2
- 26 Sarkar S, Sakey S, Mathan K, Bharadwaj B, Kattimani S, Rajkumar RP. Assessing

- 1
2
3 catatonia using four different instruments: Inter-rater reliability and prevalence in
4 inpatient clinical population. *Asian J Psychiatr*. 2016;23:27-31.
5
6 doi:10.1016/j.ajp.2016.07.003
7
8
9
10 27 Statistics South Africa: Nelson Mandela Bay [Internet]. Republic of South Africa, c2011
11 [cited 20 February 2020]. Available from:
12
13 http://www.statssa.gov.za/?page_id=993&id=nelson-mandela-bay-municipality.
14
15
16
17 28 Statistics South Africa: Statistics South Africa to release the Quarterly Labour Force
18 Survey (QLFS), 2nd Quarter 2019 [Internet]. Republic of South Africa [cited 24 August
19 2029]. Available from: <http://www.statssa.gov.za/?p=12358>
20
21
22
23
24 29 Mental Health Care Act 2002 (Act no. 17 of 2002) General Regulations [Internet].
25 Government Gazette, Republic of South Africa, 15 December 2004, No. 27117, c2004
26 [cited 17 February 2020]. Available from:
27
28 https://www.gov.za/sites/default/files/gcis_document/201409/a17-02.pdf.
29
30
31
32
33 30 World Health Organization. Social determinants of mental health [Internet]. Geneva:
34 World Health Organization, c2014 [cited 23 March 2020]. Available from:
35
36 https://www.who.int/mental_health/publications/gulbenkian_paper_social_determinants_of_mental_health/en/.
37
38
39
40
41
42 31 Lund C, Breen A, Flisher AJ, et al. Poverty and common mental disorders in low-and
43 middle-income countries: a systematic review. *Soc Sci Med* 2010;71:517–528.
44
45 doi:[10.1016/j.socscimed.2010.04.027](https://doi.org/10.1016/j.socscimed.2010.04.027)
46
47
48
49 32 American Academy of Pediatrics. Addressing food insecurity: a toolkit for pediatricians
50 [Internet]. c2017 [cited 21 April 2020]. Available from: [https://frac.org/wp-](https://frac.org/wp-content/uploads/frac-aap-toolkit.pdf)
51
52
53
54 content/uploads/frac-aap-toolkit.pdf Braun V, Clarke V. Using thematic analysis in
55 psychology. *Qual Res Psychol* 2006;3:77-101. doi:10.1191/1478088706qp063oa
56
57
58
59
60

- 1
2
3 33 Mason S, Barrow H, Phillips A, et al. Brief report on the experience of using proxy
4 consent for incapacitated adults. *J Med Ethics* 2006;32:61-62.
5
6 doi:10.1136/jme.2005.012302
7
8
9
10 34 World Medical Association. World Medical Association Declaration of Helsinki. Ethical
11 principles for medical research involving human subjects. *Bull World Health Organ*
12 2001;79:373-4.
13
14
15
16
17 35 Department of Health, Republic of South Africa. Ethics in health research: principles,
18 processes and structures, 2nd edition [Internet]. Pretoria: National Department of Health,
19 c2015 [cited 23 March 2020__]. Available from:
20 <https://www.ru.ac.za/media/rhodesuniversity/content/ethics/documents/nationalguidelines>
21 [/DOH_\(2015\)_Ethics_in_health_research_Principles,_processes_and_structures.pdf](https://www.ru.ac.za/media/rhodesuniversity/content/ethics/documents/nationalguidelines/DOH_(2015)_Ethics_in_health_research_Principles,_processes_and_structures.pdf).
22
23
24
25
26
27
28
29
30

31 **AUTHOR CONTRIBUTIONS**

32
33 Z Zingela conceived the idea and devised the project and its main conceptual ideas assisted
34 by S van Wyk and M Fink. L Stroud and J Cronje supervised the development of this
35 manuscript and provided editorial input.
36
37
38
39
40
41

42 **FUNDING STATEMENT**

43
44 This work was supported by the South African Medical Research Council (SAMRC), grant
45 tracking number 2017SAMRC0SIR0000157977 and an educational grant from the Health
46 and Welfare Sector Education and Training Authority (2018/2019HWSETA219986789).
47
48
49
50
51
52

53 **COMPETING INTERESTS STATEMENT**

54
55 The authors have no competing interests to declare.
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1
Assessment Tools

Figure 2
The Study Process

For peer review only

Figure 1: Assessment Tools





Figure 2: Study Process



APPENDICES

APPENDIX 1: DATA COLLECTION SHEET

Enrolment No:	Tick applicable box or insert answer in area shaded in white											
Unit	Is the Patient Catatonic now? (Fill in the BFCRS item 1 to 14 to answer this question), 2 or more signs mean Yes, there is catatonia											
DNH	If No then tick this box and fill in ONLY Sections A,G,H,I, and J					If Yes then tick this box and fill in sections A, B, C, D, E, F, G, H, I, and J.						
A. Age		Sex		Ethnicity				1st admission	Catatonic symptoms before?	DSM -5 Diagnosis in file?	Substance Use?	Another medical condition
< 16	6 - 36	>	F (0)	M (1)	B	C	I	W	Yes	Yes	Yes	Yes
	35 - 65								No	No	No	No
										
									No	No	No	No
								No of previous admissions	No of times had catatonia previously	No of previous diagnoses?		No of medical conditions?
								Not known	Not known	Not known	Not known	Not known
B. BFCR Scale Score		BZD Given Yes / No If yes Doses given 1 -2		Name of BZD given: Lorazepam Clonazepam				Blood Pressure	Pulse	Body Temp	Respiratory Rate/ O2 Sats	
									<70 71-100	<35 35 -37	<90% 91 – 93	

C. Length of time and degree of response to BZD	1 st hour after admission	2-3 days		4-6 days	Degree of Response	
					Mild = Less than 25% reduction in No. of symptoms	
	2 to 6 hours after admission	7-10 days	11-14 days	>14 days	Moderate = 25% to 50% reduction in No. of symptoms	
	7 to 47 hours after admission	Reason ECT was not given after the 1 st 3 days of admission (from clinical notes)			Good = Response of more than 50% reduction in No. of symptoms	
					Response to BZD not sustained	
D. ECT and response	Yes	Number of Sessions	Response		Response to ECT not sustained	
		<4	Nil		Maintenance ECT prescribed or required?	
		5-9	Remission of catatonia			
	10-12	Other (specify).....				
No	>12	Time to 50% improvement	Time to full Resolution	Yes, prescribed?	No, not prescribed	
		<3 days	<3 days	If so what is the No. of sessions?		
		4-7 days	4-7 days			
		>1 week	>1 week			
E. Duration of Catatonia prior to admission if known OR Not Known	Hours to 3 days	Duration of Catatonia Prior to admission?	Any other additional information?			
	4 days to 2 weeks	NOT known OR				
	3 to 4 weeks	< 3 days				
	More than 4 weeks	4 to 7 days				
		>7 days				
F. Type of onset	Hours to days	Gradual	Fluctuating	Mostly Excited Form?		Mostly Slowed Form?

				Excited/ Stereotypy/ Mannerism	Stupor/ Withdrawal/ Rigidity/ Mutism/ Staring		
G. Food Insecurity	1. Within the past 12 months, we worried whether our food would run out before we got money to buy more.						
	Often True	Sometimes true	Never true	Don't know	Other		
	2. Within the past 12 months, the food we bought just didn't last and we didn't have money to get more.						
	Often true	Sometimes true	Never true	Don't know	Other		
H. Substances	YES	NO	Alcohol	Cannabis	Amphet	Heroin	Metamphet
			Cocaine	Opioids	Nicotine	Other (Specify)	

I. Medical Illness	No	Yes	If Yes, chose from the following if on history only		If Yes, choose from the following if current		If HIV			
			HPT	DM	HPT	DM	On HAART?	No		
			Epilepsy	HIV	Epilepsy	HIV	If HIV on HAART, Regime?	If HIV, CD4?		
			Head Trauma	TB	Head Trauma	TB	If HIV, Viral Load?	Other (specify)		
			SLE or Auto/I	Other (specify)		Other (specify)				
J. Investigations:	CK (u/l)		CK ≤ 200	Fe μmol/l	Fe 9 to 30	VitB12 pmol/l	B12 ≤ 107		Auto/I Screen	
	1. CK – Creatinine Kinase 2. Fe – Iron 3. B12 – Vitamin B12 4. TSH – Thyroid Stimulating Hormone 5. T4 – Thyroid Hormone 6. ANF – Nuclear Factor Rheumatoid Factor	CK	CK	Fe	Fe	B12	B12	RF	ESR	ANA
		201 -1000	≥ 1000	≤ 9	≥ 30	108 - 221	≥ 221			
								< 14IU/ml	< 29	Pos
								OR > 14IU/ml	OR > 29	Neg
Endocrine	TSH miu/l		≤ 0.38	≥ 5.33	Cortisol	≤ 184		≥ 618		
	Normal TSH		0.38 to 5.33		Normal (AM)	185 to 617				
	T4 pmol/l		≤ 7.2	≥ 16.4	Cortisol (PM)	≤ 276 (pm)		≥ 276		
Normal T4		7.2 to 16.4		≤ 276						
END OF INPATIENT DATA CAPTURING SECTIONS										

BEGINNING OF OUTPATIENT FOLLOW UP SECTION FIR PATIENTS WHO HAD CATATONIA

K. Follow-up Period ONLY	Date of Discharge	1 month	2 months	3months	Other
Please tick the applicable box	Recurrence of Catatonia? Yes No	Recurrence of Catatonia? Yes No	Recurrence of Catatonia? Yes No	Other?	
	Re-Admission? Yes No	Re-Admission? Yes No	Re-Admission? Yes No	Other?	
Please describe (in your own words) your experience/ of the catatonic episode in terms of your thoughts, feelings and behaviour	Uyacelwa uchaze (ngawakho amazwi) ngamava akho ngexesha ubune catatonia ngokwengcing a zakho, indlela obuziva ngayo nezinto obuzenza.	PARTICIPANT RESPONSE RECORDED VERBATUM (USE AUDIO RECORDER) Thoughts Feelings Behaviour			

APPENDIX 2:

CATATONIA RATING SCALE

APPENDIX VII

BUSH-FRANCIS CATATONIA RATING SCALE

Use presence or absence of items 1-14 for screening
Use the 0-3 scale for items 1-23 to rate severity

<p>1. Excitement:</p> <p>Extreme hyperactivity, constant motor unrest which is apparently non-purposeful. Not to be attributed to akathisia or goal directed agitation</p> <p>0 = Absent 1 = Excessive motion 2 = Constant motion, hyperkinetic without rest periods 3 = Full-blown catatonic excitement, endless frenzied motor activity</p>	<p>2. Immobility/stupor:</p> <p>Extreme hypoactivity, immobile, minimally responsive to stimuli</p> <p>0 = Absent 1 = Sits abnormally still, may interact briefly 2 = Virtually no interaction with external world 3 = Stuporous, non-reactive to painful stimuli</p>
<p>3. Mutism:</p> <p>Verbally unresponsive or minimally responsive</p> <p>0 = Absent 1 = Verbally unresponsive to majority of questions; incomprehensible whisper 2 = Speaks less than 20 words/ 5 min 3 = No speech</p>	<p>4. Staring:</p> <p>Fixed gaze, little or no visual scanning of environment, decreased blinking.</p> <p>0 = Absent 1 = Poor eye contact, repeatedly gazes less than 20 seconds between shifting of attention; decreased blinking 2 = Gaze held longer than 20 seconds, occasionally shifts attention 3 = Fixed gaze, non-reactive</p>
<p>5. Posturing/catalepsy:</p> <p>Spontaneous maintenance of posture(s), including mundane (e.g. setting or standing for long periods without reacting).</p> <p>0 = Absent 1 = Less than 1 minute 2 = Greater than one minute, less than 15 minutes 3 = Bizarre posture, or mundane maintained more than 15 minutes</p>	<p>6. Grimacing:</p> <p>Maintenance of odd facial expressions.</p> <p>0 = Absent 1 = Less than 10 seconds 2 = Less than 1 minute 3 = Bizarre expression(s) or maintained more than 1 minute</p>
<p>7. Echopraxia/echolalia:</p> <p>Mimicking of examiner's movements/speech.</p> <p>0 = Mimicking of examiner's movements/speech 1 = Occasional 2 = Frequent 3 = Constant</p>	<p>8. Stereotypy:</p> <p>Repetitive, non-goal-directed motor activity (e.g. finger-play; repeatedly touching, patting or rubbing self); abnormality not inherent in act but in frequency.</p> <p>0 = Absent 1 = Occasional 2 = Frequent 3 = Constant</p>
<p>9. Mannerisms:</p> <p>Odd, purposeful movements (hopping or walking tiptoe, saluting passers-by or exaggerated caricatures of mundane movements); abnormality inherent in act itself.</p> <p>0 = Absent 1 = Occasional 2 = Frequent 3 = Constant</p>	<p>10. Verbigeration:</p> <p>Repetition of phrases or sentences (like a scratched record).</p> <p>0 = Absent 1 = Occasional 2 = Frequent 3 = Constant</p>
<p>11. Rigidity:</p> <p>Maintenance of a rigid position despite efforts to be moved, exclude if cog-wheeling or tremor present.</p> <p>0 = Absent 1 = Mild resistance 2 = Moderate 3 = Severe, cannot be repositioned</p>	<p>12. Negativism:</p> <p>Apparently motiveless resistance to instructions or attempts to move/examine patient. Contrary behavior, does exact opposite of instruction</p> <p>0 = Absent 1 = Mild resistance and/or occasionally contrary 2 = Moderate resistance and/or frequently contrary 3 = Severe resistance and/or continually contrary</p>
<p>13. Waxy Flexibility:</p> <p>During repositioning of patient, patient offers initial resistance before allowing himself to be repositioned, similar to that of a bending candle.</p> <p>0 = Absent 3 = Present</p>	<p>14. Withdrawal:</p> <p>Refusal to eat, drink and/or make eye contact.</p> <p>0 = Absent 1 = Minimal PO intake/interaction for less than 1 day 2 = Minimal PO intake/interaction for more than 1 day 3 = No PO intake/interaction for 1 day or more.</p>

BUSH-FRANCIS CATATONIA RATING SCALE (CONT.)

<p>15. Impulsivity:</p> <p>Patient suddenly engages in inappropriate behavior (e.g. runs down hallway, starts screaming or takes off clothes) without provocation. Afterwards can give no, or only a facile explanation.</p> <p>0 = Absent 1 = Occasional 2 = Frequent 3 = Constant or not redirectable</p>	<p>16. Automatic obedience:</p> <p>Exaggerated cooperation with examiner's request or spontaneous continuation of movement requested.</p> <p>0 = Absent 1 = Occasional 2 = Frequent 3 = Constant</p>
<p>17. Mitgehen:</p> <p>"Anglepoise lamp" arm raising in response to light pressure of finger, despite instruction to the contrary.</p> <p>0 = Absent 3 = Present</p>	<p>18. Gegenhalten:</p> <p>Resistance to passive movement which is proportional to strength of the stimulus, appears automatic rather than willful.</p> <p>0 = Absent 3 = Present</p>
<p>19. Ambitendency:</p> <p>Patient appears motorically "stuck" in indecisive, hesitant movement.</p> <p>0 = Absent 3 = Present</p>	<p>20. Grasp reflex:</p> <p>Per neurological exam</p> <p>0 = Absent 3 = Present</p>
<p>21. Perseveration:</p> <p>Repeatedly returns to same topic or persists with movement.</p> <p>0 = Absent 3 = Present</p>	<p>22. Combativeness:</p> <p>Usually in an undirected manner, with no, or only a facile explanation afterwards.</p> <p>0 = Absent 1 = Occasionally strikes out, low potential for injury 2 = Frequently strikes out, moderate potential for injury 3 = Serious danger to others</p>
<p>23. Autonomic abnormality:</p> <p>Circle: temperature, BP, pulse, respiratory rate, diaphoresis.</p> <p>0 = Absent 1 = Abnormality of one parameter [excluding pre-existing hypertension] 2 = Abnormality of two parameters 3 = Abnormality of three or more parameters</p>	<p>TOTAL: _____</p>

APPENDIX 3: INFORMED CONSENT FORM INFORMED CONSENT – ENGLISH

INFORMED CONSENT FOR A STUDY ON CATATONIA

Dear Participant or Relative

We are requesting your consent to enroll you in a study on catatonia and how the symptoms respond to the treatment you are going to be given.

YES, I AGREE TO BE ENROLLED

I
 agree in **voluntarily** taking part in the study as explained to me by the doctor/ nurse

OR

(In cases where the patient is incapable of giving consent but is not opposed to taking part in the study, then a relative or custodian may provide informed consent by also signing below)

I being theof
 **willingly** agree that he/she may take part in the study which has been explained to us by the doctor/ nurse

Signature of participant/relative/ custodian:

.....

Signed by at.....on the
 of.....2019

NO, I DO NOT AGREE TO BE ENROLLED

I

do not agree in taking part in the study as explained to me by the doctor/ nurse OR

I being theof
 do not agree that he/she may take part in the study which has been
 explained to us by the doctor/ nurse

Signature of participant/relative/ custodian:

.....

FOR OFFICE USE ONLY: ASSESSMENT OF CAPACITY TO CONSENT BASED ON UBACC

<i>Does the patient....</i>	<i>Yes</i>	<i>No</i>
<i>1. Understand the information relevant to the decision?</i>
<i>2. Retain the information long enough to consider it?</i>
<i>3. Weigh the information as part of the decision-making process?</i>
<i>4. Communicate their decision in some way?</i>

Please Note: Should there be a no answer to any of the 4 questions above then the patient lacks capacity to consent and a relative or custodian may then be requested to provide informed consent.

1
2
3
4 **INFORMED CONSENT - ISIXHOSA**
5
6

7 **IPHEPHA-MVUME LOPHANDO NGESIGULO SE-CATATONIA**
8
9

10
11 *Mthathi-nxaxheba obekekileyo okanye Mzali okanye sizalwane esibekileyo*
12
13

14 Sicela imvume yakho yokuphanda nzulu ngeempawu zesi sigulo i-catatonia, nokuba unyango
15 ozakulufumana luzakusebenzela njani na.
16

17 Ndiye ndanikwa iphepha elichaza ngolu phando kwaye ndiluchazelwe ngu
18
19

20
21
22
23
24
25 **EWE NDIYAVUMA**
26

27
28 Mna (faka igama lakho apha)
29 ndiyazikhethela ukulungenela olu phando ndiluchazelwe ngugqirha okanye umongikazi, kwaye
30 andinyanzeliswanga.
31
32

33 **OKANYE**
34
35

36
37 Ukuba umntu akakwazi ukunika imvume ngasizathu sithile, kodwa abe engali ukulungenela
38 uphando, kungatyikitya umzali okanye isizalwane
39

40 Isayinwe ngu..... e..... ngomhla we.....
41
42 kwinyanga ye.....ku 2019
43
44

45 **HAYI NDIKHETHA UKUNGALUNGENELI OLU PHANDO**
46

47 Mna (faka igama lakho apha) ndikhetha ukuba ndingalungeni olu phando
48 ndiluchazelwe ngugqirha okanye umongikazi
49

50 Mna ndingu.....(Chaza uhlobene njani nomthathi-nxaxheba)
51 ka.....(igama lomthathi nxaxheba)
52
53
54
55
56
57
58
59
60

1
2
3
4 Isaynwe e..... ngomhla we..... kwinyanga ye.....ku
5 2019

6
7 Utyikitya apha wena okanye umzali okanye isizalwane
8
9

12 APPENDIX 4: INFORMATION LEAFLETS IN ENGLISH AND XHOSA

14 4.1 - INFORMATION LEAFLET (XHOSA)

17 **Iphepha lokwazisa umthathi-nxaxheba kuphando lwesigulo i-Catatonia**

18 Mthathi-nxaxheba obekekileyo okanye Mzali okanye sizalwane esibekekileyo

19 Ngale ncwadi sikwazisa malunga ngophando nzulu oluqhutywa ziinzululwazi ezifuna ukufunda nzulu
20 ngesigulo ekuthiwa yi-catatonia kweli ziko lempilo. Unyango obuhleli uzakulufumna alusayi kutshintsha
21 okanye luphazamiseke wakuthatha inxaxheba kolu phando.

24 **Yintoni i-catatonia?**

25 I-catatonia sisigulo esiye sibangele ukuphazamiseka kwindlela umntu ashukuma ngayo apha emzimbeni.
26 Kwabanye abantu sibangela ukuba umzimba lo ucothe kakhulu okanye ungakwazi kushuma, umntu azive
27 eqinile, athi nokuba uyafuna ukushumisa umzimba wakhe njengesiqhelo angakwazi. Ide ibangele loo nto
28 ngelinye ixesha ukuba umntu aphelele ehleli ndawoninye okanye emile ndawoninye de kugqithe imizuzu
29 emininzi okanye iiyure zibe liqela. Iyakwazi nokubangela ukuba umntu angakwazi ukuphuma
30 kwasebhedini, angakwazi kuzityisa, angakwazi kuzihlamba, asoloko elele ebhedini okanye ehleli
31 esitulweni.

32 Kwelinye icala i-catatonia iyakwazi ukubangela ukuba umntu athi ngoku sele eqalile ukushukuma esithi
33 wenza into ethile, suka umzimba lo uqine, aphelele amalungu omzimba afana neengalo, izandla, imilenze
34 okanye iinyawo zilenga emoyeni angakwazi ukuyigqibezela laa nthsukumo ebeyiqalile. Intamo nentloko
35 nazo ziyakwazi ukuphetha zikekele ngenxa yoku kuqina komzimba kuvela ngesiquphe.

36 Okokugqibela, i-catatonia iyakwazi ukuphinda ibangele intshukumo engaphaya kunesiqhelo, aphelele
37 umntu eshuku-shukuma kakhulu, angahlali ndawonye okanye angazinzi. Abanye baye bazule ndawoninye,
38 abanye baqhwabe izandla unomphelo okanye banqwale kungenjalo baninike intloko into engapheliyo.
39 Iyakwazi nokuvela ngokuba omnye umntu abetha-bethe amanqindi emoyeni, omnye athi nokuba
40 usebhedini kube ngathi unyomfa ibhaysikili into engapheliyo. Babakhona nabaphetha bethetha into enye,
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

okanye benze isikhalo esiphindaphindwayo okanye nayiphina intsholo abaye bayiqhube imizuzu emininzi okanye iiyure zide zibe liqela. Bakhona ke nabanye abaye balinganise loo nto ithethwa ngumntu ophambi kwabo kungenjalo balinganisa loo nto bayibona isenziwa ngumntu ophambi kwabo.

Ibangelwa yintoni i-catatonia?

I-catatonia iyakwazi ukubangelwa zizigulo ezithile zengqondo kungenjalo nezinye izigulo zomzimba ziyakwazi ukuhamba ne-catatonia. Ingxaki esiye siyifumane thina boogqirha neenzululwazi kukungazi xa siqala ukumbona umntu onale catatonia ukuba ingaba eyakhe ibangelwa sisigulo sengqondo na okanye sesomzimba kusini na. Yiloo tno side sabona ukuba kungakuhle ukuba sinokuyiphonononga nzulu le ngxaki.

Luqulethe ntoni olu phando?

Sijonge ekubeni wonke umntu oze kulaliswa kweli candelo, ahlolwe, kukhangelwe ukuba akahlaselwanga ziimpawu ezithile zale-catatonia kusini na. Wothi uhlolwe ngugqirha wakho ebehleli ezakuhlola kakade. Ukuba zikhona iimpawu ezithile ugqirha acinga ukuba uziqaphele apha kuwe, usenakho ukubuza ngazo umzekelo mhlawumbi ukuba ziqale nini, njani, kwaye ingaba uyaqala ukuba nazo na njalonzalo. Uzakube phofu ebhala loo nto umxelela yona. Apha ekubhaleni kwakhe kodwa akazokulibhala igama lakho nokuba ungubani kwaye uhlala phi. Oku kuhlolwa nokubuzwa nge-catatonia kungathatha imizuzu emihlanu ukuya kweli shumi kuphela. Ulwazi esilulokelelayo ngawe kukuba nje iimpawu zesi sigulo unazo na kwaye nale mibuzo sesiyikhakanyile kuphela.

Zimbini izinto esifuna ukuziqwalasela kolu phando nge-catatonia:

1. Ingaba bangaphi abantu abafunyanwa sesi sigulo kule ngingqi?

2. Ingaba zikhona izinto ezingunobangela wokuba abanye abantu bafunyanwe sesi sigulo abanye basinde, mhlawumbi njengobubudala bomntu, isini okanye ezinye izigulo zomzimba?

Nayiphi na into esinokuyifunda eyongezelela kulwazi esele sinalo ngesi-sigulo ingasinceda kakhulu ekubeni sikwazi ukusinyanga ngcono kwixa elizayo. Ngako oko ubukho bakho nokuthatha kwakho inxaxheba kolu phando kuya kunceda abantu abaninzi abanokuthi bafunyanwe sesi sigulo.

Alukho olunye uvavanyo oza kulwenza oludibene nolu phando. Naluphi na olunye uvavanyo okanye unyango ozakuthi ulufumane emva kokuba umongikazi okanye ugqirha egqibile ukukuhlola, lunyango lwesiqhelo obuhleli uzakulufumana kakade kugirha wakho.

1
2
3
4
5
6 **Ukuba ndifunyaniswe ndinazo imipawu ze-catatonia loo nto ithetha ukuthini?**

7 Ukuba ufunyaniswe unazo ezinye zezi mpawu ze-catatonia, ugqira wakho wokunika unyango lakho
8 lwesiqhelo okanye enze uvavanyo ebehleli ezakulwenza kakade olunxulumene nempilo yakho.
9

10
11
12
13 **Kuza kwenziwa ntoni ngeziphumo zolu phando?**

14 Iziphumo zolu phando zizakudityaniswa zibhalwe kufndiswe abanye oogqirha neenzululwazi malunga nesi
15 sigulo, kwiinkomfa zoogqirha neenzululwazi.
16

17
18
19
20 **Ndithini ukuba ndinemibuzo?**

21 Ukuba unemibuzo ngolu phando, cela ukuthetha nogqirha wakho okanye umongikazi ozakube encedisa
22 kolu phando.
23

24
25
26 **Siyabulela!**

27 Sibulela kakhulu ngexesha lakho nokuzixhesha kwakho ngolu phando.
28
29

30
31 **4.2 - INFORMATION LEAFLET (ENGLISH)**

32
33
34 **Information Leaflet about a Study of Catatonia**

35
36
37
38
39
40 Dear Participant / Parent/ Relative

41
42
43
44 This leaflet is provided to inform you about a study being conducted by researchers who would like to
45 investigate a condition called catatonia at his health facility. The usual care you were going to get will not
46 be changed or disturbed through taking part in this study.
47
48

49
50 **What is catatonia?**

51
52 Catatonia is a condition that affects the way a person moves his whole body or body parts. In some people
53 it slows down the body considerably to the point where some will stop moving completely, causing the
54 person to feel very stiff such that they are unable to move even when they want to. This may lead to a
55
56
57
58
59
60

1
2
3
4 person remaining in one position for a very long time (whether sitting or standing) to the point of many
5 minutes or even hours. It can even cause some people to be bedridden, unable to feed themselves, or wash
6 or attend to other daily needs.
7
8

9
10
11 Catatonia can also cause a person to appear frozen even after initiating a particular action, resulting in body
12 parts like legs, arms hands or feet being frozen in awkward or unusual looking positions. The head and or
13 neck may also be tilted at awkward angles. The change in movement can often occur suddenly.
14
15

16
17
18 Lastly catatonia can also cause an abnormality of excessive movement which is more than normal. A
19 person may show excessive movement that lasts up to many minutes or hours with a seeming inability to
20 stay still. Some people may pace up and down, others may clap or wave for long periods lasting minutes to
21 hours, while others may show head nodding, head shaking, grimacing, etc. Some people have been seen to
22 do shadow boxing or cycling movements even when lying down. It may also appear as repetitive speech of
23 the same phrase, a cry or shout or other odd sound that can last for hours. Others may repeat what they hear
24 around them non- stop or they may mimic actions of those around them as well.
25
26
27
28
29

30 **What causes catatonia?**

31
32
33 Catatonia may be seen with a number of mental illnesses but it can also be associated with some other
34 medical conditions. The problem we run into as doctors is when a person presents with the first time with
35 this syndrome it may be difficult in the beginning to know what the underlying cause is i.e. whether the
36 cause is a mental condition or another medical condition. This is why conducting research on catatonia is
37 so important.
38
39
40
41
42

43 **What does this research involve?**

44
45 We are looking at ensuring that everybody who is admitted into this unit s examined and screened for
46 symptoms and signs of catatonia. Your admitting doctor will examine you as usual, which will include an
47 initial screen for catatonia through examination only. Following this, a trained research assistant who is a
48 nurse will proceed to do a full screen using a rating scale, to ensure that no other signs of catatonia were
49 missed. If the research assistant finds any additional signs of catatonia, they will tell your treating doctor. In
50 addition, the nurse may ask you questions like when did the symptoms start and how fast did they appear
51 etc. She or he will note down you answers but will not include details like your name or your address which
52
53
54
55
56
57
58
59
60

1
2
3
4 can identify who you are. This further screening by the nurse not expected to take longer than 5 to 10
5 minutes. The information to be collected for the study about your condition is about the signs and
6 symptoms and the few questions already mentioned to do with the illness, nothing more. There are two
7 questions we would like to investigate about catatonia:
8
9

10
11 1. How many people experience this condition in this area?
12

13
14 2. Are there particular characteristics that make some people more prone to it and others less
15 vulnerable to it like age, gender or other medical conditions?
16

17 Whatever we can learn about this condition, over and above what we know already will help us to come up
18 with improved ways to diagnose it and to treat it in future. Taking part in this research will therefore help
19 many people in future who may also get this illness.
20
21
22

23
24 There are no other tests you will be expected to take part in for this study. Whatever other tests or treatment
25 interventions that follow will be those that your doctor would have undertaken anyway to help you manage
26 your condition and get you better.
27
28
29

30 31 **If I am found to show some of the symptoms or signs of catatonia what does that mean?** 32

33
34
35 If you are found to have some signs and symptoms of catatonia, the research nurse will inform your treating
36 doctor, so that your doctor can give you the appropriate and usual treatment for your condition. Your doctor
37 may also decide to do more tests which would be what they would have done anyway even if you were not
38 part of the study, in order to manage your condition.
39
40
41
42

43 44 **What will be done with the results of the study?** 45

46 The results of the study will be collected and put together to present to scientific congresses so that other
47 doctors and scientists can learn from them.
48
49

50 51 **What should I do if I have more questions?** 52

53 If you have more questions, ask your treating doctor or the researcher, research assistant or nurse.
54
55

56 **Thank you! Thank you very much for your patience and for spending the few minutes on this study.**
57
58
59
60

APPENDIX 5: INSTITUTIONAL PERMISSIONS –DORA NGINZA HOSPITAL



Province of
EASTERN CAPE
HEALTH

DORA NGINZA REGIONAL HOSPITAL

DEPARTMENT OF PSYCHIATRY & MENTAL HEALTH UNIT
Spenith Street - Zerde - Port Elizabeth - 6205.
Private Bag X 11851 - Port Elizabeth - 6205.
Telephone +27 41 405 4350 - Fax +27 414054007

DEPARTMENT OF PSYCHIATRY REQUEST FOR CEO APPROVAL OF DEPARTMENTAL RESEARCH

To	Mr P Tsibolane Chief Executive Officer Dora Nginza Hospital
From	Dr A Bronkhorst, Prof S van Wyk and Prof Z Zingela Department of Psychiatry
Subject	DEPARTMENT OF PSYCHIATRY REQUEST FOR CEO APPROVAL OF DEPARTMENTAL RESEARCH
Date	08 November 2018

Introduction

The Department of Psychiatry and Walter Sisulu University have identified research projects in catatonia as a priority for the Eastern Cape due to the severity of the illness and the potentially negative outcomes resulting from delay in recognition of the cognition

Requested support

CEO approval and support for the research project on Catatonia: "Catatonia as a manifestation of serious mental illness: prevalence, presentation, management and outcomes in a mental health unit", is hereby requested on behalf of the investigators to initiate this study in the Department of Psychiatry in Dora Nginza Hospital.

Conclusion

This project is also expected to yield support for other ongoing and planned registrar research projects on Catatonia. Thank you for considering this request.

A Bronkhorst

S van Wyk

Z Zingela

The request for approval is hereby **granted / not granted** (please delete as appropriate)

Signature: Designation: CEO Date: 08.11.18

Name: M. P. TSIBOLANE

Dora Nginza Regional Hospital
Chief Executive Officer
Mr M.P. Tsibolane

Signature:

Date:

APPENDIX 6: INSTITUTIONAL PERMISSIONS

APPROVAL FROM EC HEALTH RESEARCH COMMITTEE

APPENDIX VI



Eastern Cape Department of Health

Enquiries: Madoda Xokwe
 Date: 19 December 2017
 e-mail address: madoda.xokwe@echealth.gov.za

Tel No: 040 808 0710
 Fax No: 043 642 1409

Dear Prof. Z. Zingela

Re: Catatonia As A Presentation For Severe Mental Illness: Prevalence Of Catatonia In Two Mental Health Units In Urban And Rural South Africa (EC_201712_015)

The Department of Health would like to inform you that your application for conducting a research on the abovementioned topic has been approved based on the following conditions:

1. During your study, you will follow the submitted protocol with ethical approval and can only deviate from it after having a written approval from the Department of Health in writing.
2. You are advised to ensure, observe and respect the rights and culture of your research participants and maintain confidentiality of their identities and shall remove or not collect any information which can be used to link the participants.
3. The Department of Health expects you to provide a progress on your study every 3 months (from date you received this letter) in writing.
4. At the end of your study, you will be expected to send a full written report with your findings and implementable recommendations to the Epidemiological Research & Surveillance Management. You may be invited to the department to come and present your research findings with your implementable recommendations.
5. Your results on the Eastern Cape will not be presented anywhere unless you have shared them with the Department of Health as indicated above.

Your compliance in this regard will be highly appreciated.

SECRETARIAT: EASTERN CAPE HEALTH RESEARCH COMMITTEE



APPENDIX 7: ETHICS APPROVAL



PO Box 77000, Nelson Mandela University, Port Elizabeth, 6001, South Africa mandela.ac.za

Chairperson: Research Ethics Committee (Human)
Tel: +27 (0)41 504 2347
sharlene.govender@mandela.ac.za

NHREC registration nr: REC-042508-025

Ref: [H20-HEA-PSY-002] / Approval]

18 August 2020

Prof L Stroud
Faculty: Health Sciences

Dear Prof Stroud

CATATONIA AS A MANIFESTATION OF SERIOUS MENTAL ILLNESS: PREVALENCE, PRESENTATION, MANAGEMENT AND OUTCOMES OF CATATONIA IN A MENTAL HEALTH UNIT

PRP: Prof L Stroud
PI: Dr Z Zingela

Your above-entitled application served at the Research Ethics Committee (Human) (meeting of 29 July 2020 2020) for approval. The study is classified as a high risk study. The ethics clearance reference number is H20-HEA-PSY-002 and approval is subject to the following conditions:

1. The immediate completion and return of the attached acknowledgement to Imtiaz.Khan@mandela.ac.za, the date of receipt of such returned acknowledgement determining the final date of approval for the study where after data collection may commence.
2. Approval for data collection is for 1 calendar year from date of receipt of above mentioned acknowledgement.
3. The submission of an annual progress report by the PRP on the data collection activities of the study (form RECH-004 available on Research Ethics Committee (Human) portal) by 15 November this year for studies approved/extended in the period October of the previous year up to and including September of this year, or 15 November next year for studies approved/extended after September this year.
4. In the event of a requirement to extend the period of data collection (i.e. for a period in excess of 1 calendar year from date of approval), completion of an extension request is required (form RECH-005 available on Research Ethics Committee (Human) portal)
5. In the event of any changes made to the study (excluding extension of the study), completion of an amendments form is required (form RECH-006 available on Research Ethics Committee (Human) portal).
6. Immediate submission (and possible discontinuation of the study in the case of serious events) of the relevant report to RECH (form RECH-007 available on Research Ethics Committee (Human) portal) in the event of any unanticipated problems, serious incidents or adverse events observed during the course of the study.
7. Immediate submission of a Study Termination Report to RECH (form RECH-008 available on Research Ethics Committee (Human) portal) upon expected or unexpected closure/termination of study.
8. Immediate submission of a Study Exception Report of RECH (form RECH-009 available on Research Ethics Committee (Human) portal) in the event of any study deviations, violations and/or exceptions.
9. Acknowledgement that the study could be subjected to passive and/or active monitoring without prior notice at the discretion of Research Ethics Committee (Human).


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

2

Please quote the ethics clearance reference number in all correspondence and enquiries related to the study. For speedy processing of email queries (to be directed to Imtiaz.Khan@mandela.ac.za), it is recommended that the ethics clearance reference number together with an indication of the query appear in the subject line of the email.

We wish you well with the study.

Yours sincerely



Dr S Govender
Chairperson: Research Ethics Committee (Human)

Cc: Department of Research Development
Faculty Manager: Health Sciences

[Appendix 1: Acknowledgement of conditions for ethical approval](#)

Peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



FACULTY OF HEALTH SCIENCES
POSTGRADUATE EDUCATION, TRAINING, RESEARCH AND ETHICS UNIT

**HUMAN RESEARCH COMMITTEE
CLEARANCE CERTIFICATE**

PROTOCOL NUMBER : 067/2017

PROJECT : PREVALENCE OF CATATONIA IN TWO MENTAL HEALTH UNITS IN URBAN AND RURAL SOUTH AFRICA

INVESTIGATOR(S) : PROF Z ZINGELA

DEPARTMENT : PSYCHIATRY & BEHAVIOURAL SCIENCES

DECISION OF THE COMMITTEE : APPROVED


DATE OF APPROVAL : 07 MAY 2020

DURATION : 1 YEAR (07 MAY 2020 – 07 MAY 2021)

CONDITIONS : NONE

N.B You are required to provide the committee with a progress or outcome report of the research after every 6 months. The committee expects a report on any changes in the protocol as well as any untoward events that may occur at any time during the study not later than 7 days of knowing as the investigator/s.

WALTER SISULU UNIVERSITY
ACADEMIC HEALTH SERVICE COMPLEX OF THE
EASTERN CAPE
POSTGRADUATE EDUCATION AND TRAINING
FACULTY OF HEALTH SCIENCES
WALTER SISULU UNIVERSITY
P/BAG X 1, WSU, 5117, E.C
TEL: (047) 502 2100 / FAX: (047) 502 2101


.....
DR EJ NDEBIA
CHAIRPERSON

07.05.2020
.....
DATE

DECLARATION OF INVESTIGATOR(S)

(To be completed in duplicate and one copy returned to the Research Officer at Office AB 02 GF 03 Administration Building, Sisson Street Campus, Fort Gale, Mthatha, WSU)

I/We fully understand the conditions under which I am/we are authorized to carry out the abovementioned research and I/we guarantee to ensure compliance with these conditions. Should any departure to be contemplated from the research procedure as approved I/we undertake to resubmit the protocol to the Research Ethics Committee. I/We agree to a completion of a 6-monthly/ yearly progress report. The committee reserves the right to withdraw approval in the event that there are serious ethical violations.

..... (Signature)
N. B. Please quote the protocol number in all enquiries.

..... (Date)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only